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Abstract  
During the last ten years, third generation aromatase inhibitors (AIs) have proved to be effective 
treatment for estrogen receptor positive (ER+) breast cancer and are today recommended as first 
line endocrine therapy for postmenopausal ER+ breast cancer patients, making up the majority of 
breast cancer patients. However, a major problem is development of resistance against AIs. Since 
molecular mechanisms of AI resistance are largely undisclosed, it is of great importance to gain 
insight into these mechanisms. Therefore, the aim of this project was to study the molecular basis for 
resistance to AIs to unravel new targets for treatment. Two cell lines resistant to the non-steroidal AI 
letrozole (LetR-1 and LetR-3), two cell lines resistant to the steroidal AI exemestane (ExeR-1 and ExeR-
3), and the parental cell line MCF-7 were characterized with respect to growth properties and 
expression of selected proteins. Furthermore, a kinase inhibitor screen was used to identify potential 
kinases driving growth of the AI resistant cells. 
 
Dose-response growth experiments revealed that the parental MCF-7 cell line was growth stimulated 
by the androgen testosterone and that this stimulation was completely blocked by treatment with 
AIs, demonstrating that testosterone stimulates growth via conversion to estradiol by the 
endogenous aromatase enzyme. The four AI resistant cell lines were also growth stimulated by 
testosterone. However, the testosterone-stimulated growth was only partially reduced by AI 
treatment, and the AI resistant cell lines were able to grow continuously in the presence of letrozole 
as well as exemestane, indicating that the AI resistant cells are resistant to both letrozole and 
exemestane. Furthermore, dose-response growth experiments showed that MCF-7 cells were growth 
inhibited by the anti-estrogens tamoxifen and fulvestrant, and that fulvestrant was most efficient as 
it completely abrogated the testosterone stimulation. The AI resistant cell lines were only partially 
growth inhibited by tamoxifen, and fulvestrant exerted growth inhibition to below the basal growth 
level for the AI resistant cell lines, demonstrating that ER is a major driver of AI resistant cell growth.  
 
Western blot analyses showed that ER level was higher in the AI resistant cell lines compared to the 
parental cell line MCF-7, and both estradiol and testosterone down regulated ER expression whereas 
AI treatment showed no change in ER level, demonstrating that the AI resistant cell lines express ER 
and that the ER protein is destabilized upon binding of estradiol as seen in parental cells. Also, the 
estrogen up regulated proteins; PgR A, PgR B, IGF1-R and Bcl-2 were expressed in the resistant cell 
lines with estradiol and testosterone treatments, showing that ER is functional in the four AI resistant 
cell lines. 
  
  
Findings from the kinase inhibitor screen suggested that Aurora kinases as well as CDKs and Akt 
signaling kinases might be important for growth of the AI resistant cells. The importance of 
particularly Aurora kinase A was supported by the finding of a generally increased level of p-Aurora A 
in the AI resistant cells, and arrest of cells in G2/M phase upon treatment with the CDK inhibitor 
AZD5438 and the Aurora kinase- and CDK- inhibitor JNJ-7706621. To further investigate the 
importance of Aurora kinase A for AI resistant cell growth, siRNA-mediated knockdown of the Aurora 
A protein was performed, and showed that Aurora A could efficiently be shut down by siRNA-
mediated knockdown in both the parental cell line and in LetR-1 and ExeR-1 cells, and knock down of 
Aurora A preferentially inhibited growth of the AI resistant cell lines.  
 
In conclusion, the investigations showed many similarities between the letrozole resistant cell lines 
and the exemestane resistant cell lines. The most important finding was ER as the major driver of AI 
resistant cell growth, and total inhibition of AI cell growth with the anti-estrogen fulvestrant, 
indicating that fulvestrant might be used as a new treatment upon relapse with an AI. Also, Aurora 
kinase A was important for growth of the AI resistant cell lines, and as recently published data have 
shown that Aurora A kinase can activate the ER via phosphorylation, activation of Aurora kinase A 
may be responsible for the ER mediated growth. This indicates that combined treatment with an AI 
and an Aurora A inhibitor could be a treatment option for ER+ breast cancer patient upon acquired 
resistance to AIs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Resumé in Danish 
I løbet af de sidste ti år har tredje-generations aromatase hæmmere (AI) vist sig at være effektiv 
behandling for østrogenreceptor positiv (ER+) brystkræft og anbefales i dag som første-linje endokrin 
behandling for postmenopausale kvinder med ER+ brystkræft, som udgør størstedelen af 
brystkræftpatienterne. Et stort problem er dog udvikling af resistens overfor AI, og eftersom 
kendskab til de molekylære mekanismer for udvikling af AI resistens er meget begrænset, er det af 
stor betydning at få indsigt i disse mekanismer. Formålet med speciale var derfor at undersøge de 
grundlæggende molekylære mekanismer for AI resistens med henblik på at finde nye målrettede 
behandlinger. To cellelinjer resistente overfor den non-steroide AI letrozol (LetR-1 og LetR-3), to 
cellelinjer resistente overfor den steroide AI exemestan (ExeR-1 og ExeR-3) og den parentale cellelinje 
MCF-7 blev karakteriseret med hensyn til vækstegenskaber og ekspression af udvalgte proteiner. Der 
blev desuden udført et kinase hæmmer screen for at identificere potentielle behandlingsmål og 
molekylære resistensmekanismer for AI resistens. 
 
Vækstforsøg viste, at den parentale cellelinje MCF-7 blev stimuleret af testosteron, og at denne 
stimulering kunne blokeres fuldstændigt ved behandling med en AI, hvilket viser, at testosteron 
stimulerer væksten via omdannelse til estradiol ved hjælp af endogent aromatase-enzym. De 
resistente cellelinjer blev også vækststimuleret af testosteron. Dog blev den testosteron-stimulerede 
vækst kun delvist reduceret ved behandling med en AI, og de AI resistente cellelinjer var i stand til at 
vokse kontinuerligt under tilstedeværelse af letrozol samt exemestan, hvilket tyder på, at de AI 
resistente cellelinjer er resistente overfor både letrozol og exemestan. Vækstforsøg viste også, at 
MCF-7 blev vækst-hæmmet ved behandling med anti-østrogenerne tamoxifen og fulvestrant, og 
fulvestrant var mest effektiv, da dette anti-østrogen fuldstændigt hæmmede den testosteron-
stimulerede vækst. De resistente cellelinjer blev kun delvis hæmmet af tamoxifen, mens fulvestrant 
udøvede væksthæmning til under det basale vækstniveau for de AI resistente cellelinjer. Dette viser, 
at ER er en væsentlig drivkraft for væksten af de AI resistente cellelinjer. 
 
Western blot analyser viste, at ER niveauet var højere i de resistente cellelinjer, sammenlignet med 
den parentale cellelinje. Både østradiol og testosteron ned-regulerede ER ekspressionen i de 
resistente cellelinjer, hvorimod behandling med AI ikke gav nogen ændring i ER ekspression. Dette 
viser, at ER destabiliseres ved binding af østradiol, som det også ses i de parentale celler. De østrogen 
op-regulerede proteiner PgR A, PgR B, IGF1-R og Bcl-2 var udtrykt i forøget mængde i de resistente 
cellelinjer behandlet med østradiol og testosteron. Sammenfattede viser disse analyser, at de 
resistente cellelinjer har funktionel ER.    
  
Data fra kinase hæmmer screenet tyder på, at Aurora kinaser, cyklin-afhængige kinaser (CDK) og Akt- 
signalerings kinaser kan være vigtige for væksten af de resistente cellelinjer. Betydningen af særligt 
Aurora kinase A blev understøttet ved fund af et generelt øget niveau af p-Aurora A i de AI resistente 
cellelinjer samt blokering af cellerne i G2/M fasen ved behandling med CDK hæmmeren AZD5438 og 
Aurora kinase- og CDK- hæmmeren JNJ-7706621. For yderligere at undersøge vigtigheden af Aurora 
kinase A for AI resistent cellevækst, blev der udført et knockdown forsøg af Aurora A proteinet, der 
viste, at Aurora A effektivt kan lukkes ned vha. knockdown i både MCF-7, LetR-1 og ExeR-1. Den 
præferentielle væksthæmning af de AI resistente cellelinjer peger på en vigtig funktion af Aurora 
kinase A i AI resistent cellevækst.   
 
Det konkluderes, at de letrozol og de exemestan resistente cellelinjer har mange ligheder, og der var 
krydsresistens mellem de to typer AI. Det vigtigste fund var ER som drivkraft for væksten af de AI 
resistente celler og total blokering af væksten af de AI resistente cellelinjer med anti-østrogenet 
fulvestrant, hvilket indikerer at fulvestrant måske kan bruges som en ny behandling ved tilbagefald 
med en AI. Aurora kinase A var også vigtig for væksten af de resistente cellelinjer, og da nyligt 
publicerede data har vist, at Aurora kinase A kan aktivere ER via fosforylering, kan aktivering af 
Aurora kinase A være ansvarlig for den ER medierede cellevækst. Disse resultater peger på, at 
effektiv behandling for AI resistent brystkræft kan være behandling med fulvestrant eller kombineret 
behandling med en AI og en Aurora A-hæmmer.  
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NF-κB Nuclear factor kappa-light-chain-enhancer of activated B cells 
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PIP3 Phosphatidylinositol-3,4,5-triphosphate 
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RT Room temperature 
RTK Receptor tyrosine kinase 
SD Standard deviation  
SERM Selective estrogen receptor modulator 
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STAT Signal transducer and activator of transcription 
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1 Introduction 
In the following sections, a short introduction to breast cancer will be given, with a description of the 
etiology, epidemiology and the anatomy of the human female breast. Then, a description of estrogen 
dependent breast cancer, the importance of the aromatase enzyme for endogenous estrogen 
synthesis and endocrine treatment will be given. Some of the central signaling pathways important 
for breast cancer will be outlined and resistance mechanisms known to be important for AI 
resistance will be described. Finally, the model system used to unravel molecular mechanisms in AI 
resistant breast cancer will be presented.  
 Breast Cancer – Epidemiology and Etiology 1.1
Breast cancer is the most prevalent type of female cancer in the Western world and is also the 
leading cause of cancer deaths among females [2]. In Denmark, breast cancer comprises about 27% 
of cancers diagnosed in women. Yearly approximately 4800 women are diagnosed with breast cancer 
and more than 1200 Danish women die of the disease every year [3]. Male breast cancer does also 
occur, but is rare, with approximately 30 new incidences in Danish men in 2011 [4]. Because of the 
high incidence of breast cancer among women, there is a need for more research within the area to 
obtain better diagnostics, better treatment, as well as to improve prevention.  
 
Cancers arise from multistep series of mutations and alterations in three types of genes; oncogenes, 
tumor-suppressor genes and stability genes. The risk of developing cancer therefore increases with 
age [5]. Some mutations are hereditary, like those in the breast cancer susceptibility genes 1 and 2 
(BRCA-1 and BRCA-2), but only make up 5-10% of the breast cancer incidences [6]. A number of 
environmental and life style factors can increase the risk of developing breast cancer, such as alcohol 
consumption, early menarche, obesity after menopause, hormone-replacement therapy and physical 
inactivity [2, 6, 7]. Other factors such as early first time pregnancy, physical activity, as well as 
lactation have been found to be breast cancer preventive [6]. The primary risk factor for the 
development of breast cancer is hormonal, mainly caused by exposure to estrogen [8]. Estrogen 
dependent breast cancer was first described in 1896 where it was published that surgical removal of 
the ovaries decreased tumor growth in women with metastatic breast cancer [9]. Two mechanisms 
of estrogen action during breast cancer development have been described; 1) Estrogens induce 
proliferation in the breast epithelium whereby the risk of mutations increases and thus increasing 
the risk of malignant transformation, or 2) Estrogen metabolism leads to metabolites which can be 
carcinogenic in that they cause oxidative DNA damage or binds directly to the DNA [7]. 
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 Anatomy of the Human Mammary Gland 1.1.1
Development of the female breast is initiated already during embryogenesis and results in males and 
females having the same rudimentary mammary gland [10]. When females undergo puberty the 
mammary gland matures; however, the gland is not fully developed until first full pregnancy [11]. The 
mammary gland consists of a branching network of ducts lined with epithelial cells, which drain into 
the nipple. The luminal epithelial cells are responsible for milk production and are surrounded by a 
layer of myoepithelium, which have contractile properties and are involved in lactation. The gland is 
embedded in fibroblast stroma and surrounded by adipose tissue [10-12]. During puberty, pregnancy 
and lactation the mammary gland undergoes morphogenic changes regulated by the steroid and 
peptide hormones estrogen, progesterone and prolactin [13]. A schematic overview of the mammary 
gland structure is given in figure 1.  
 
Figure 1: Overall Structure of the Female Breast. From the nipple long ducts terminate in alveolus networks called 
lobes. The ducts and alveoli penetrate the stroma and adipose tissue. The rib, the muscle underlying the breast 
followed by loose connective tissue is also showed. Suspensory ligaments and the skin are indicated. Breast cancers 
most often arise in luminal epithelial cells lining the normal breast ducts and are called ductal carcinomas. Modified 
from [10].  
 Estrogen Dependent Breast Cancer 1.2
Breast cancer is a clinically heterogeneous, where tumors may have different prognosis and therapy 
responses. Approximately 80% of breast cancer tumors are classified as estrogen receptor α positive 
(ER+), which is defined by ≥ 1% of the cancer cells expressing the ER protein [14, 15]. The majority of 
these tumors are estrogen dependent or estrogen responsive which mean that the cells utilize 
estrogen for growth and survival [10]. The main focus of this thesis will be on ER+ breast cancer 
which can be treated with endocrine therapy (see later). Upon carcinogenesis the normal structure 
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of the tissue, showing an organized composition of epithelial cells, is disrupted [10, 16]. Figure 2 
depicts the histology of a normal breast tissue (A) and an ER+ breast tumor (B). 
 
 
Figure 2: Histological Overview of Normal and Breast Cancer Tissue. A. Normal breast tissue displays an organized 
structure of epithelial cells, lining the ducts of the lumen. B. ER+ breast cancer tissue displays a disrupted structure 
and the ER is more frequently expressed. ER+ cells stain brown. Modified from [10]. 
 
In normal breast tissue, only a minor fraction of the luminal epithelial cells are ER+ and these cells 
are non-proliferating. Estrogen-stimulated proliferation of surrounding epithelial cells occurs through 
a paracrine mechanism during pubertal growth. Most breast cancers arise in the luminal epithelial 
cells and are called ductal carcinomas [10]. To date it is not known how tumor cells transform from 
quiescent ER+ cells to proliferative ER+ cells [17].  
 Estrogens and Androgens  1.3
Estrogens are steroid hormones synthesized primarily by the ovaries and to a lower extent in adipose 
tissue, bone, vascular endothelium and adrenal glands [18]. The most potent estrogen is 17β-
estradiol which can be metabolized into the less potent estrone and estriol [19]. Estrogen synthesis is 
regulated by the hypothalamic pituitary-gonadal (HPG)-axis, where a negative feedback loop causes 
the level of estrogen to cycle. Upon menopause, synthesis of estrogens by the ovaries ceases and 
eventually terminates [19]. At menopause, mean plasma estradiol levels fall from about 400 pmol/L 
to about 25 pmol/L. However, in postmenopausal women the estradiol concentration in breast 
carcinoma tissue is around 10 times the concentration in plasma [20]. In postmenopausal women, 
synthesis of estrogens occurs in peripheral tissues (e.g. adipose tissue) and depends on the 
conversion of androgen precursors by the enzyme aromatase [18]. The aromatase mediated 
synthesis of estrogens continues beyond menopause and thus low levels of estrogens are still 
produced and are sufficient to stimulate growth of an ER+ breast tumor. In addition to involvement 
of estrogens in the menstrual cycle, estrogens also have beneficial effects on the cardiovascular 
system and on bone maintenance [18, 21]. 
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 The Human Estrogen Receptor – Structure and Functional Domains  1.3.1
ER is a member of the nuclear receptor family which contains steroid hormone receptors, thyroid 
hormone receptors, retinoid receptors, eicosanoid receptors, vitamin D receptors and orphan 
receptors [22]. Two types of ERs have been identified; ER alpha (ERα) and beta (ERβ) [23]. While ERα 
is present only in the nuclei of epithelial cells lining the ducts and lobules, ERβ is present in the nuclei 
of both epithelial and myoepithelial cells [24]. ERα is the primary mediator of estrogen-induced 
breast cancer and has been found to be expressed in high levels in many breast tumors, while ERβ 
primarily is expressed in normal breast tissue [25]. Therefore, the focus in this study will be on ERα, 
which henceforth will be denoted as ER. ER consists of six functional domains denoted A-F [26] as 
shown in figure 3. The A/B domain lies in the N-terminal and modulates transcription of estrogen 
regulated genes through the ligand independent transactivation domain, activation function 1 (AF-1) 
[27]. In the C domain, a DNA-binding domain (DBD) is found, which recognizes and  binds to estrogen 
responsive elements (EREs). When estrogen is present, the binding is enhanced. The D domain, 
which is a hinge region between C and E, is believed to be important for binding of co-regulative 
proteins [28, 29]. In the E domain, the ligand binding domain (LBD) as well as the ligand-dependent 
transactivation domain, activation function 2 (AF-2), is located [27, 28]. The transactivation activity of 
AF-2 is regulated by the binding of ligand (e.g. estrogen) to the receptor, while activation of AF-1 is 
ligand independent and is primarily due to phosphorylation of the receptor [26, 30]. The F domain is 
situated in the C-terminal and has a specific modulatory function. This affects the agonist/antagonist 
effectiveness of anti-estrogens and the transcriptional activity of the ligand bound ER in the cells 
[31]. 
 
Figure 3: The Estrogen Receptor α Protein. From the N-terminal is the A/B domain containing the AF-1 
transactivation domain. The A/B domain is followed by the C domain containing the DNA binding domain (DBD). 
Domain D functions as a flexible hinge. Domain E contains both the ligand binding domain (LBD) as well as the ligand 
dependent transactivation domain AF-2. Finally, at the C-terminal is the F domain. Modified from [30].  
 
 Aromatase and Breast Cancer  1.4
As mentioned, the aromatase enzyme converts androgens (e.g. testosterone) to estrogens (e.g. 
estradiol), which can stimulate the growth of human breast cancer cells [18]. After menopause, 
estrogens are no longer produced in the ovaries, but in peripheral tissues such as adipose tissue and 
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stromal cells, which produce sufficient amounts to stimulate tumor growth [32]. In the following 
section a description of the aromatase gene and aromatase enzyme in relation to breast cancer will 
be given.  
 The Aromatase Gene CYP19A1  1.4.1
The human aromatase enzyme is a member of the cytochrome P450 family and is encoded by the 
CYP19A1 gene, which is located on chromosome 15q21.1 [1]. The gene is comprised of a 30 kb 
coding region and a 93 kb regulatory region [33], which together consists of a heme group and a 
polypeptide chain of 503 amino acid, with a molecular weight (Mw) of 55 kDa [34]. Expression of 
aromatase is controlled by several promoters that lie upstream of tissue-specific exons. Altogether 
there has been found 10 promoters, named II, I.f, I.1, I.2, I.3, I.4, I.5, I.6, I.7 and 2a, which are 
regulated by a set of regulatory sequences in DNA and transcription factors that bind to these 
specific sequences [33]. Understanding the complex promoter structure of the aromatase gene is 
very important, as it defines the tissue-specific regulation of estrogen biosynthesis. The ovaries, 
testis, adipose tissue, brain, bone and breast cancer tissues each utilize their own promoters. Ovaries 
and testis utilizes promoter II, adipose tissue and bone uses promoter I.4, brain use promoter I.f, 
placenta use the I.1 promoter while breast cancer tissue utilizes promoter I.3, I.7 and II [33, 35, 36]. 
The normal breast adipose tissue maintains low level of aromatase, primarily through promoter I.4. 
Promoters I.3, I.7 and II are rarely used in normal breast adipose tissue; however, as mentioned, the 
three promoters are increased in breast cancer tissue [33]. Accordingly, blockade of promoter I.3, II 
and I.7 mediated transcription might provide a breast-specific therapy.  
 
The aromatase enzyme is located in the endoplasmic reticulum and coverts C19 steroids (androgens, 
e.g. testosterone) to C18 steroids (estrogens, e.g. estradiol), shown in figure 4.  
 
 
Figure 4: Aromatase mediated conversion of androgens to estrogens. The aromatase enzyme catalyzes the 
conversion of androgens to estrogens. Here the conversion of the androgen testosterone to the estrogen estradiol is 
shown. Modified from [37].  
 
Aromatase is closely linked to nicotinamide adenine dinucleotide phosphate (NADPH) – cytochrome 
P-450 reductase (NADPH-CPR). NADPH-CPR functions as an electron donor, which is essential for the 
INTRODUCTION 
 
20 
 
aromatization reaction. When aromatase receives electrons from reduced NADPH-CPR, it converts 
androgens to estrogens by successive rounds of oxidation. Conversion of androgens to estrogens can 
either be conversion of testosterone to estradiol or androstenedione to estrone, respectively [34].  
Breast tumors have elevated estrogen levels compared to normal breast tissue [38], and this is in 
agreement with higher expression of aromatase mRNA in breast cancer tissue [39]. 
Immunohistochemical analyses have disclosed that aromatase is expressed in the carcinoma cells, 
but also in many other cells in the breast e.g. macrophages and fat cells [40, 41]. Thus, estrogens are 
produced in the breast tissue, but also in peripheral tissues, and it has been shown that circulating 
estrogens are important for the supply of estrogens to the tumor cells [36, 42]. Since the aromatase 
enzyme is the key enzyme for estrogen synthesis, inhibition of aromatase is targeted treatment for 
estrogen dependent breast cancer and AIs are therefore important for treatment of breast cancer.  
 Endocrine Treatment of Breast Cancer  1.5
Treatment of breast cancer includes surgical removal of the breast (mastectomy), surgical removal of 
the tumor (tumorectomy), chemotherapy, radiotherapy, endocrine therapy and biological treatment 
(targeted treatment). Approximately 90% of the breast cancer patients will be offered adjuvant 
treatment to reduce the risk of recurrence and death. Neo-adjuvant treatment, which means 
treatment before surgery, is primarily used to determine if the tumor responds to the selected 
treatment, but is also in some cases used to downstage the tumor [43]. The only well-established 
predictive factors for endocrine therapy are ER and the progesterone receptor (PgR) [44]. Patients 
whose tumors are both ER+ and PgR+ have more than 70% likelihood of responding to endocrine 
therapy, while those with both ER negative (ER-) and PgR negative (PgR-) tumors have less than 10% 
response rate. The majority of patients with ER+ and/or PgR+ tumors are therefore offered adjuvant 
endocrine therapy, which blocks the growth stimulation exerted by estrogens. The types of 
endocrine therapy include aromatase inhibitors (AIs), selective estrogen receptor modulators 
(SERMs), selective estrogen receptor down regulators (SERDs) and progestins [45, 46]. 
Postmenopausal women are recommended 5 years adjuvant treatment with AIs, while 
premenopausal women are recommended 5 years with the SERM tamoxifen [47]. In the following 
sections, different endocrine therapies will be introduced with most emphasis on AIs.  
 Aromatase Inhibitors  1.5.1
AIs were developed in 1981 [48], and today, third generation AIs (explained later) are used in the 
clinic [20]. AIs act by suppressing plasma estrogen levels in postmenopausal women by inhibiting or 
inactivating aromatase, the enzyme responsible for conversion of androgens to estrogens [20] (figure 
5). Over the last ten years, AIs have proved to be effective treatment for ER+ breast cancer and are 
now recommended as first line therapy for postmenopausal ER+ breast cancer patients [49]. In 
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premenopausal women, the estrogen produced in the ovaries depends on gonadotropin stimulation. 
Therefore, when premenopausal women are treated with an AI, a decrease in estrogen will activate 
hypothalamus to increase gonadotropin secretion, which stimulates the ovaries to increase the 
androgen production, leading to estrogen production and thus growth [42]. This counteracts the 
effect of the AI, since total estrogen is increased. In postmenopausal women, this problem is not 
applicable as the production of estrogens comes from peripheral tissues and not the ovaries. 
 
 
Figure 5: Mechanism of Action for AIs and Tamoxifen. Estradiol binds to the ER, leading to dimerization, 
conformational change and binding to EREs, which leads to proliferation. AIs reduce the synthesis of estrogens by 
blocking or inhibiting aromatase, the enzyme responsible for conversion of androgens to estrogens. Aromatase can 
be present both outside and inside the breast cancer cells as indicated. Tamoxifen competes with estradiol for ER 
binding and thereby antagonize the effect of estradiol. Modified from [42]. 
  
 Classification of Aromatase Inhibitors  1.5.1.1
AIs can be divided in first, second and third generation inhibitors, according to the chronological 
order for their clinical development. Further, the AIs are divided in type 1 (steroidal) or type 2 (non-
steroidal) inhibitors according to their mechanism of action [20] (see table 1). The first generation 
inhibitor aminoglutethimide was the first drug to be used as an AI [48]. Second generation inhibitors 
include formestane and fadrozole [20]. Third generation inhibitors, which display high affinity and 
specificity towards aromatase and have reduced side effects compared to first and second 
generation inhibitors, are approved by the Food and Drug Administration (FDA) and include letrozole, 
exemestane and anastrozole [20, 50]. The third generation inhibitors letrozole and exemestane are 
investigated in this thesis.  
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Table 1: Classification of Aromatase Inhibitors (AIs).  
Generation Type 1 (steroidal) Type 2 (non-steroidal) 
First None Aminoglutethimide 
Second Formestane Fadrozole 
Rogletimide 
Third Exemestane (Aromasin) Anastrozole (Arimidex) 
Letrozole (Femara) 
Vorozole 
Based on [20].  
 
Exemestane is a steroidal inhibitor while letrozole is a non-steroidal inhibitor, and the structures of 
the two inhibitors are shown in figure 6. Treatment with exemestane or letrozole results in a 
decrease in serum estrogen concentrations; however, the two types of AIs differ in their mechanism 
of action. A steroidal inhibitor binds to the substrate-binding site of the aromatase enzyme. After 
binding, the inhibitor is converted to a reactive intermediate that covalently bind to the enzyme, 
causing an irreversible binding. Non-steroidal inhibitors, on the other hand, bind non-covalently to 
the heme moiety of the aromatase enzyme and prevent binding of androgens (e.g. testosterone) by 
saturating the binding site. Unlike the steroidal inhibitors, inhibition with non-steroidal inhibitors is 
reversible by competitive inhibition of androgens [32]. The enzyme activity can reappear if the AI is 
removed, but regardless, the inhibition exists whenever the AI is present [51]. Due to the different 
mechanisms of action, the two AIs may have different resistance mechanisms (see later).  
 
Exemestane and letrozole are administered orally. Letrozole have a half-life of approximately 48 
hours [52] and the half-life of exemestane is 27 hours [53], allowing a once-daily dosing schedule 
[20]. Studies have shown that letrozole improves disease free survival (DFS) and overall survival (OS) 
in comparison to tamoxifen in both the advanced disease and adjuvant setting for postmenopausal 
women with ER+ breast cancer [54, 55]. Also in a neo-adjuvant setting letrozole has proved superior 
to tamoxifen in postmenopausal patients with ER+ breast cancer [56]. Furthermore, pre-clinical data 
have shown that combination of the non-steroidal AI anastrozole and the pure anti-estrogen 
fulvestrant was more effective in maintaining suppression of tumor growth than anastozole alone 
[57]. The AI exemestane has proven to be an effective and well tolerated endocrine treatment for 
postmenopausal women with metastatic breast cancer and in the adjuvant setting treatment with 
tamoxifen for 2-3 years followed by treatment with exemestane was superior to 5 years treatment 
with tamoxifen [58]. 
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Figure 6: Structure of the Aromatase Inhibitors Exemestane and Letrozole. Exemestane is a steroidal AI, while 
letrozole is a non-steroidal AI. Both AIs are third generation inhibitors. Modified from [59].  
 
 Side Effects by Treatment with Aromatase Inhibitors  1.5.1.2
The third generation AIs first appeared to be well tolerated, with a low incidence of serious short-
term side effects. Some of the first reported side effects included hot flashes, vaginal dryness, 
skeletal pain and headache. Comparative trials indicated that such adverse effects were very similar 
in nature and frequency to those of tamoxifen [54, 56, 60, 61]. AIs has demonstrated to exhibit less 
adverse toxicity compared to tamoxifen, particularly concerning development of deep vein 
thrombosis and pulmonary emboli [62]. However, during the last few years, treatment with AIs has 
shown that the incidence of bone fractures and joint pain is higher among patients treated with 
letrozole versus tamoxifen [55]. Musculoskeletal adverse effects now appears to be the most 
common side effect seen with AI treatment and is also the most common cause of discontinuation of 
treatment [63]. The reason for the higher incidence of bone fractures in patient treated with AIs 
compared to patients treated with tamoxifen, could be that tamoxifen reduces bone 
demineralization through its agonist effect in postmenopausal women [64, 65] whereas AIs may 
enhance this process by lowering the level of circulating estrogens [20]. 
 Anti-estrogens  1.5.2
Anti-estrogens include both SERMs, e.g. tamoxifen and SERDs, e.g. fulvestrant. Tamoxifen is a non-
steroidal inhibitor of ER and has been found to have both antagonistic and agonistic effects upon 
binding. Tamoxifen binds to ER, but ER is still able to dimerize, translocate to the nucleus and bind to 
EREs. As the conformation of tamoxifen bound ER does not allow co-activator recruitment, 
transcription of target genes is impaired (figure 5). However, the AF-1 site is not blocked upon 
tamoxifen binding and the agonistic actions of tamoxifen are thought to be mediated through AF-1 
induced transcription [66]. The agonistic effects of tamoxifen result in maintenance of some of the 
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beneficial effects of estrogens in bone upon tamoxifen treatment [67], but may also be involved in 
resistance to tamoxifen (see later). If breast cancer patients develop resistance to tamoxifen, they 
may be treated with the steroidal anti-estrogen fulvestrant (Faslodex or ICI 182, 780) as second-line 
treatment [68]. Fulvestrant preserves pure estrogen antagonistic activity [69], and function by 
binding to ER, preventing dimerization of ER and leading to degradation of ER via the proteasome 
pathway [70, 71].  
 Signal Transduction in Breast Cancer 1.6
As mentioned before, treatment with anti-estrogens blocks the growth stimulation exerted by 
estrogens and thus tumor growth can be reduced. Estrogens regulate gene expression of a large 
number of genes [72] via ER and are important regulators of growth and differentiation in the normal 
mammary gland and are also important in the development and progression of breast carcinomas 
[73]. ER can both activate and repress transcription. Normal cells use signal transduction in multiple 
cellular functions, e.g. cell differentiation, controlled proliferation, homeostasis, cell survival and cell 
death, and cancer cells can take advantage of these signal transduction pathways in order to grow 
[74]. In the following sections, a general insight to signal transduction in breast cancer will be given.  
 Estrogen Receptor Signaling  1.6.1
When ER is in an inactive state it is bound to co-repressor (CoR) complexes, e.g. the nuclear receptor 
co-repressor (NCoR). CoRs can recruit histone deacetylase complexes (HDACs), which maintain 
histones in a deacetylated state, favoring chromatin condensation. The chromatin condensation 
thereby represses gene transcription of genes controlled by ER. Binding of estrogen to the AF-2 
causes a conformational change in the AF-2, which results in binding of co-activators (CoA), such as 
the cAMP response element binding protein (CREB). The CoAs bind histone acetyltransferases (HATs) 
which mediate acetylation of the histones, causing the chromatin to decondensate and thereby 
favoring gene transcription [10]. ER can also be activated via AF-1 in a ligand independent activation 
where ER is activated by phosphorylation, caused by protein-kinase-cascades downstream of the 
activated receptor tyrosine kinases (RTKs). The phosphorylation of AF-1 occurs via at least two 
pathways; the mitogen activated protein kinase (MAPK) pathway and the phosphoinositol 3 kinase 
(PI3K) pathway, which both can be activated by RTKs (described later). ER can also act via a rapid 
non-genomic mechanism where estrogen-ER complexes in the cytosol activate several signaling 
pathways. In breast cancer cells, these pathways include the MAPK and the PI3K pathway [75, 76]. 
Some of the target genes of ER are the transcription factor Myc and cyclins, such as cyclin D1, cyclin 
E1 and cyclin E2, which all lead to proliferation and survival of the cell (figure 7) [77, 78].  
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Figure 7: Mechanisms of Estrogen Receptor Activation. In classic estrogen signaling, ligand bound ER activates gene 
expression, either through a) direct binding of ER to estrogen responsive elements (EREs) together with CoA and 
HATs or b) via protein-protein interactions with other transcription factors, e.g. activation protein 1 (Ap-1), to 
facilitate binding to serum responsive elements (SREs) and activation of transcription. ER can also be activated by 
receptor tyrosine kinases (RTKs), e.g. epidermal growth factor receptors (EGFR) and phosphorylation by Erk or Akt 
leads to ligand independent activation of ER. c) Ligand binding leads to protein complexes that involve signaling 
molecules that activates intracellular signaling cascades, which induces transcription factor (TF) activation. d and e) 
transcription activation which is independent of ER binding to DNA. Generally, all shown mechanisms lead to growth, 
proliferation and survival of the cell. Modified from [78].  
 Receptor Tyrosine Kinases  1.6.2
RTKs play an important role in cancer development and are ideal targets for cancer therapeutics. 
Many RTKs are cell surface receptors for specific growth factors, cytokines and hormones, and are 
important regulators of intracellular signal-transduction pathways mediating multicellular 
communication, cellular homeostasis and development [79]. As mentioned, estrogen target genes 
can be expressed in the absence of estrogen via protein-kinase-cascades downstream of activated 
RTKs. RTKs include the human epidermal growth factor receptor (HER) family, vascular endothelial 
growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR) and the platelet-derived 
growth factor receptor (PDGFR) [80]. HER signaling is important for normal growth and development 
in the breast. Dysregulation of HER, however, can lead to tumor development [81]. Based on this, the 
HER family is of interest in connection with breast cancer. Furthermore, crosstalk between ER and 
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RTKs is of great importance in the regulation of ER signaling. However, RTK activation and thus 
intracellular signaling also affects a number of other cellular processes, as shown for HER signaling in 
figure 8. Most RTKs consist of an extracellular ligand binding domain, a transmembrane domain and 
a cytoplasmic kinase domain with a C-terminal tail. The C-terminal tail contains tyrosine residues 
which can undergo auto-phosphorylation. Binding of an extracellular ligand to an RTK causes 
dimerization of the receptor chains, which brings the kinase domains of two receptor chains 
together. This leads to cross-phosphorylation of multiple tyrosines. When phosphorylation of 
tyrosines occurs outside the kinase domain of the RTK, docking sites for binding of specific 
intracellular signaling proteins are created. These signaling proteins often contain Src-homology 
region 2 (SH2) domains which can bind to the phosphorylated tyrosine residues on the RTK. The 
signal proteins also contain Src-homology region 3 (SH3) domains, which ensure binding to other 
signaling molecules and activate several signaling pathways [80]. Some of the RTKs that are known to 
be important in cancer development will be described in the following sections. 
 Human Epidermal Growth Factor Receptor Signaling 1.6.3
As mentioned above, HER receptors (also called ErbB receptors) and their ligands are important in 
breast cancer progression. In the HER family four different members have been identified: Epidermal 
growth factor receptor (EGFR, ErbB1 or HER1), HER2 (ErbB2 or HER2/Neu), HER3 (ErbB3) and HER4 
(ErbB4) [82]. HER2 does not bind a specific ligand and are therefore proposed to function as a co-
receptor and dimerization partner and is highly used as a dimerization partner for other HERs [82, 
83]. HER2 plays the most important role in breast cancer because it is up regulated in approximately 
15-20% of breast cancers and because overexpression correlates with aggressive tumors [84, 85]. 
The other members, EGFR, HER3 and HER4, have several ligands [82]. Binding of ligand (for instance 
epidermal growth factor (EGF), heregulin or amphiregulin) to EGFR, HER3 or HER4, leads to a 
conformational change which allowing receptor dimerization and subsequent initiation of 
downstream signaling pathways such as the MAP kinase pathway and the PI3K/Akt pathway [86], 
which will be described next. The HER signaling pathway is shown in figure 8.  
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Figure 8: Human Epidermal Growth Factor Receptor Downstream Signaling. Ligand binding to human epidermal 
growth factor receptors (HERs or ErbB) causes dimerization and autophosphorylation of the C-terminal tyrosine 
residues, which serves as docking sites for signaling proteins containing e.g. Src-homology 2 (SH2) domains such as 
SH2 domain containg protein (Shc) and growth factor receptor binding protein (Grb2). The mitogen activated protein 
(MAP) kinase pathway is coupled to Shr and/or Grb2, and signals through kinases rat sarcoma (Ras), rapidly 
accelerated fibrosarcoma (Raf), mitogen activated protein kinase (MEK) and extracellular signal regulated kinase 
(ERK) and stimulates proliferation, cell cycle control and angiogenesis. HER signaling can also activate the 
phosphoinositide 3-kinase (PI3K)-Akt pathway which stimulates cell cycle control, survival and anti-apoptosis through 
PI3K and Akt and their downstream transcription factors. Modified from [81].  
 Mitogen Activated Protein Kinase Cascade  1.6.4
The mitogen activated protein (MAP) kinase pathway can be activated by ligand binding to RTKs.  As 
mentioned before, ligand binding leads to phosphorylation of the C- terminal tyrosine residues which 
serves as docking sites for signaling proteins containing Src-homology 2 (SH2) domains such as SH2 
domain containing protein (Shc) and growth factor receptor binding protein (Grb2)[81]. Grb2 binds 
to Shc making a complex which can recruit the guanine nucleotide exchange factor, son of sevenless 
(SOS). Furthermore, SOS activates the small G-protein rat sarcoma (Ras) to exchange guanosine 
diphosphate (GDP) for guanosine triphosphate (GTP). Ras bound to GTP can activate rapidly 
accelerated fibrosarcoma (Raf) which is a MAP kinase kinase kinase (MAPKKK). This activation occurs 
through another phosphorylation, which in turn phosphorylates and activates the mitogen activated 
protein kinase 1/2 (MEK 1/2). MEK 1/2 is a MAPKK and can phosphorylate the MAPK extracellular 
signal protein kinase 1/2 (ERK 1/2) [80, 81], which then translocates to the nucleus. In the nucleus, 
ERK 1/2 causes activation of transcription factors, inducing cellular proliferation and migration (see 
figure 8). The ERK 1/2 pathway may also be activated upon ligand binding to plasma membrane 
localized ER [87]. Activation of this pathway causes expression of the transcription factor c-Myc, 
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thereby increasing the expression of cyclin D, involved in phosphorylation of the Retionoblastoma 
(Rb) protein, which in turn leads to progression through the cell cycle and thus proliferation [88, 89].  
 Phosphoinositol 3 Kinase and Akt Signaling 1.6.5
As mentioned earlier, activation of the PI3K/Akt pathway stimulates cell cycle control and survival 
[81, 90]. Activation of PI3K can occur through several RTKs, such as EGFR and insulin-like growth 
factor-1 (IGF1-R), cell adhesion molecules such as integrins, and G-protein-coupled receptors 
(GPCRs). Activation of the PI3K/Akt pathway is found in many cancer types and has shown to play a 
major role in breast cancer cell proliferation [91]. The pathway is activated by binding of the 
regulatory 85 kDa subunit (p85) to PI3K, resulting in conversion of phosphatidylinositol 3,4-
bisphosphate (PIP2) to phosphatidylinositol 3,4,5-triphosphate (PIP3). Both PIP2 and PIP3 act as 
secondary messengers and PIP3 can recruit the 3-phosphoinositide-dependent kinase 1 (PDK1) which 
is involved in the phosphorylation of Akt (also called protein kinase B (PKB)) [81], see figure 9. The 
active Akt translocates to the nucleus and phosphorylates several target proteins involved in 
regulation of cell proliferation and survival, such as glycogen synthase kinase 3 beta (GSK3β) and 
nuclear factor-kappa B (NF-κB) [92, 93]. Furthermore, Akt can phosphorylate and activate the 
mammalian target of rapamycin (mTOR) either directly or indirectly by phosphorylation. mTOR, 
which function as a serine/threonine protein kinase, phosphorylates p70S6K (70kDa ribosomal 
protein S6 kinase); a protein that regulates protein synthesis [94]. There exist two distinct complexes 
of mTOR; mTOR complex 1 and mTOR complex 2. mTOR complex 1 stimulates cell growth by 
promoting protein synthesis and by inhibiting protein degradation, while mTOR complex 2 helps 
activating Akt [89]. Activation of Akt by mTOR complex 2 leads to phosphorylation of a protein from 
the Bcl-2 family, called Bad, which in its phosphorylated state inhibits apoptosis, thus mediating 
survival [89, 95]. It has been found that activation of the PI3K/Akt/mTOR pathway is predictive of 
poor disease outcome following endocrine therapy [96]. The PI3K/Akt pathway has also been found 
to be activated through plasma membrane localized ER in the non-genomic pathway [87]. The tumor 
suppressor phosphatase and tensin homolog (PTEN) dephosphorylates PIP3 and thereby prevents 
activation of Akt. Thus, loss of PTEN indirectly stimulates PI3K activity [91]. 
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Figure 9: Phosphatidylinositol 3 kinase and Akt signaling. The figure shows a schematic depiction of PI3K/Akt 
signaling. When a growth factor binds to RTK, PI3K catalyze the phosphorylation of PIP2 to yield PIP3, which 
subsequently leads to phosphorylation and activation of Akt. Akt facilitate the phosphorylation of various target 
molecules, thus regulating cell cycle, apoptosis, cell growth and survival. Based on [90].  
 
 Cell Cycle Control and Cancer  1.7
During cell cycle, the cell content is duplicated and the cell is then divided into two daughter cells. 
Cells have evolved a complex network of regulatory proteins, called the cell-cycle control system, 
which controls progression through the cell cycle and is an extremely important mechanism of the 
cells to ensure homeostasis and survival [89]. Cancer cells often lack some of these control 
mechanisms, resulting in uncontrolled cell division [97]. The cell cycle is divided in the interphase and 
the mitotic phase (M phase). The interphase can be further divided into the gap phases 1 and 2 (G1 
and G2 phases) that ensure time for growth, and the DNA synthesis phase (S phase) which allow 
duplication of the DNA. In the M phase, the nucleus divides (mitosis) and the cell undergoes 
cytokinesis. Figure 10 shows the four phases of the cell cycle. Furthermore, the M phase is divided in 
five main stages; prophase, prometaphase, metaphase, anaphase and telophase. At prophase, the 
replicated chromosomes condense. In prometaphase the chromosomes can attach to spindle 
microtubules via their kinetochores (large chromosome embedded structures, see later). At 
metaphase the microtubules attach sister chromatids to opposite poles of the spindle, and at 
anaphase, the sister chromatids separate to form two daughter chromosomes. During telophase, the 
two sets of daughter chromosomes decondense and division of the cytoplasm begins [89].  
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Figure 10: Schematic Illustration of the Cell Cycle Phases. The interphase consists of the G1, S and G2 phase. G1 and 
G2 ensure time for growth and in S phase DNA synthesis occur. In the M phase, nucleus divide and cell undergo 
cytokinesis. G1 is the gap between M phase and S phase and G2 is the gap between S phase and M phase. Modified 
from [89]. 
 
Several check points which are tightly regulated, are located through the cell cycle to ensure correct 
cell division. There are three major checkpoints in the cell cycle. The first is called Start (or restriction 
point) and is found in late G1 phase. This check point controls that the environment for cell division is 
optimal before proceeding into S phase. The second checkpoint is the G2/M checkpoint, which 
control if the DNA is properly replicated and if the environment is suitable for mitosis. The last 
checkpoint is Metaphase-to-anaphase transistion, which ensures that all chromosomes are attached 
to the mitotic spindle so that cytokinesis will result in two identical daughter cells [89]. The check 
points are controlled by various proteins, including the cyclins and cyclin-dependent kinases (CDKs). 
CDKs are activated by binding to cyclins and regulate Start- and G2/M checkpoint. The levels of CDKs 
are generally kept at a constant level throughout the cell cycle while the level of cyclins fluctuates. 
When a cyclin form a complex with a CDK, the kinase is activated and triggers specific cell cycle 
events; however, when cyclins are not present, the CDKs are inactive. Nine CDKs have been 
identified, and of these, five are active during the cell cycle. CDK 2, CDK 4 and CDK 6 are active during 
G1 phase, CDK 2 is active during S phase, and CDK 1 is active during M phase [97]. The cyclins are 
defined by the stage of the cell cycle at which they function. The G1/S cyclins activates CDKs in late 
G1 phase and thereby triggers cell cycle entry. S cyclins binds to CDKs after cell cycle entry and help 
stimulate chromosome duplication. M cyclins binds to CDKs that stimulate entry into mitosis [89]. 
Cyclin A can bind to CDK 2 and this complex is required during S phase. Cyclin A can also bind CDK 1, 
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which is important to promote entry into mitosis, and furthermore, mitosis is regulated by cyclin B in 
complex with CDK 1 [97].  
 
The two tumor suppressors, the retinoblastoma protein (Rb) and the tumor protein 53 (p53) are cell 
cycle regulators, which often are disrupted in cancer cells [98]. The tumor suppressor p53 is 
important in cell cycle progression and mutations in p53 are the most common genetic change 
identified in human cancers [99]. p53 mutations have also been found in breast cancers and are 
associated with more aggressive disease and decreased overall survival. However, the frequencies of 
p53 mutations are lower in breast cancer than in other tumors [100, 101]. p53 is activated by cell 
damage or stress and is important for cell cycle arrest and induction of cell death [99]. p53 mediates 
the transcription of CDK inhibitor 1 (p21) upon activation by phosphorylation. When p21 binds to the 
CDK-cyclin complexes in G1, the complexes becomes inactive and mediates arrest in the G1 phase 
[98]. Mitogens (stimulatory extracellular signals) stimulate cell division by binding to cell surface 
receptors and thus initiate intracellular signaling pathways, such as the MAP kinase pathway. The 
active MAP kinase pathway can activate the transcription factor Myc, which increases the expression 
of many delayed-response genes, including some that lead to increased G1-CDK (cyclin D-CDK 4) 
protein. Cyclin D-CDK 4 triggers phosphorylation of the Rb protein and causes it to release its E2F 
bound protein upon phosphorylation. The E2F protein functions as a transcription factor and when 
Rb becomes inactivated, the E2F protein mediates transcription of proteins required for entry into 
the S phase, e.g. cyclin E (G1/S cyclin) and cyclin A (S cyclin). Cyclin E has a positive feedback loop, 
driving cells into S phase. One substrate of cyclin E-CDK2 is the p27 protein (called p27), the 
phosphorylation of which leads to its degradation as the cell enter the S phase [89, 98] (see figure 
11). Cyclin D, cyclin E and CDK4 is highly expressed in many breast cancers [98, 102]. Cyclin D1 is 
activated by CDK4 and 6, and as described earlier cyclin D1 can activate the ER in a ligand-
independent manner thereby inducing growth of ER positive breast cancer. This is thought to be the 
mechanism by which cyclin D1 exerts is oncogenic activity and it is consistent with the fact that most 
breast cancers with overexpressed cyclin D1 are ER positive [103]. Activation of the ER by binding of 
estrogen leads to increased transcription of the cyclin D1 gene indicating that ER and cyclin D1 
regulate each other [104]. 
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Figure 11: Overview of the Regulatory Cascade in the G1 Phase. Mitogens stimulate intracellular signaling pathways, 
which in turn lead to increased G1-CDK (cyclin D-CDK 4) protein. Cyclin D-CDK 4 triggers phosphorylation of the Rb 
protein and causes it to release its E2F bound protein upon phosphorylation. When Rb becomes inactivated, the E2F 
protein mediates transcription of cyclin E, which drives cells into the S phase. Cyclin E has a positive feedback loop, 
enhancing the effect. One substrate of cyclin E-CDK2 is the p27 gene, whose phosphorylation leads to its degradation 
as the cell enters the S phase. Based on [98]. 
 
 Aurora Kinases 1.7.1
Aurora kinases also play an important role in cell cycle control, as they regulate correct progression 
through mitosis and cytokinesis. The Aurora kinases constitute a family of serine/threonine kinases 
and three types are identified; Aurora A, Aurora B, and Aurora C [105, 106]. The Aurora kinases have 
different functions throughout the cell cycle [107] (see figure 12) and the kinases are found 
overexpressed in various human cancers [105]. Dysfunction of the Aurora kinases has been 
associated with a failure to maintain a stable chromosome content and can thereby contribute to 
tumorgenesis [106]. The least studied of the Aurora kinases is Aurora C and little is known about this 
kinase. However, studies have shown that Aurora C plays an important role during spermatogenesis 
[108, 109]. Due to the limited knowledge, Aurora C will not be outlined further.   
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Figure 12: Function and Localization of Aurora A and Aurora B in the Cell Cycle. In G1 phase, the levels of Aurora A 
(green squares) and Aurora B (red circles) kinases are reduced, but levels increases with different localization during 
the M phase. In prophase, Aurora A is located around the centrosomes, whereas Aurora B is concentrated in the 
nucleus. In metaphase, Aurora A is located on the microtubules near the spindle poles, while Aurora B is located in 
the inner centromere. In anaphase, Aurora A is mostly concentrated on the microtubules, but some might also be 
located in the spindle midzone. Aurora B is concentrated in the spindle midzone and at the cell cortex. In cytokinesis, 
both Aurora A and Aurora B are concentrated in the midzone. From [107].  
 
 Aurora Kinase A 1.7.1.1
Aurora kinase A is important for centrosome maturation in the G2 phase where it regulates 
centrosome separation and assembly of the bipolar spindle in mitosis. Several studies have shown 
that Aurora A also plays an important role in promoting timely mitotic entry by controlling initial 
centrosomal activation of the cyclin B-CDK 1 complex. Condensation of chromosomes into compact 
structures is essential for correct sister chromatid separation and is governed by condensin-
complexes, which are protein complexes important in chromosome assembly [110, 111]. Aurora A is 
located on chromosome 20q13, which is a known hotspot for amplification in tumors [106] and 
overexpression of Aurora A has been detected in human breast, bladder, colon, ovarian and 
pancreatic cancer [105]. Amplification of Aurora A has also been reported to correlate with 
chromosomal instability (CIN) in breast cancer [112, 113]. It has previously been showed that the 
centrosome amplification observed when Aurora A is overexpressed is an indirect effect of a failure 
to perform cytokinesis, generating tetraploid cells with two centrosomes [114]. A recent study has 
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shown that Aurora A directly interacts with ER and phosphorylates ER on serine 167 and serine 305, 
leading to an increase in ER DNA-binding and transcriptional activity [115].The regulation of ER by 
Aurora A has shown to determine tamoxifen sensitivity, and Aurora A has been suggested to play an 
important role in tamoxifen resistance [115]. Therefore, it could be speculated that Aurora kinase A 
also might be important for growth of AI resistant cell lines. Furthermore, immunohistochemical 
analysis of breast tumors revealed that overexpressed Aurora A appeared to be phosphorylated on 
Thr288, which is known to be required for its enzymatic activation [116]. The phosphorylation on 
Thr288 is promoted by PAK1; a serine/threonine protein kinase, which is important in e.g. cell cycle 
events [117].   
 Aurora Kinase B  1.7.1.2
Aurora kinase B plays an important role for proper condensation and chromosomal association of the 
condensin-I-complex and also controls chromosome cohesion. Chromosome cohesion is caused by a 
ring-form cohesin complex, which is related to the condensin complexes. Cohesin traps the two sister 
chromatids in a ring-like structure and cohesion persists between sister chromatids until the 
metaphase to anaphase transition checkpoint. Aurora B is an important regulator of mitotic spindle 
assembly and furthermore, is also required for kinetochore-microtubule bi-orientation. For bi-
orientation to happen, the microtubules of the mitotic spindle interact with chromosomes through 
kinetochores, which constitute the main microtubule binding site of the chromatids. Kinetochores 
are required for chromosome movement and checkpoint signaling in mitosis. Equal segregation of 
the sister chromatids can only be achieved when the paired chromatids have a bi-orientation on the 
mitotic spindle, which means that the two sister chromatids have to be attached to opposite poles of 
the bipolar spindle [89, 106]. Aurora B is also required for efficient cytokinesis, where the cytoplasm 
is divided into two new daughter cells [106]. The Aurora B gene is located on chromosome 17p13, a 
region that is not commonly amplified in tumors [106]. However, overexpression of the Aurora B 
gene has been seen in certain tumor types, e.g. in colon cancer [105]. Amplification of Aurora B has 
also been found in breast cancer, where the amplification occurs due to an increased cell 
proliferation rate in breast carcinoma [118]. Aurora B overexpression disrupts chromosome bi-
orientation because of increased disruption of kinetochore-microtubule attachments, and 
overexpression also causes abnormal cytokinesis [119]. A study has shown that the Aurora B 
inhibitor, AZD1152 HQPA (barasertib), induces polyploidy (cells containing more than two 
homologous sets of chromosomes) in tumor cells [105].  
 
Both Aurora A and Aurora B are targets of a multi-subunit E3-ubiquitin ligase called the Anaphase 
Promoting Complex/Cyclosome (APC/C). The APC/C, in conjunction with its specificity factor Cdh1, 
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targets these proteins for destruction during mitotic exit and as such ensures that G1 cells contain 
low levels of these proteins [106].  
 Resistance to Endocrine Therapy 1.8
As mentioned previously, the action of estrogen is mediated by ER via several signaling pathways, 
and ER activates transcription of many target genes [30]. Endocrine therapies, such as anti-estrogens 
or AIs, targets estrogen action and are widely used for breast cancer patients. However, many 
women will develop resistance to these endocrine therapies [78]. Two types of resistance are known; 
1) de novo/intrinsic resistance, which is resistance present prior to onset of endocrine treatment, 
and 2) acquired resistance, which develops through prolonged treatment [120]. The mechanisms of 
acquired resistance towards AIs are not fully elucidated and the next paragraphs will give an 
introduction to the resistance mechanisms known in AI resistance. Also, a short introduction to 
known resistance mechanisms in anti-estrogen resistance will be addressed.  
 Aromatase Inhibitor Resistance  1.8.1
Resistance mechanisms to AIs seem to differ between the steroidal and non-steroidal AIs and cross-
resistance between the two types does not seem to occur [121, 122]. Most clinical studies have 
looked at the efficacy of a steroidal AI in patients becoming resistant to therapy with a non-steroidal 
AI, and only limited clinical data suggests benefit for using a non-steroidal AI after a steroidal AI 
[122]. In general, the clinical studies investigating efficacy of a steroidal AI after a non-steroidal AI, 
include a small number of patients. However, the findings across the different studies seem 
consistent and indicate lack of cross-resistance between a steroidal and a non-steroidal AI, allowing a 
switch from non-steroidal inhibitor to steroidal inhibitor upon development of resistance [121, 122]. 
The main mechanisms behind lack of cross-resistance towards the different AIs are to date not 
known [122].   
 
Pre-clinical studies that have investigated the mechanisms of AI resistance, have highlighted a 
number of growth factor signal transduction pathways that are activated and utilized by breast 
cancer cells to circumvent response to AI therapy. Up regulation or increased activation of growth 
factor receptors such as the EGFR, HER2 and IGFR and downstream signaling intermediates such as 
MAPK and PI3K/Akt signaling, have been observed in AI resistant cell models [123, 124]. These 
signaling pathways may contribute to acquired resistance to AIs through phosphorylation of the ER, 
leading to ligand-independent transcription of ER-responsive genes and tumor growth when 
estrogen is not present [125-127]. Targeting these different signaling pathways, including ER itself, 
may therefore represent potential strategies to overcome AI resistance. Several approaches using 
signal transduction inhibitors to target growth factor signaling pathways such as the HER pathways, 
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or utilizing endocrine agents to target the ER have been used to overcome resistance to AIs. In a 
xenograft-model, ER has been found to be up regulated in response to treatment with the non-
steroidal AI letrozole; however, as the tumor progressed towards resistance, ER levels decreased and 
signaling via the MAP kinase pathway was up regulated [128]. Therefore, resistance towards 
letrozole seems to depend on increased hormone-independent signaling through growth factor 
receptors. An in vitro study has shown that resistance towards the steroidal AI exemestane may 
occur via activation of EGFR by the ligand amphiregulin, leading to MAPK pathway activation 
resulting in cell proliferation in an ER dependent manner [123]. Signaling mechanisms important for 
endocrine resistance are shown in figure 13 below.  
 
 
Figure 13: Signaling Mechanisms Important for Endocrine Resistance. The figure shows signaling pathways 
important for endocrine resistance and which are currently targeted in clinical trials, combined with aromatase 
inhibitors. (1) IGF1 or IGF1-R neutralizing antibodies. (2) HER-2 blocking therapy (e.g. trastuzumab). (3) Inhibitors of 
PI3K/Akt and/or mTOR pathway. (4) Src inhibitors. (5) AMPK activator. (6) Inhibitors of Ras-Raf-MEK-MAPK pathway. 
(7) Gamma secretase inhibitor. (8) HDAC inhibitors. (9) CDK 4/6 inhibitor. Modified from [129].  
 
Clinical studies have shown that combination of an AI and a kinase inhibitor enhances clinical benefit 
in patients with breast cancer, e.g. the Bolero study, where combination of exemestane and the 
kinase inhibitor everolimus (an mTOR inhibitor) demonstrated increased efficacy compared to 
exemestane alone with respect to progression-free survival in postmenopausal women with 
hormone receptor positive breast cancer [130]. Furthermore, a clinical study has shown that 
combination of letrozole and the EGFR/HER2 inhibitor lapatinib improves progression-free survival in 
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patients with metastatic breast cancer [131]. By combining AIs with kinase inhibitors or signal 
transduction antagonists, more efficient treatment may be obtained.  
 Anti-estrogen Resistance 1.8.2
ER co-repressors and co-activators, which directly influence the balance of agonistic versus 
antagonistic effect of tamoxifen, are critical in determining the endocrine sensitivity. Reduced 
expression level of the co-repressors NCoR-1 was observed in tamoxifen resistant breast cancer cells 
and has been associated with significantly shorter relapse free survival in postmenopausal women 
treated with tamoxifen [132, 133]. Based on this, transcriptional activation of ER depends on co-
regulators and the up or down regulation of these might interfere with tamoxifen sensitivity and 
subsequently lead to resistance. Tamoxifen resistance can also be caused by overexpression of HER2 
which leads to increased cross talk between ER and the HER2 signaling pathways, thus activating ER 
in an estrogen independent manner [134].  
As mentioned earlier, the anti-estrogen fulvestrant is a pure estrogen antagonist and ER is down 
regulated upon treatment with fulvestrant. Due to this, resistance mechanisms towards fulvestrant 
cannot include crosstalk with the ER. Acquired resistance towards fulvestrant has been found to be 
associated with changes in e.g. the HER signaling system with increased levels of the HER1-3 and loss 
of HER4. Expression of HER ligands and activation of ERK 1/2 has also been shown to be increased 
[135, 136]. Furthermore, the PI3K/Akt pathway has demonstrated to be involved in fulvestrant 
resistance [137].  
 Model Systems for Endocrine Therapy  1.9
Breast cancer cell lines are widely used as model systems to explore the molecular mechanisms 
involved in cell growth and cell death. The cell lines derive from patients and functions as simple in 
vitro models. As important as these cell models are, they are not without limitations. Since breast 
cancer is a heterogeneous disease [138, 139], model systems do not necessarily mimic the actual 
mechanisms occurring in a patient. The model system used in the thesis is based on the endogenous 
aromatase production. Many tumors require estrogen from outside the cell and in this model system 
it is no possible to examine this situation. Other limitations using this model system is lack of the 
opportunity to study interactions with other cell types. Most AI-resistant cell models are with 
epithelial breast cancer cells, which express high levels of aromatase. However, in breast tissue, the 
stromal cells surrounding the epithelial cells also express aromatase and by focusing the in vitro 
studies solely with epithelial cells, the paracrine effects contributed by stromal cells in the breast 
tissue will be overlooked [140]. Results from in vitro breast cancer cell models should be taken with 
great caution and tested in translational research to disclose the clinical relevance.  
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 Model System for Estrogen Dependent Breast Cancer 1.9.1
The MCF-7 cell line is one of the most investigated ER+ breast cancer cell lines. It is derived from a 
female patient with metastatic breast cancer [141] and is an ER+, PgR+ and HER2- (non-amplified) 
cell line, which displays estrogen responsive cell growth [142]. The cell line can either be grown in 
vitro in cell cultures or as xenotransplants in athymic nude mice [143]. The MCF-7 cells used in this 
thesis were adapted to grow in medium with 1% serum (1% FBS) in order to mimic the estrogen 
concentration measured in serum of postmenopausal women [144].   
 Model System for Aromatase Inhibitor Resistant Breast Cancer  1.9.2
To study the mechanisms involved in AI resistance, two different model systems can be used; Long-
term estrogen deprived (LTED) breast cancer cell models [145-147] and models for acquired AI 
resistance [124, 127]. The LTED cell models are established by transfer of MCF-7 cells from growth 
medium with FBS, which contain estrogen compounds, to medium with steroid-stripped serum or 
serum-free medium, thereby selecting cells which can grow estrogen independently [144]. This 
model system mimics the situation in patients treated with an AI, in which the breast cancer cells do 
not express endogenous aromatase. However, breast cancer cells often express endogenous 
aromatase [36, 41] and are thus able to convert circulating androgens to estrogens. In order to mimic 
this situation, models with endogenous estrogen synthesis have been established by ectopic 
expression of the aromatase gene (CYP19A1) [50] where endogenous aromatase activity is obtained 
by estrogen stimulated growth by conversion of androgen to estrogen. By long-term treatment with 
an AI, cell lines with acquired resistance to AIs have been established [124, 127].  
 
At the Breast Cancer Group there has been established culture conditions for the MCF-7 cell line, 
where cell growth can be stimulated by androgen (testosterone) conversion to estrogen (estradiol) 
via the endogenous aromatase enzyme [148, 149]. The parental MCF-7 cell line normally grows in 
medium supplemented with 1% FBS, where the growth rate is close to maximum [144]. To gain 
estrogen stimulated cell growth, a medium without or with a low level of estrogen is required. 
Newborn calf serum (NCS) contains very low levels of estrogen compounds [149], and in medium 
with 10% NCS, growth stimulation can be gained with estradiol or with testosterone via conversion 
to estradiol by the endogenous aromatase enzyme [149]. By using these conditions, under which cell 
growth is dependent on aromatase mediated conversion of testosterone to estradiol, AI resistant cell 
lines have been established by outgrowth of selected clones surviving continuous treatment with 
high dose of the third generation AI letrozole and exemestane. Cell lines resistant to the third 
generation AI anastrozole and the second generation AI formestane have also been established. 
These AI resistant cell models are useful tools to explore the molecular mechanisms for AI resistance.
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2 Aim  
The aim of this Master Thesis was to unravel molecular mechanisms for breast cancer cell lines 
resistance to aromatase inhibitors (AIs) to identify targets for treatment. Two cell lines resistant to 
the non-steroidal AI letrozole (LetR-1 and LetR-3), two cell lines resistant to the steroidal AI 
exemestane (ExeR-1 and ExeR-3) and the parental cell line MCF-7 were characterized with respect to 
growth properties and expression of selected proteins. Furthermore, a kinase inhibitor screen was 
used to identify potential treatment targets and molecular resistance mechanisms. 
 
More specifically, the goals were: 
1) To study the growth properties of the AI resistant cell lines and the parental MCF-7 cell lines, 
with respect to response to testosterone, to treatment with the AIs letrozole and 
exemestane, and to treatment with the anti-estrogens tamoxifen and fulvestrant. 
2) To determine the expression level of ER, estrogen regulated proteins, HER receptors and 
downstream signaling kinases in the resistant cell lines as well as the parental cell line. 
3) To perform a kinase inhibitor screen to identify kinases driving growth of the AI resistant cell 
lines.  
4) To validate a selection of the identified kinase inhibitors; by dose-response growth 
experiments and cell cycle analyses, to explore the potential as new treatment for AI 
resistant breast cancer cells.  
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3 Materials and Methods  
As mentioned before, one parental cell line, two cell lines resistant to the non-steroidal AI letrozole 
and two cell lines resistant to the steroidal AI exemestane were utilized in this Master Thesis. The 
parental cell line was MCF-7, the two non-steroidal AI resistant cell lines were LetR-1 and LetR-3 and 
the two steroidal AI resistant cell lines were ExeR-1 and ExeR-3. The methods and the materials used 
in the investigations are described in the next sections.  
 Cell Culturing 3.1
The parental MCF-7 cell line and the AI resistant cell lines are cultured differently. Their standard 
culturing conditions are given in the next paragraphs.  
 The Parental MCF-7 Cell Line  3.1.1
The MCF-7/S0.5 (MCF-7) cell line was obtained from the Human Cell Culture Bank (Mason Research 
Institute) and has been gradually adapted to grow at a low serum concentration [144] in order to 
mimic the estrogen concentration measured in serum of postmenopausal women [150]. The cells 
were routinely propagated in T25 NunclonTM ∆ flasks (Nunc, Thermo Fisher Scientific, Roskilde, 
Denmark) in 5 ml phenol-red free Dulbecco’s Modified Eagles Medium/Ham’s F12 (DMEM/F12) 
(Gibco, Invitrogen). The standard growth medium was DMEM/F12 supplemented with 1% heat 
inactivated Fetal Bovine Serum (1% FBS) (Perbio, ThermoFisher Scientific, Batch no. 140), 2.0 mM 
GlutaMAXTM-I (Gibco, Invitrogen) and 6 ng/mL insulin (Sigma-Aldrich, St. Louis, MO, USA). Passage of 
the cell line was performed once a week by washing the cells twice in 1 mL trypsin (Gibco, Invitrogen) 
and incubating for 6 minutes (min) at 37 °C. Cells were resuspended in 5 mL standard growth 
medium and cell number was manually determined by counting the cells using a Bürker-Türk 
chamber. Cells were seeded at densities ranging from 1.0-1.2x105 in T25 flasks (Nunc), kept at 37 °C 
in a humid air incubator with 5% CO2 and the medium was renewed with standard growth medium 
every second to third day. In all experiments (except that testing growth stimulation with estradiol 
and testosterone) cells were seeded in 1% FBS and then switched to 10% Newborn Calf Serum (10% 
NCS) (Gibco, Life Technologies, Batch no. 8122180) or 10% NCS + testosterone (10-7M) (Sigma-
Aldrich) on day 1. 10% NCS contains proteins, such as albumin, which can bind growth factors and 
has a low content of estrogen [151]. As mentioned earlier, addition of testosterone leads to 
production of estradiol and thus growth of the breast cancer cells. Penicillin 2.5x10-4 U/L and 
streptomycin 2.5x10-4 µg/mL (P/S) (Gibco, Invitrogen) were added to the growth medium in all 
experiments.  
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 Aromatase Resistant Cell Lines  3.1.2
 Letrozole Resistant Cell Lines 3.1.2.1
The letrozole resistant cell lines were obtained from MCF-7 cells seeded in 1% FBS and then shifted 
to 10% NCS with testosterone (10-7M) (MCF-7/S0.5/10N/T). When the letrozole resistant cell lines 
were established, the MCF-7/S0.5/10N/T cells were treated with letrozole (10-6M) (Selleck Chemicals, 
Münich, Germany) for one week and then the culture was trypsinized and seeded in multiwell dishes 
with different amounts of cells, ranging from 20 cells per well to 640 cells per well. Isolated single 
colonies of growing cells were found in the wells seeded with 40 or 80 cells per well. After about one 
month, surviving colonies could be isolated and after further 1.5 months, isolated colonies were 
established as cell lines which could be passaged weekly. The passage was performed in the same 
way as passage of the MCF-7 cell line. These cell lines could now be called resistant to letrozole, 
because they could grow continuously in the presence of letrozole and had a split ratio close to the 
parental cell line (A.E. Lykkesfeldt, unpublished data). The establishment of the letrozole resistant 
cell lines is shown in Appendix 5.  
Standard growth medium consisted of DMEM/F12 supplemented with 10% NCS, 2.0 mM 
GlutaMAXTM-1 and 6 ng/mL insulin. Since the parental cell line MCF-7 was cultured with testosterone 
(10-7M), the letrozole resistant cell lines were also cultured in standard medium with testosterone 
(10-7M) in addition to letrozole (10-6M). However, in some experiments the letrozole resistant cell 
lines was seeded in 10% NCS only. The two letrozole resistant cell lines used in this thesis were from 
two different clones and were called MCF-7/S0.5/10N/T/LetR-1 (LetR-1) and MCF-7/S0.5/10N/T/LetR-
3 (LetR-3). In all experiments P/S were added to the standard medium.  
 Exemestane Resistant Cell Lines  3.1.2.2
The exemestane resistant cell lines were also obtained from the MCF-7/S0.5/10N/T. To establish 
these cell lines, MCF-7/S0.5/10N/T cells were treated with exemestane (10-7M) (Selleck Chemicals) 
for one week and the culture was trypsinized and seeded in multiwell dishes with different amounts 
of cells from 20- to 640 cells per well. Isolated colonies of growing cells were found in the wells 
seeded with 20, 40 or 80 cells/ well. It took about one month before surviving colonies could be 
isolated and further 1.5 months before the isolated colonies were established as cell lines which 
could be passage weekly. The passage was performed in the same way as passage of the MCF-7/S0.5 
cell line. These cell lines were called resistant to exemestane, because they could grow continuously 
in the presence of exemestane (A.E. Lykkesfeldt, unpublished data). The establishment of the 
exemestane resistant cell lines is shown in Appendix 5.  
Standard growth medium consisted of DMEM/F12 supplemented with 10% NCS, 2.0mM 
GlutaMAXTM-1 and 6 ng/mL insulin. The exemestane resistant cell lines were cultured in standard 
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medium with testosterone (10-7M) in addition to exemestane (10-7M). However, in some 
experiments the exemestane resistant cell lines was seeded in 10% NCS only. The two exemestane 
resistant cell lines used in this thesis were from two different clones and were called MCF-
7/S0.5/10N/T/ExeR-1 (ExeR-1) and MCF-7/S0.5/10N/T/ExeR-3 (ExeR-3). In all experiments P/S were 
added to the standard medium.  
 Crystal Violet Colorimetric Assay 3.2
Crystal violet is a cationic dye which binds DNA and negatively charged proteins. After having treated 
the cell lines for five days, a crystal violet colorimetric assay was performed, which was based on a 
linear correlation between staining intensity and cell number [152]. The staining was used to 
measure the number of remaining cells after different treatments. If there was a reduction of cell 
number, this could be due to inhibition of cell growth, or induction of cell death and/or cell cycle 
arrest. To investigate whether wash with 1% Phosphate Buffered Saline (1% PBS) before crystal violet 
staining was necessary, an optimization experiment was performed, see appendix 1. Based on this 
experiment, following experiments were performed with 1 x 1% PBS wash before coloring. The 
growth medium was gently removed by pipetting and the cells were washed in 1% PBS. After wash, 
cells were stained with 0.5% crystal violet (w/v) (Sigma-Aldrich) in solution with 25% methanol (BDH 
Prolabo, VWR, Batch.no 08K180508) for 10 min at room temperature (RT). Cells seeded in a 96-well 
plate were added 100 µL staining solution, while cells seeded in a 24-well plate were added 250 µL. 
Excess dye were gently removed by pouring the wells and the plate was rinsed in tap water. The 
wells were allowed to dry overnight (ON) before the crystal violet solution was dissolved in citrate 
buffer with shaking for 30 min at RT. 125 µL citrate buffer was used for 96-well plates and 500 µL was 
used for 24-well plates. The citrate buffer was made of 0.1M sodium citrate-dihydrate (Sigma-
Aldrich) in solution with 50% EtOH. Wells with visible dark blue color were diluted 5X. The color 
density was measured by a spectrophotometer, Multiscan Ex Platereader (Thermo Electron 
Coorporation, Waltham, MA, USA) at 570 nm, giving optical density (OD) values. Cell growth was 
expressed as percent of cells compared to vehicle (10% NCS or 10% NCS + testosterone (10-7M)) 
treated controls and statistical analyses were performed on all results as described in section 2.6.  
 Western Analysis 3.3
Western blotting (WB) is a technique used to detect e.g. specific proteins in a given sample. The 
proteins are separated by gel electrophoresis (SDS-PAGE) according to molecular weight and can 
then be transferred to a membrane where they are added antibodies specific to the target protein. 
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 Seeding of Cells, Treatment and Harvesting 3.3.1
The cells were seeded in 6-well plates (Nunc) at densities ranging from 4.0-5.0x105 cells/well, with 2 
mL medium in each well. The parental cell line and the four resistant cell lines differ slightly in growth 
characteristics. Therefore seeding densities were adjusted trying to obtain similar cell densities at the 
time of treatment, aiming at a maximum of 80% confluence at the end of the experiment. The AI 
resistant cell lines were cultured in standard growth medium containing 10% NCS (added P/S), 
testosterone (10-7M) and letrozole (10-6M) (for LetR-1 and LetR-3) or exemestane (10-7M) (for ExeR-1 
and ExeR-3). Note that testosterone along with letrozole or exemestane was withdrawn (for most 
experiments) one week before the experiments were started. The parental cell line MCF-7, were 
cultured in standard growth medium (1% FBS) with P/S. The day after seeding medium was switched 
to 10% NCS or 10%NCS + testosterone (10-7M). Medium was renewed on the second and fifth day. 
Two days after seeding, cells were treated with testosterone (10-7M), estradiol (10-12M), letrozole (10-
6M) or exemestane (10-7M) for study of growth properties. For validation of hits from the kinase 
inhibitor screen, cells were treated with selected kinase inhibitors (see section 2.5). The controls 
were added 10% NCS + testosterone (10-7M) + 0.1% DMSO + 0.1% ethanol (EtOH). Following five days 
of treatment, the cells were washed with 1% PBS and lysed in 40-100 μL radioimmunoprecipitation 
buffer (RIPA buffer) on ice for 10 min. The volume of RIPA buffer was adjusted according to the 
confluence of the cells. The more confluent, the more RIPA buffer was used. RIPA buffer contained 
100 mM sodium chloride (J.T. Baker), 20 mM Tris-HCL (pH 8.0) (Applichem) 1% (v/v) Triton X-100 
(Sigma-Aldrich), 0.5% (w/v) sodium dodecyl sulphate (SDS) (Sigma-Aldrich) and 1 mM (w/v) ethylene 
diamine tetraacetic acid (EDTA) (Merck, Darmstadt, Germany). Before use, the RIPA buffer was 
added 1 nM dithiothreitol (DTT) (Sigma-Aldrich), 1 mM sodium fluoride (Sigma-Aldrich), 100 μM 
sodium orthovanadate (Sigma-Aldrich), 150 μM phenylmethylsulphonyl fluoride (PMSF) (Sigma-
Aldrich) and 1pill/10 mL Complete Mini Protease Inhibitor Cocktail (Roche, Indianapolis, IN, USA). 
After adding RIPA buffer, cell lysates were collected and transferred to eppendorf tubes (Almeco cm-
lab A/S, Esbjerg, Denmark). The tubes were centrifuged for 30 min at 15,000 g at 4°C and 
supernatants were collected and stored at -80 °C until use. During protein measurement and sample 
preparation cell lysates were kept on ice. 
 Measurement of Protein Concentrations in Cell Lysates 3.3.2
The lysates were diluted 1:10 or 1:15 depending on protein quantity. The total protein 
concentrations were determined using a Bio-Rad Protein Assay (Bio-Rad Laboratories, Munich, 
Germany) according to the manufacturer's instructions. The assay utilizes the principle of the 
Bradford protein assay to measure the concentration of soluble proteins. The dye, coomassie brilliant 
blue, binds to aromatic amino acid residues of the proteins which results in a shift in the absorbance 
MATERIALS AND METHODS 
45 
 
from 465 nm to 595 nm and thereby the protein concentration can be analyzed 
spectrophotometrically at 595 nm [153]. For each experiment, protein standards (25, 50, 100, 200, 
300, 400, 800 μg/mL Bovine Serum Albumin, purity ≥ 96%) (Sigma Aldrich) were measured and a 
standard curve was made to deduce the protein concentrations of the cell lysates. 
 Sample Preparations 3.3.3
Samples were prepared with cell lysate equivalent to 12-20 μg total protein. All samples were 
adjusted to the same volume with RIPA buffer and XT sample buffer (Bio-Rad Laboratories) 
corresponding to one fourth of the total sample volume was added. 
 SDS-PAGE 3.3.4
The samples were heated for 2 min at 96 °C, spun down and loaded on a 3-8% Criterion™ XT Tris-
acetate precast polyacrylamide gel (Bio-Rad Laboratories) together with the molecular weight 
protein markers; PageRuler™ Pre-stained Protein Ladder and PageRuler™ Unstained Protein Ladder 
(Fermentas Life Sciences, Burlington, Canada). 6-10 µL of each protein marker was loaded on each 
gel. To separate the proteins by their molecular weight the gel was run at 150 volt for 60 min in XT 
BioRad tricine running buffer (Bio-Rad Laboratories) diluted 1:20 in milli-Q water.  
 Wet Electroblotting 3.3.5
Proteins in the 3-8% gel were transferred onto a polyvinylidene fluoride Immunobilon-P membrane 
(Millipore, Bedford, MA, USA) by using wet electroblotting. Before use, the membrane was soaked in 
96% EtOH for 2 min and equilibrated in transfer buffer. The transfer buffer contained 15.2 g/L tris-
base (VWR), 72 g/L glycine (Merck), and 20% EtOH. Criterion™ Blotter Filter Paper (Bio-Rad 
Laboratories) was used for transfer. The transfer stack was arranged in following order from cathode 
to anode: sponge, filter paper, gel, membrane, filter paper, sponge. Wet blotting was performed in 
cold transfer buffer at 30 volt for 60 min. After transfer, the membrane were dyed in 0.1% (w/v) 
Ponceau S solution (Sigma-Aldrich) for 15 min, decolorized 2 times for 5 min in 5% (v/v) acetic acid 
solution (Sigma-Aldrich) and left in fume hood to dry.   
 Antigen Detection 3.3.6
The membrane was activated in 96% EtOH for 10 seconds and washed twice in Tris-Buffered Saline 
(TBS) for 10 min at RT. Subsequently unspecific binding was blocked by treatment with blocking 
buffer for one hour at RT. Blocking buffer consists of 5% (w/v) non-fat dried milk (Irma), 5% FBS and 
0.2% (v/v) Tween 20 (Merck) in TBS. Following blocking, the membrane was incubated with primary 
antibody diluted in blocking buffer on a shaking table ON at 4 °C. Table 2 shows detailed antibody 
information. 
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Table 2: Primary Antibodies used for Western Analysis. Antibodies used for western analysis listed in alphabetical 
order. Molecular weight (Mw).  
Antigen  Mw (kDa) Antibody Dilution Company  Catalog# 
Akt  60 Polyclonal, rabbit 1:2000 CST
a 
9272 
p-Akt (Ser473) 60 Monoclonal, rabbit 1:1000 Invitrogen
b 
44-621G 
Aromatase (CYP19)  55 Monoclonal, mouse, IgG 1:250 Acris
c 
SM2222PS 
Aurora A 48 Monoclonal, rabbit 1:1000 CST 4718 
Aurora B 40 Monoclonal, rabbit 1:1000 CST 3094 
p-Aurora A (Thr288)/  
p-Aurora B (Thr232)/ 
p-Aurora C (Thr198) 
48, 40, 25 Monoclonal, rabbit 1:2000 CST 2914 
Bcl-2 26 Monoclonal, mouse 1:2000 DAKO
d
 M0887 
EGFR 170 Monoclonal, mouse 1:500 DAKO M7298 
ER 67 Monoclonal, rabbit  1:5000 NEOM
e 
RM-9101 
ERK1/2 42 + 44 Polyclonal, rabbit 1:2000 CST 9102 
p-ERK1/2 (Thr202/Tyr204) 42 + 44 Monoclonal, rabbit 1:1000 CST 4377 
HER4 180 Monoclonal, rabbit 1:500 CST 4795 
Hsp70 70 Monoclonal, mouse 1:500.000 NEOM MS-482-PO 
IGF1-Rα 130 Polyclonal, rabbit 1:500 Santa Cruz
f 
SC-712 
PgR B/A 116 + 81 Polyclonal, rabbit  1:2000 NEOM RM-9102 
β-actin 42 Monoclonal, mouse, IgG1 1:500.000 Sigma
g
 A5441 
a
(Cell Signaling Technology, Danvers, MA, USA), 
b
Life Technologies (Invitrogen),  
c
Acris, Herford, Germany, 
d
(Dako, Glostrup, Denmark), 
e
(Neomarkers, Fremont, CA, USA), 
f
(Santa Cruz Biotechnology, Santa Cruz, CA, 
USA), 
g
(Sigma-Aldrich, St. Louis, MO, USA).   
 
Following incubation the membrane was washed four times for 15 min at RT with 0.1% Tween 20 in 
TBS (TBS-tween) and incubated with horse radish peroxidase (HRP) conjugated secondary antibody 
diluted in blocking buffer for 1 hour at RT. Washing was performed five times for 10 min at RT with 
TBS-tween. The secondary antibodies were polyclonal rabbit anti-mouse HRP linked 
immunoglobulins diluted 1:2000 (Dako, Cat #P026, Glostrup, Denmark) and polyclonal goat anti-
rabbit HRP linked immunoglobulins diluted 1:2000 (Dako, Cat #P0448). The investigated proteins 
were visualized by incubating the membranes in the chemiluminescent HRP substrate ECL plus (GE 
healthcare, Waukesha, WI, USA) for 2 min at RT, followed by detection by the Image Reader LAS-
1000 (Fuji Film, San Jose, CA, USA). The signals were handled in Image Gauge V2.2 software (Fuji 
Film). If only one protein had to be detected on the membrane, the membrane was washed with 
TBS-tween for 10 min at RT, wrapped in plastic and stored at 4 °C. If desired to detect more than one 
protein, the membrane was washed with TBS-tween and incubated with Re-blot Plus, Mild Stripping 
Solution (Millipore, Cat #: 2504) for 10 min at RT, according to manufactures instructions. After 
stripping, the membrane was washed twice in blocking buffer for 5 min at RT followed by incubation 
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of a primary antibody ON at 4 °C. The membrane was then treated as described from the top of this 
section.  
 Functional Kinase Inhibitor Screen 3.4
To identify kinases driving growth of AI resistance cell lines (LetR-1, LetR-3, ExeR-1 and ExeR-3) the 
Selleck Chemicals Kinase Inhibitor Screening Library (96-well) (Selleck Chemicals) containing 195 
kinase inhibitors, was applied to the parental cell line (MCF-7) as well as the four AI resistant cell 
lines. The 195 kinase inhibitors were pre-dissolved in DMSO at a concentration of 10 mM and prior to 
screening; all inhibitors were diluted to 1 mM in DMSO. The kinase inhibitors are listed in appendix 8 
and screen setup is illustrated in appendix 9.  
 Seeding of Cells and Treatment 3.4.1
To estimate how many cells should be seeded per well of the parental cell line and the four resistant 
cell lines, optimization experiments were performed, see Appendixes 2-4. For the kinase inhibitor 
screen 2000 cells/well of MCF-7 and 500 cells/well of LetR-1, LetR-3, ExeR-1 and ExeR-3 were seeded in 
100 μL standard growth medium plus P/S in 96-well white plates (nunc). There was also seeded one 
clear plate with MCF-7 and AI resistant cells to check for possible infections. The cells were allowed 
to adhere for two days before additional 100 μL experimental medium containing the kinase 
inhibitors was given, resulting in a final concentration of 1 µM for each of the kinase inhibitors. The 
samples treated with kinase inhibitors were distributed over three 96-well plates for each cell line 
and all plates contained 6-10 internal control samples treated with vehicle (0.1% DMSO). On day 3 of 
the experiment, 100 µL medium was removed from each well and renewed.  
 Cell Viability Assay 3.4.2
After 5 days of treatment with the kinase inhibitors, cell number was measured by using CellTiter-
Glo® Reagent (CTGR) (Promega Corporation, Madison, WI, USA). 100 μL experimental medium was 
removed and replaced by 50 μL CTGR. CTGR is a blend of CellTiter-Glo® Buffer (Promega) and 
lyophilized CellTiter-Glo® substrate (Promega). Ultra-GloTM Recombinant Luciferase present in the 
CTGR catalyzes the mono-oxygenation of Beetle luciferin to oxyluciferin in the presence of 
magnesium and adenosintriphosphate (ATP). CTGR also induce cell lysis and the luminescent end 
product oxyluciferin can thus be recorded by a luminometer. Since the amount of ATP generated by 
the cells is proportional to cell number when investigating up to 50,000 cells/well [154], cell number 
could be determined. The luminescent signal was allowed to settle for 10 min before measurement 
on a Varioskan Flash platereader (Thermo Electron Coorporation, Waltham, MA, USA). The growth 
inhibitory effect of the individual kinase inhibitors was calculated relative to the internal control 
samples on each plate, followed by a calculation of the fold change relative to the growth of the 
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parental cell line. When there was a two-fold or higher inhibition of the resistant cell lines compared 
to the parental cell line, the kinase inhibitor was found to be a hit.  
 Validation Studies for Selected Kinase Inhibitors 3.5
Kinase inhibitors further used for validation studies were AZD5438, A-674563, JNJ-7706621, gefitinib 
(Iressa), WP-1130 and barasertib (Selleck Chemicals). Cells were seeded in 24-well plates in their 
standard growth medium with 8000 cells/well. The day after seeding, MCF-7 cells were switched 
from 1% FBS to 10% NCS + testosterone (10-7M). On day 2, cells were treated with the selected 
kinase inhibitor with concentrations of 0.5, 1.0 and 1.5 µM. After 5 days of treatment crystal violet 
assay was performed as described in section 2.2. 
 Flow Cytometric Analysis 3.5.1
Flow cytometry is a method which can be used for measuring and quantifying cellular characteristics, 
organelles and/or structural components. In the flow cytometer each cell passes through a chamber 
one at a time while they are excited by the beam of at least one laser. In this way, each cell can be 
measured individually, and the signals can be collected for analysis. The distribution of the cells in the 
different cell cycle phases can be determined by measuring the amount of DNA in each cell. The DNA 
content of a cell duplicates during the S phase and by measuring the amount of DNA in a cell, it is 
possible to determine its position in the cell cycle. The DNA can be stained by the nucleic acid dye 
propidium iodide (PI) after the cell membrane has been made permeable by ethanol and the DNA 
content for each individual cell can then be measured by flow cytometry [155]. Because of time 
limitation, only LetR-1 and ExeR-1 as well as the parental cell line were chosen to be investigated 
further.  
 Cell Cycle Analysis 3.5.1.1
For cell cycle analysis, cells were seeded in 6-well plates with 4.5×104 cells/well for the parental cell 
line MCF-7 and 4.0 ×104 cells/well for the AI resistant cell lines LetR-1 and ExeR-1. All cells were 
seeded in their standard growth medium +P/S and were allowed to grow and adhere for 5 days 
before treatment. For each cell line, treatment was done with 1 µM AZD5438, 1 µM A-674563, 1 µM 
JNJ-7706621 or 1 µM barasertib for 1, 24 and 48 hour(s). Control sample was treated with 0.1% 
DMSO for 48 hours prior to analysis. After treatment, cells were washed in 1 mL PBS, which was 
collected in tubes together with the growth medium (10% NCS). For achieving single cells the cells 
were trypsinated 20 min at 37 °C by adding 300 μL trypsin (Gibco, Invitrogen) and were spun down  
for 5 min at 200 g. Pellets were resuspended in 1 mL ice cold EtOH to permeabilize the cells and were 
kept in -20 °C ON. The day after, cells where spun down for 5 min at 200 g and the pellet was 
resuspended in 400 μL PBS containing 20 μg/mL PI (Sigma-Aldrich) and 40 μg/mL RNaseA (Roche) 
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and were incubated in the dark for 30 min at RT. RNaseA acts by removing RNA from the cells and 
thereby prevent RNA staining and subsequent artifacts [156]. A FACSCalibur flow cytometer (BD 
Biosciences, San Jose, CA, USA) was used to analyze cell cycle distribution and phase fractions were 
measured with CellQuest Pro software (BD Biosciences). The flourochrome components from PI were 
excited at 536 nm and the emission along with the light scatter could be recorded at 517 nm. 10,000 
cells were analyzed per sample. MCF-7, LetR-1 and ExeR-1 cells were also seeded in additional 6-well 
plates to measure protein expression. All cells were seeded in their standard growth medium +P/S 
and were allowed to grow and adhere for five days before treatment. Treatment was the same as 
treatment for cell cycle analysis described above, except treatments were done for 1 and 24 hour(s). 
After treatment cells were harvested in RIPA buffer and subjected to western analysis, as described 
in section 2.3, to investigate the protein expression of phosphorylated and total Aurora kinases, 
phosphorylated and total Akt and phosphorylated and total Erk 1/2.  
 Transient Knockdown utilizing Short Interference RNA (siRNA) 3.5.2
To investigate the effect of Aurora A on growth, the protein was knocked down utilizing siRNAs. 
siRNA was transferred to the cells by nucleofection, which is a non-viral method to transfer 
substrates, such as siRNA, into mammalian cells. Nucleofection utilizes electroporation where an 
electric pulse generates areas of cell membrane break down by which siRNA can enter the cytoplasm 
and nucleus [157]. 
 Nucleofection  3.5.2.1
Knockdown of Aurora A was performed with the parental MCF-7 cell line, the letrozole resistant cell 
line LetR-1 and the exemestane resistant cell line ExeR-1. The cells were seeded in T25 flasks at a 
density of about 2.5×105 cells per flask and grown in their standard growth medium. Following 5 days 
of growth the cells were detached with 1 mL AccuMax solution (PAA Laboratories GmbH, Pasching, 
Austria) diluted 1:5 in PBS for 5-10 min at 37 °C, and resuspended in 2-3 mL growth medium. Cell 
number was determined utilizing a Bürker-Türk chamber and cell suspensions equaling 1-1.5×106 
cells were transferred to eppendorf tubes, centrifuged 2 min at 200 g at RT and supernatants were 
discarded. Pellets were resuspended in 100 μL Cell Line Nucleofector Solution V (Amaxa, Lonza, 
Cologne, Germany) and siRNAs were added. An Aurora A-targeting siRNA (Sigma-Aldrich, cat. 
#SASI_Hs01_00079240) and a MISSION® siRNA Universal Negative Control #1 (Sigma-Aldrich, cat. 
#SIC001) were used. Cells were transfected with 300 nM siRNA in the 100 µL volume. The cells were 
transferred to an electroporation cuvette (Sigma-Aldrich) and nucleofected on the Nucleofector II 
Device (Amaxa) according to the manufacturer’s instructions. Following nucleofection, the cuvette 
was flushed in growth medium and the solution was transferred to 15 mL growth medium in a 15 mL 
tube (SARSTEDT, Nümbrecht, Germany). Transfected cells were seeded in 6-well plates to measure 
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protein expression and in 24-well plates to measure cell growth. Medium was replaced at day 1 with 
the cell line specific standard growth medium for LetR-1 and ExeR-1 and 10% NCS + testosterone (10-
7M) for MCF-7 cells. Two days after transfection, cells from 6-well plates were harvested in RIPA 
buffer and subjected to western analysis, as described in section 2.3, to investigate the protein 
expression of Aurora A. Cells in 24-well plates were stained with crystal violet on day 1, 2, 3 and four 
after transfection, as described in section 2.2, to determine cell number. Cell growth was expressed 
as percent of cells relative to cells transfected with siRNA Universal Negative Control (at day 4).  
 Statistical Analysis 3.6
Statistical analyses were performed on results from the cell growth assays in order to determine 
significant growth inhibition differences between the parental cell line and the AI resistant cell lines. 
For crystal violet staining, the diluted wells were subtracted 0.061 from the OD value and the 
undiluted wells were subtracted 0.112. Data from the experiments are shown and expressed as 
mean +/- standard deviation (SD) as a percentage of controls or as OD value +/- SD. Hereafter, a two-
tailed Student’s T-test was applied followed by Bonferroni’s correction. All statistics were performed 
using Excel (Microsoft, Seattle, CA, USA) and the level of statistical significance was set to p < 0.05, 
indicated by asterisks (*). Statistical analyses were performed on data from the kinase inhibitor 
screen to determine significant differences in inhibition effect between the MCF-7 cell line and the 
LetR-1, LetR-3, ExeR-1 and ExeR-3 cell lines. Inhibition effect was calculated per well by comparing to 
the average of DMSO treated wells (controls) of the given plate. One-tailed Student’s T-test was 
performed on triplicate values comparing parental and resistant cell lines. The level of statistical 
significance was set to p < 0.05, indicated by asterisks (*). Fold changes were calculated by 
comparing mean inhibitory effects on resistant cell lines to the mean inhibitory effect on the parental 
cell line. A volcano plot was generated plotting -log10 (p-value) against log2 (fold change) visualizing 
the data generated. 
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4 Results 
The aim of this thesis was to characterize the molecular basis for resistance to the two different 
types of aromatase inhibitors (AIs); the steroidal and non-steroidal type. Two breast cancer cell lines 
resistant to the non-steroidal AI letrozole (LetR-1 and LetR-3), two breast cancer cell lines resistant to 
the steroidal AI exemestane (ExeR-1 and ExeR-3) and their parental cell line MCF-7 were used. The 
first part of the characterization was to investigate whether the AI resistant cell lines remain 
estrogen responsive and whether they respond to second line endocrine therapy with the anti-
estrogens tamoxifen and fulvestrant, and another type of AI.  The second part was focused on 
discovery of the kinases, which are the main drivers of growth of the AI resistant cell lines. A kinase 
inhibitor library comprising 195 different kinase inhibitors was applied to the resistant cell lines as 
well as the parental cell line. The analyses identified several kinase inhibitors, which exhibited a 
preferential growth inhibition of the resistant cell lines. Six of these kinase inhibitors were selected 
for validation studies, and four of them demonstrated significant growth inhibition of the AI resistant 
cell lines. FACS analysis with these four kinase inhibitors was performed to study the effect on cell 
cycle phase distribution. The Aurora kinase A, which plays an important role in cell cycle regulation, 
was one of the most important kinases responsible for growth of the AI resistant cell lines.  
Therefore, an Aurora A knockdown experiment with MCF-7, LetR-1 and ExeR-1 cells was performed. 
The results of these investigations will be described in the following paragraphs. 
 Growth Stimulation of MCF-7 Cells with Estradiol and Testosterone 4.1
Previous studies have shown that the MCF-7 cell line can be growth stimulated with testosterone in 
medium containing NCS, which is low on estrogen compounds [149]. This growth stimulation occurs 
via conversion of the androgen testosterone to estradiol. In order to confirm these results, dose-
response growth experiments with the parental cell line MCF-7, treated with different 
concentrations of estradiol (A) or testosterone (B), were performed (figure 14). Cells were seeded in 
24-well plates in standard growth medium (1% FBS) and then switched to 10% NCS on day 1. Two 
days after seeding, experimental medium containing the indicated concentrations of estradiol and 
testosterone was added. Following five days of treatment, cell number was determined by crystal 
violet colorimetric assay, where OD value is proportional to cell number. Note that, in this 
experiment, 10% NCS was used as control. 
 
RESULTS 
52 
 
 
 
Figure 14: Growth Response to Estradiol and Testosterone. 8.000 MCF-7 cells were seeded in 24-well plates in 
medium containing 1% FBS. On day 1 the medium was switched to 10% NCS. Experimental medium with 10% NCS, 
containing 0.1% EtOH in control and A) estradiol or B) testosterone in the indicated concentrations were added on 
day 2 and renewed on day 5. Crystal violet staining was performed on day 7. Two independent experiments were 
performed with four sample replicates. Mean cell numbers in percentage of vehicle treated controls and standard 
deviations are shown. Asterisks indicate statistically significant difference from controls.  
 
The results showed that estradiol gave greater growth stimulation than testosterone. There was a 
significant and maximal growth stimulation of MCF-7 cells with a testosterone concentration of 10-
6M and an estradiol concentration of 10-11M. This is in agreement with earlier observations [149]. 
Furthermore, the testosterone-stimulation of MCF-7 cells indicates that endogenous aromatase is 
functional.  
 Growth Response to Letrozole and Exemestane Treatments  4.2
To investigate if the AI resistant cell lines were resistant and if they were responsive to treatment 
with another AI, dose-response growth experiments with letrozole and exemestane for the parental 
cell line as well as the four resistant cell lines were performed. The resistant cell lines were 
withdrawn from testosterone and the respective AI one week before the experiment was started. 
The resistant cell lines were seeded in 24-well plates in 10% NCS medium. MCF-7 was seeded in 24-
well plates in 1% FBS and then switched to 10% NCS on day 1. Two days after seeding, experimental 
medium containing 10% NCS + testosterone (10-7M) and the indicated concentrations of letrozole 
and exemestane was added. Following five days of treatment, cell number was determined by crystal 
violet colorimetric assay. In this experiment and in following dose-response growth experiments, 
10% NCS + testosterone (10-7M) is used as control. Note that 10% NCS + testosterone (10-7M) + 
letrozole (10-6M) is the basal growth medium for the letrozole resistant cell lines and that 10% NCS + 
testosterone (10-7M) + exemestane (10-7M) is the basal growth medium for the exemestane resistant 
cell lines.   
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Figure 15: Growth Response to Letrozole and Exemestane. 8.000 MCF-7 cells were seeded in 24-well plates in 
medium containing 1% FBS. On day 1 the medium was switched to 10% NCS. 11.000-12.000 LetR-1, LetR-3, ExeR-1 and 
ExeR-3 were seeded in 24-well plates in 10% NCS medium. Experimental medium, containing 10% NCS + Testosterone 
(10-7M) with 0.1% EtOH + 0.1% DMSO and A and D) letrozole or B and C) exemestane in the indicated concentrations 
were added on day 2 and renewed on day 5. Crystal violet staining was performed on day 7. Two independent 
experiments were performed with four sample replicates. Mean cell numbers in percentage of vehicle treated 
controls and standard deviations are shown. Asterisks indicate statistically significant effect of AI treatment. 
 
 
Figure 15 depicts cell number relative to vehicle treated controls, when treated with letrozole or 
exemestane with increasing concentrations. The resistant cell lines grows better in 10% NCS than the 
parental MCF-7 cell line. MCF-7, LetR-1, LetR-3 and ExeR-3 were growth stimulated by the androgen 
testosterone. ExeR-1, however, displayed no stimulation by testosterone in the experiment in Figure 
15B, but in most other experiments ExeR-1 was growth stimulated by testosterone with about 2 fold 
as seen in Figure 15D, 16B and 16D. Concentrations of 10-9M-10-6M letrozole and 10-9M-10-6M 
exemestane exerted a dose-dependent inhibition of the testosterone stimulated growth of MCF-7 
cells. Both letrozole and exemestane at concentrations of 10-6M and 10-7M, respectively, completely 
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inhibited the testosterone stimulation of MCF-7 cells. Figure 15A and 15C shows the two letrozole 
resistant cell lines, when treated with increasing concentrations of letrozole and exemestane, 
respectively. For LetR-1, concentrations of 10-7M-10-6M letrozole and 10-6M exemestane significantly 
inhibited the testosterone stimulated growth, and for LetR-3, concentrations of 10-8M-10-6M letrozole 
and 10-6M exemestane significantly inhibited the testosterone stimulated growth.  Figure 15B and 
15D shows the two exemestane resistant cell lines, when treated with increasing concentrations of 
letrozole and exemestane, respectively. For ExeR-1, exemestane did not inhibit growth; however, 
concentrations of 10-8M-10-6M letrozole significantly inhibited the testosterone stimulated growth of 
ExeR-1 cells. For ExeR-3, concentrations of 10-6M exemestane and 10-8M-10-6M letrozole significantly 
inhibited the testosterone stimulated growth. It should be noted that there was a difference in 
growth rate for ExeR-1 cells in experiment performed with an early passage of ExeR-1 (figure 15B), 
compared to experiments performed at a later point (figure 15D, 16B and 16C). Lastly, the AI 
resistant cell lines were far less growth inhibited by letrozole and exemestane compared to the 
parental MCF-7 cell line, and although the resistant cell lines were partially growth inhibited by 
letrozole and exemestane, respectively, they were able to grow continuously in the presence of the 
AIs.  
 Growth Response to Tamoxifen and Fulvestrant Treatments 4.3
To study if the AI resistant cell lines were responsive to anti-estrogen treatment, both the parental 
and the four resistant cell lines were treated with the two anti-estrogens tamoxifen and fulvestrant. 
The resistant cell lines were withdrawn from testosterone and the respective AI one week before the 
experiment was started. Figure 16 shows a dose-response growth experiment with tamoxifen and 
fulvestrant for the parental cell line MCF-7 as well as the four resistant cell lines. The resistant cell 
lines were seeded in 24-well plates in 10% NCS medium. MCF-7 was seeded in 24-well plates in 1% 
FBS and then switched to 10% NCS on day 1. Two days after seeding, experimental medium 
containing 10% NCS + testosterone (10-7M) and the indicated concentrations of tamoxifen and 
fulvestrant was added. Following five days of treatment, cell number was determined by crystal 
violet colorimetric assay.  
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Figure 16: Growth Response to Tamoxifen and Fulvestrant. 8.000 MCF-7 cells were seeded in 24-well plates in 
medium containing 1% FBS. On day 1 the medium was switched to 10% NCS. 11.000 LetR-1, LetR-3, ExeR-1 and ExeR-3 
were seeded in 24-well plates in 10% NCS. Experimental medium containing 10% NCS + Testosterone (10-7M), 0.1% 
EtOH + 0.1% DMSO and A and B) tamoxifen or C and D) fulvestrant in the indicated concentrations were added on 
day 2 and renewed on day 5. Crystal violet staining was performed on day 7. Two independent experiments were 
performed with four sample replicates. Mean cell numbers in percentage of vehicle treated controls and standard 
deviations are shown. Asterisks indicate statistically significant effect of anti-estrogen treatment. 
 
Figure 16 depicts cell number relative to vehicle treated controls, when treated with tamoxifen or 
fulvestrant in increasing doses. The results showed that the parental and the four AI resistant cell 
lines were growth stimulated by testosterone, but growth in 10% NCS alone was higher for the AI 
resistant cell lines compared to MCF-7. The testosterone stimulated growth of MCF-7 cells was 
significantly growth inhibited by tamoxifen concentrations of 10-7M-10-6M and fulvestrant 
concentrations of 10-9M-10-7M. However, only fulvestrant completely annulled the testosterone 
stimulation. Figure 16A and 16C shows the two letrozole resistant cell lines, treated with tamoxifen 
and fulvestrant, respectively. For LetR-1, concentrations of 10-7M-10-6M tamoxifen and 10-9M-10-7M 
fulvestrant significantly inhibited the testosterone stimulated growth. For LetR-3, concentrations of 
10-6M tamoxifen and 10-8M-10-7M fulvestrant significantly inhibited the testosterone stimulated 
growth.  Figure 16B and 16D shows the two exemestane resistant cell lines, treated with tamoxifen 
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and fulvestrant, respectively. For both ExeR-1 and ExeR-3, tamoxifen concentrations of 10-7M-10-6M 
and fulvestrant concentrations of 10-9M-10-7M significantly inhibited the testosterone stimulated 
growth. The parental MCF-7 cell line was growth inhibited by both anti-estrogens; however, 
fulvestrant was most efficient as it completely abrogated the testosterone stimulation. All four AI 
resistant cell lines were only partially growth inhibited by tamoxifen, and fulvestrant exerted growth 
inhibition below the basal growth level for the AI resistant cell lines.  
 Long Term Treatment with Fulvestrant  4.4
To examine if AI resistant cell lines could be propagated in fulvestrant for two weeks, growth of LetR-
1 cells in standard medium (10% NCS medium + testosterone (10-7M) + letrozole (10-6M)) with 
fulvestrant (10-7M) for two weeks was determined. Also, the growth of LetR-1 grown in standard 
medium (10% NCS medium + testosterone (10-7M) + letrozole (10-6M)) for two weeks was 
determined. Figure 17 shows the increase in cell number per week of treatment for LetR-1, both with 
and without fulvestrant treatment. Cells were seeded in T25 flasks in standard growth medium or 
standard growth medium containing fulvestrant. After one week of treatment, cell number for both 
LetR-1 cells grown in standard medium and LetR-1 cells grown in standard medium + fulvestrant was 
determined using a Bürker-Türk counting chamber. Each culture flask was trypsinated and seeded in 
a new T25 flask. LetR-1 cells grown in standard medium was again seeded in standard medium and 
LetR-1 cells grown in standard medium + fulvestrant was again seeded in standard medium + 
fulvestrant. After further one week, cell number was determined by crystal violet colorimetric assay, 
and the increase in cell number per week of treatment is shown in figure 17. The increase in cell 
number per week was based on Nt/No [144], where Nt is number of cell after one week, and No is 
number of cells seeded in a T25 flask.  
 
 
Figure 17: Long Term Treatment of LetR-1 with and without Fulvestrant Treatment. Nt/No = increase in cell number 
in one week. No: Number of cells seeded in a T25 culture flask. Nt: Number of cells after one week. 2.0x105 LetR-1 
cells were seeded in two T-25 flasks, one containing 10% NCS+Testosterone (10-7M)+ Letrozole (10-6M)+ Fulvestrant 
(10-7M) and one containing 10% NCS+ Testosterone (10-7M)+ Letrozole (10-6M). After one and two weeks, 
respectively, cell number was calculated using a Bürker-Türk chamber.  
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After one week, the increase in cell number in the fulvestrant treated LetR-1 cells is severely reduced 
compared to growth in standard medium and after two weeks only a two-fold increase was 
observed.  
 Protein Expression Detected by Western Analysis 4.5
Western analyses were used to determine protein expression of ER, estrogen regulated proteins, 
HER receptors and downstream signalling kinases. One week prior to experiments, testosterone (10-
7M) + letrozole (10-6M) were withdrawn from medium for LetR-1 and LetR-3 cells and testosterone 
(10-7M) + exemestane (10-7M) were withdrawn from medium for ExeR-1 and ExeR-3 cells. This was 
applicable for all samples from the letrozole and exemestane resistant cell lines, except the ones 
called “T+L(10-6) not withdrawn” and “T+E(10-7) not withdrawn” in figure 18,19, 20 and 21 where 
cells were grown continuously in medium containing testosterone and letrozole or testosterone and 
exemestane, respectively. MCF-7 cells were seeded in 1% FBS and then switched to 10% NCS on day 
1 (except the 1% FBS sample). Cells were seeded in 6-well plates and two days after seeding, MCF-7 
cells were treated with testosterone, testosterone + letrozole, testosterone + exemestane and 
testosterone + fulvestrant. However, due to technical difficulties, only MCF-7 cells in 1% FBS, 10% 
NCS, 10% NCS + testosterone + letrozole and 10% NCS + testosterone + fulvestrant was possible to 
examine (in the western blot for LetR-1 and ExeR-1, see figure 18). No band was detected for IGF1-R 
for LetR-3 and ExeR-3 and therefore, IGF1-R is not shown for these two cell lines (figure 19). LetR-1 
and LetR-3 cells were treated with vehicle (10% NCS + 0.1% DMSO + 0.1% EtOH), estradiol (10-12M), 
testosterone and testosterone + letrozole (both with and without withdrawn of testosterone + 
letrozole for one week before onset of experiment). ExeR-1 and ExeR-3 cells were treated with vehicle 
(10% NCS + 0.1% DMSO + 0.1% EtOH), estradiol, testosterone and testosterone + exemestane (both 
with and without withdrawn of testosterone and exemestane for one week before onset of 
experiment). Following five days of treatment, cells were harvested for western analysis. The 
aromatase protein CYP19 was also tried measured, but no visible band was detected (data not 
shown). 
 Protein Expression of ER and Estrogen Regulated Proteins 4.5.1
Western blot analyses was performed to disclose differences in expression of ER and the estrogen up 
regulated proteins progesterone receptor A and B (PgR A and PgR B), insulin-like growth factor 
receptor 1 (IGF1-R) and B-cell lymphoma 2 (Bcl-2), in parental MCF-7 cells and in the AI resistant cell 
lines. Figure 18 shows ER and estrogen up regulated proteins in the MCF-7, LetR-1 and ExeR-1 cell 
lines and figure 19 depicts ER and estrogen up regulated proteins in MCF-7, LetR-3 and ExeR-3 cells.  
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Figure 18: Expression of ER and Estrogen Regulated Proteins in LetR-1 and ExeR-1 Detected by Western Analysis. 
Western blots showing ER and the estrogen up regulated proteins; Bcl-2, PgR A and B and IGF1-R. Proteins are from 
lysates from MCF-7, LetR-1 and ExeR-1. Cells were seeded in 6-well plates in their standard growth medium. On day 1 
MCF-7 cells were switched from 1% FBS to 10% NCS (except the 1% FBS sample). On day 2 cells were treated with the 
indicated substances and concentrations given in Molar (M). In the samples named “T+L 10-6 not withdrawn” and 
“T+E 10-7 not withdrawn”, cells were grown continuously in medium containing testosterone (10-7M) + either 
letrozole (10-6M) or exemestane (10-7M), respectively. Cells were harvested for western analysis on day 7. 12 µg total 
protein were loaded in each lane and heat shock protein 70 (Hsp70) and β-actin were used as loading controls.  
 
 
 
 
Figure 19: Expression of ER and Estrogen Up Regulated Proteins in LetR-3 and ExeR-3 Detected by Western Analysis. 
Western blots showing ER and the estrogen up regulated proteins; Bcl-2 and PgR A and B. Proteins are from lysates 
from MCF-7, LetR-1 and ExeR-1. Cells were seeded in 6-well plates in their standard growth medium. On day 1 MCF-7 
cells were switched from 1% FBS to 10% NCS (except the one 1% FBS sample). On day 2 cells were treated with the 
indicated substances and concentrations given in Molar (M). In the samples named “T+L 10-6 not withdrawn” and 
“T+E 10-7 not withdrawn”, cells were grown continuously in medium containing testosterone (10-7M) + either 
letrozole (10-6M) or exemestane (10-7M), respectively. Cells were harvested for western analysis on day 6. 12 µg total 
protein were loaded in each lane and heat shock protein 70 (Hsp70) and β-actin was used as loading controls. 
 
The western blots showed that the parental MCF-7 cell line generally had a higher expression of all 
proteins in 1% FBS compared to 10% NCS (figure 18 and 19). Estradiol and testosterone up regulated 
the expression of Bcl-2, PgR A and PgR B and both AIs reduced the expression of these proteins to 
the level in the 10% NCS culture. Fulvestrant treated MCF-7 cells expressed hardly detectable level of 
ER and low level of IGF1-R, PgR A and PgR B as in the 10% NCS culture.   
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The AI resistant cells expressed similar level of ER in 10% NCS and in 10% NCS + testosterone + either 
letrozole or exemestane, respectively. The ER level was higher in all AI resistant cell lines compared 
to MCF-7 cells, and estradiol and testosterone down regulated ER expression whereas AI treatment 
resulted in ER level as in the 10% NCS culture. The estrogen up regulated proteins PgR A, PgR B, IGF1-
R and Bcl-2 were up regulated with both estradiol and with testosterone treatments. Where AI cells 
were grown continuously in medium containing testosterone + either letrozole or exemestane, 
respectively, there appeared no major differences from samples where testosterone + either 
letrozole or exemestane were withdrawn for one week before onset of experiment, except PgR A, 
PgR B and Bcl-2, which were lower in LetR-3 cells grown continuously with testosterone and letrozole 
than those withdrawn for one week. The experiment showed that there were some differences 
between the parental MCF-7 cell line and the AI resistant cell lines; AI resistant cells expressed higher 
ER level in the 10% NCS culture than MCF-7 cells. AI resistant cell lines displayed similar expression of 
PgR A, PgR B, Bcl-2 and IGF1-R as MCF-7 cells when treated with estradiol and testosterone and AI 
treatment inhibited the expression of the estrogen up regulated proteins in AI resistant cell lines and 
MCF-7, except in LetR-3 and ExeR-3, in which only PgR A expression was inhibited by the AI.  
 Protein Expression of HER and Downstream Signaling Kinases 4.5.2
Western analyses were performed to investigate expression of HERs like EGFR and HER4, and 
downstream signalling pathways like extracellular signal-regulated kinases (Erk 1/2) and Akt (figure 
20 and 21). Both total and phosphorylated (p) form of Erk 1/2 and Akt were investigated. Due to 
technical difficulties p-Akt and total Akt are not shown for LetR-3 and ExeR-3 (figure 21). 
Unfortunately, the western blot for LetR-3 and ExeR-3 was not particularly good, resulting in 
difficulties to interpret them. The loading control Hsp70 varied a lot between samples in this blot and 
also it seemed like something was missing from the p-Erk 1/2 band, especially in ExeR-3 samples.   
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Figure 20: Expression of HER and Downstream Signaling in LetR-1 and ExeR-1 Detected by Western Analysis. 
Western blots showing the epidermal growth factors EGFR and HER4, total and phosphorylated (p) form of ERK 1/2 
(Thr202/Tyr204) and total and p-form of Akt (Ser473). Proteins are from lysates from MCF-7, LetR-1 and ExeR-1. Cells 
were seeded in 6-well plates in their standard growth medium. On day 1 MCF-7 cells were switched from 1% FBS to 
10% NCS. On day 2 cells were treated with the indicated substances and concentrations given in Molar (M). In the 
samples named “T+L 10-6 not withdrawn” and “T+E 10-7 not withdrawn”, cells were grown continuously in medium 
containing testosterone (10-7M) + either letrozole (10-6M) or exemestane (10-7M), respectively. Cells were harvested 
for western analysis on day 7. 12 µg total protein were loaded in each lane and heat shock protein 70 (Hsp70) and β-
actin were used as loading controls.  
 
 
Figure 21: Expression of HER Receptors and Downstream Signaling in LetR-3 and ExeR-3 Detected by Western 
Analysis. Western blots showing the epidermal growth factors EGFR and HER4 and total and phosphorylated (p) form 
of ERK 1/2 (Thr202/Tyr204). Proteins are from lysates from MCF-7, LetR-1 and ExeR-1. Cells were seeded in 6-well 
multi dishes in their standard growth medium. On day 1 MCF-7 cells were switched from 1% FBS to 10% NCS (except 
the one 1% FBS sample). On day 2 cells were treated with the indicated substances and concentrations given in 
Molar (M). In the samples named “T+L 10-6 not withdrawn” and “T+E 10-7 not withdrawn”, cells were grown 
continuously in medium containing testosterone (10-7M) + either letrozole (10-6M) or exemestane (10-7M), 
respectively. Cells were harvested for western analysis on day 6. 12 µg total protein were loaded in each lane and 
heat shock protein 70 (Hsp70) and β-actin was used as loading controls. 
 
EGFR expression was low in the parental MCF-7 cell line and the exemestane resistant cell lines ExeR-
1 and ExeR-3 whereas increased level of EGFR was seen in LetR-1 and LetR-3 cells, respectively. 
Compared to MCF-7 cells, the expression level of HER4 was reduced in LetR-1 and increased in LetR-3, 
ExeR-1 and ExeR-3. p-Erk 1/2 was higher in MCF-7 cells grown with 10% NCS than in the AI resistant 
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cell lines, and estradiol and testosterone decreased p-Erk 1/2 in MCF-7 cells and increased p-Erk 1/2 
in the AI resistant cell lines. Regarding the effect of estradiol and testosterone on protein expression, 
estradiol appeared to reduce EGFR expression in LetR-1 cells and estradiol and testosterone reduced 
HER4 expression in all AI resistant cell lines. In summary, the most important finding in these western 
analyses was the major increase in EGFR expression in LetR-1 and LetR-3 cells.  
 Kinase Inhibitor Screen  4.6
The AI resistant cell lines LetR-1, LetR-3, ExeR-1 and ExeR-3, as well as the parental cell line MCF-7, 
were utilized to perform two kinase inhibitor screens (one for the letrozole resistant cell lines and 
one for the exemestane resistant cell lines) to identify kinases driving growth of the AI resistant cell 
lines. A kinase inhibitor library comprising 195 different kinase inhibitors was used. Initially, the 
screen was optimized according to number of cells seeded per well (see appendixes 2-4). For both 
screens 2000 MCF-7 cells and 500 of the four AI resistant cells were seeded per well in 96-well plates. 
The four AI resistant cell lines were seeded in their standard growth medium (i.e. medium containing 
10% NCS + testosterone (10-7M) + AI) while MCF-7 cell was seeded in 10% NCS + testosterone (10-
7M). The screens were performed with triplicate samples with 1.0 µM concentration of inhibitors. For 
statistical analysis Student’s T-test was applied. In the screens, an inhibitor was designated as a hit if 
treatment entailed a twofold preferential and significant (p-value < 0.05) growth inhibition of the AI 
resistant cells (LetR-1, LetR-3, ExeR-1 and ExeR-3) compared to the parental MCF-7 cell line. 
 Kinase Inhibitor Screen with LetR-1 and LetR-3  4.6.1
To identify kinases causally involved in letrozole resistance, the parental MCF-7 cell line, as well as 
the letrozole resistant cell lines (LetR-1 and LetR-3), were exposed to the kinase inhibitor screen as 
described above. Figure 22 visualizes a volcano plot of the generated data from the kinase inhibitor 
screen with LetR-1 and LetR-3. In the volcano plot, the y-axis gives the –log10 to the statistical 
significance of the relative growth inhibition of resistant LetR-1 and LetR-3 cells versus parental MCF-7 
cells. The x-axis gives log2 to the relative growth inhibition of the resistant cells versus parental cells. 
The blue box in the figure includes the hits of the kinase inhibitor screen, e.g. the kinases which 
exerted a more than twofold greater inhibition of the resistant LetR-1 and LetR-3 cells compared to 
the parental cells (p<0.05). The hits shown in this box are hits chosen for further validation based on 
clinical relevance.  
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Figure 22: Results from the Kinase Inhibitor Screen for the Letrozole Resistant Cell Lines Visualized in a Volcano 
Plot. Data obtained from the kinase inhibitor screen plottet –log10(p-value) against log2(fold change) results in a 
volcano plot. The blue box includes four kinases (hits) which exerted a more than twofold greater inhibition of the 
letrozole resistant cells (LetR-1 and LetR-3) compared to the parental MCF-7 cells (p<0.05). The hits AZD5438, A-
674563, JNJ-7706621, WP-1130 and barasertib are indicated.  
In total, 14 hits were identified for LetR-1, while 12 kinase inhibitors exhibited a preferential growth 
inhibition of LetR-3. Six of these inhibitors were common hits in the two letrozole resistant cell lines. 
The inhibition effects as well as the targets of these kinase inhibitors are listed in table 3. All results 
from the kinase inhibitor screen can be found in appendix 6. Most of the inhibitors in 1.0 µM 
concentration exerted less than 25% growth inhibition of the parental cell line MCF-7 and only 30, 
30, and 12 of the 195 kinase inhibitors had standard deviations (SD) over 10% in the MCF-7, LetR-1 
and LetR-3 cell lines, respectively. The majority of the identified hits targeted proteins involved in cell 
cycle regulation (Aurora kinases and CDKs) and Akt-signaling. The hits AZD5438, A-674563, JNJ-
7706621, WP-1130, and barasertib, which target CDKs, Akt signaling, Aurora A/B, DUB and Aurora B, 
respectively, were selected for validation studies. Gefitinib, which target EGFR, was not a hit in the 
screen (due to the p-value of 0.054, see table 3) but was, however, also chosen for validation studies 
because of up regulation of EGFR in LetR-1 and LetR-3 cells (figure 20 and 21).  
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Table 3: Data for Hits Identified in the Kinase Inhibitor Screens. Triplicate samples of parental MCF-7 cells and AI 
resistant cells (LetR-1, LetR-3, ExeR-1 and ExeR-3) were treated with 1.0 µM of the indicated kinase inhibitors for 5 
days. Cell number was determined by a cell viability assay. Hits from the screen are indicated in red for the individual 
cell lines. Inhibitory effect and p-values are shown. 
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 Kinase Inhibitor Screen with ExeR-1 and ExeR-3  4.6.2
To identify kinases causally involved in exemestane resistance, the parental MCF-7 cell line, as well as 
the exemestane resistant cell lines (ExeR-1 and ExeR-3), were exposed to the kinase inhibitor screen. 
Figure 23 visualizes a volcano plot of the generated data from the kinase inhibitor screen with ExeR-1 
and ExeR-3. The blue box in the figure includes the hits of the kinase inhibitor screen; kinases which 
exerted a more than twofold greater inhibition of the resistant ExeR-1 and ExeR-3 cells compared to 
the parental cells (p<0.05). The hits shown in this box are hits chosen for further validation based on 
clinical relevance. 
 
 
 
Figure 23: Results from the Kinase Inhibitor Screen for the Exemestane Resistant Cell Lines Visualized in a Volcano 
Plot. Data obtained from the kinase inhibitor screen plottet –log10(p-value) against log2(fold change) results in a 
volcano plot. The blue box includes four kinases (hits) which exerted a more than twofold greater inhibition of the 
exemestane resistant cells (ExeR-1 and ExeR-3) compared to the parental MCF-7 cells (p<0.05). The hits AZD5438, A-
674563 and JNJ-7706621 are indicated.  
In total, 8 hits were identified for ExeR-1, while 7 inhibitors exhibited a preferential growth inhibition 
of ExeR-3. Four of these inhibitors were common hits in the two exemestane resistant cell lines. The 
inhibition effects as well as the target(s) of these kinase inhibitors are listed in table 3. All results 
from the kinase inhibitor screen can be found in appendix 7. The majority of the inhibitors in 1.0 µM 
concentration exerted less than 25% growth inhibition of the parental cell line MCF-7 and only 1, 24, 
and 6 of the 195 kinase inhibitors had standard deviations (SD) over 10% in the parental, ExeR-1 and 
ExeR-3 cell lines, respectively. Most of the identified hits for the exemestane resistant cell lines 
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targeted proteins involved in cell cycle regulation (Aurora kinases and CDKs) and Akt-signaling, and 
the hits AZD5438, A-674563 and JNJ-770662, were selected for validation studies. Since WP-1130 
was a hit in the letrozole resistant cell lines, this inhibitor was also chosen for validation studies with 
the exemestane resistant cell lines, to study similarities and/or differences between the two AIs. 
Gefitinib was not a hit in the screen with the exemestane resistant cell lines, but was chosen to be 
investigated further, because the inhibitor was a borderline hit in the letrozole resistant cells (p-value 
0.054).  
 Validation of Selected Hits – Growth Experiments  4.7
The first part of the validation studies were performed as dose-response growth experiments, 
comparing the resistant cell lines LetR-1, LetR-3, ExeR-1 and ExeR-3 with the parental MCF-7 cell line, 
when treated with the selected kinase inhibitors (AZD5438, A-674563, JNJ-7706621, gefitinib, WP-
1130 and barasertib). MCF-7 was seeded in 1% FBS and then switched to 10% NCS + testosterone 
(10-7M) on day 1. LetR-1 and LetR-3 were seeded in 10% NCS + testosterone (10-7) + letrozole (10-6M), 
while ExeR-1 and ExeR-3 were seeded in 10% NCS + testosterone (10-7) + exemestane (10-7M). Cells 
were seeded in 24-well plates and two days following seeding, cells were treated with 0.5, 1.0 and 
1.5 µM of AZD5438, A-674563, JNJ-7706621, gefitinib, WP-1130 or barasertib, respectively. Following 
five days of treatment, cell number was determined by colorimetric assay.    
 Validation of the CDK Inhibitor AZD5438 4.7.1
The CDK 1/2/9 inhibitor AZD5438 was a hit in LetR-1 and ExeR-1. Two dose-response growth 
experiments were conducted treating all four AI resistant cell lines and their parental cell line MCF-7 
with AZD5438. A representative dose-response growth experiment with AZD5438 is shown in figure 
24.  
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Figure 24: Growth Response to AZD5438 Treatment. 8.000 cells of MCF-7, LetR-1, LetR-3, ExeR-1 and ExeR-3 were 
seeded in 24-well plates in standard growth medium. On day 1, MCF-7 cells were switched from 1% FBS to 10% 
NCS+Testosterone (10-7M). Experimental medium, which consisted of 10% NCS+Testosterone (10-7M) for MCF-7 cells 
and 10% NCS+Testosterone (10-7M) + either letrozole (10-6M) or exemestane (10-7M) for the AI resistant cells, 
containing 0.1% DMSO in control and AZD5438 in the indicated concentrations were added on day 2 and renewed on 
day 5. Staining with crystal violet was performed on day 7. Two independent experiments were performed with 3 
sample replicates. Mean cell numbers in percentage of DMSO treated controls and standard deviations are shown. 
Asterisks indicate statistically significant difference from controls.  
 
The results showed that 1.5 µM AZD5438 significantly inhibited growth of all four AI resistant cell 
lines compared to the parental cell line MCF-7. There was no significant inhibition when cells were 
treated with 1.0 µM AZD5438, which was the concentration used in the kinase inhibitor screen.  
However, it should be noted that the SD was very high for the MCF-7 cell line treated with AZD5438. 
Regardless, the results confirmed a greater growth inhibition of LetR-1 and ExeR-1 (where AZD5438 
was identified as a hit), compared LetR-3 and ExeR-3. Altogether, the results indicate that CDK 1/2/9 
might be important for growth of the AI resistant cell lines and therefore AZD5438 was chosen to be 
investigated further. 
 Validation of the Akt Inhibitor A-674563 4.7.2
A-674563, which is an Akt inhibitor, was a common hit in all four AI resistant cell lines. Two dose- 
response growth experiments were conducted treating the AI resistant cell lines and their parental 
cell line with A-674563. A representative dose-response growth experiment with A-674563 is shown 
in figure 25.  
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Figure 25: Growth Response to A-674563 Treatment. 8.000 cells of MCF-7, LetR-1, LetR-3, ExeR-1 and ExeR-3 were 
seeded in 24-well plates in standard growth medium. On day 1, MCF-7 cells were switched from 1% FBS to 10% 
NCS+Testosterone (10-7M). Experimental medium, which consisted of 10% NCS+Testosterone (10-7M) for MCF-7 cells 
and 10% NCS+Testosterone (10-7M) + either letrozole (10-6M) or exemestane (10-7M) for the AI resistant cells, 
containing 0.1% DMSO in control and A-674563 in the indicated concentrations were added on day 2 and renewed 
on day 5. Staining with crystal violet was performed on day 7. Two independent experiments were performed with 3 
sample replicates. Mean cell numbers in percentage of DMSO treated controls and standard deviations are shown. 
Asterisks indicate statistically significant difference from controls.  
 
The results showed that 1.0 µM A-674563 significantly inhibited growth of all four AI resistant cell 
lines compared to the parental cell line MCF-7. Therefore, the results confirmed the findings in the 
kinase inhibitor screen, where treatment with 1.0 µM A-674563 showed more than twofold growth 
inhibition of the AI resistant cells compared to MCF-7 cells. Based on these results, Akt signaling also 
appears to be important for growth of the AI resistant cell lines and A-674563 was investigated 
further. 
 Validation of the Aurora and CDK Inhibitor JNJ-7706621 4.7.3
The Aurora A/B and CDK 1/2 inhibitor JNJ-7706621 was also a common hit in both the letrozole and 
exemestane resistant cell lines. Two dose-response growth experiments were conducted treating the 
AI resistant cell lines and their parental cell line with JNJ-7706621, and a dose-response growth 
experiment with JNJ-7706621 is shown in figure 26.  
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Figure 26: Growth Response to JNJ-7706621 Treatment. 8.000 cells of MCF-7, LetR-1, LetR-3, ExeR-1 and ExeR-3 were 
seeded in 24-well plates in standard growth medium. On day 1, MCF-7 cells were switched from 1% FBS to 10% 
NCS+Testosterone (10-7M). Experimental medium, which consisted of 10% NCS+Testosterone (10-7M) for MCF-7 cells 
and 10% NCS+Testosterone (10-7M) + either letrozole (10-6M) or exemestane (10-7M) for the AI resistant cells, 
containing 0.1% DMSO in control and JNJ-7706621 in the indicated concentrations were added on day 2 and 
renewed on day 5. Staining with crystal violet was performed on day 7. Two independent experiments were 
performed with 3 sample replicates. Mean cell numbers in percentage of DMSO treated controls and standard 
deviations are shown. Asterisks indicate statistically significant difference from controls.  
 
Both 1.0 µM and 1.5 µM of JNJ-7706621 significantly inhibited growth of all AI resistant cell lines 
compared to the parental cell line MCF-7. Also, ExeR-1 was significantly inhibited by JNJ-7706621 at a 
concentration of 0.5 µM. The results therefore confirmed the findings in the kinase inhibitor screen, 
where treatment with 1.0 µM JNJ-7706621 showed preferential growth inhibitory effect of the 
letrozole and exemestane resistant cell lines compared to the MCF-7 cell line. The results indicate 
that Aurora kinases, CDK 1 and CDK 2, might be important for growth of the AI resistant cell lines and 
JNJ-7706621 was therefore investigated in additional experiments.  
 Validation of the EGFR and Akt Inhibitor Gefitinib 4.7.4
Gefitinib, which targets EGFR and Akt, was not defined as a hit in any of the resistant cell lines (see 
table 3), but since EGFR was highly up regulated in LetR-1 and LetR-3 cells and because gefitinib was 
close to be a hit (p-value 0.054 for LetR-1), gefitinib was chosen to be a part of the validation studies. 
Two dose-response growth experiments were conducted treating all resistant cell lines and the 
parental cell line with gefitinib. A representative dose-response growth experiment with gefitinib is 
shown in figure 27. 
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Figure 27: Growth Response to Gefitinib Treatment. 8.000 cells of MCF-7, LetR-1, LetR-3, ExeR-1 and ExeR-3 were 
seeded in 24-well plates in standard growth medium. On day 1, MCF-7 cells were switched from 1% FBS to 10% 
NCS+Testosterone (10-7M). Experimental medium, which consisted of 10% NCS+Testosterone (10-7M) for MCF-7 cells 
and 10% NCS+Testosterone (10-7M) + either letrozole (10-6M) or exemestane (10-7M) for the AI resistant cells, 
containing 0.1% DMSO in control and gefitinib in the indicated concentrations were added on day 2 and renewed on 
day 5. Staining with crystal violet was performed on day 7. Two independent experiments were performed with 3 
sample replicates. Mean cell numbers in percentage of DMSO treated controls and standard deviations are shown.  
 
None of the chosen concentrations (0.5, 1.0 and 1.5 µM) of gefitinib significantly inhibited growth of 
the AI resistant cell lines compared to the parental cell line MCF-7. This result therefore confirmed 
the findings in the kinase inhibitor screen, where treatment with 1.0 µM gefitinib did not show 
significant growth inhibitory effect of the resistant cell lines compared to the parental cell line. Since 
neither the kinase inhibitor screen nor the validation showed growth inhibition of the AI resistant cell 
lines, gefitinib was not investigated in further experiments. 
 Validation of the DUB Inhibitor WP-1130 4.7.5
The deubiquitinase (DUB) WP-1130 was a hit in LetR-1 and LetR-3. Two dose-response growth 
experiments were conducted treating the letrozole and the exemestane resistant cell lines, as well as 
the parental cell line, with WP-1130. A representative dose-response growth experiment with WP-
1130 is shown in figure 28. 
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Figure 28: Growth Response to WP-1130 Treatment. 8.000 cells of MCF-7, LetR-1, LetR-3, ExeR-1 and ExeR-3 were 
seeded in 24-well plates in standard growth medium. On day 1, MCF-7 cells were switched from 1% FBS to 10% 
NCS+Testosterone (10-7M). Experimental medium, which consisted of 10% NCS+Testosterone (10-7M) for MCF-7 cells 
and 10% NCS+Testosterone (10-7M) + either letrozole (10-6M) or exemestane (10-7M) for the AI resistant cells, 
containing 0.1% DMSO in control and WP-1130 in the indicated concentrations were added on day 2 and renewed on 
day 5. Staining with crystal violet was performed on day 7. Two independent experiments were performed with 3 
sample replicates. Mean cell numbers in percentage of DMSO treated controls and standard deviations are shown.  
 
In this dose response experiment, none of the concentrations (0.5, 1.0 or 1.5 µM) of WP-1130 
inhibited the growth of the AI resistant cell lines. Because two independent experiments showed the 
same, WP-1130 was not chosen to be investigated in following experiments.      
 Validation of the Aurora B Inhibitor Barasertib 4.7.6
Barasertib, which is a specific Aurora B inhibitor, was a hit in the letrozole resistant cell line, LetR-1. 
Two dose response growth experiments were conducted treating all AI resistant cell lines and their 
parental cell line with barasertib. A representative dose-response growth experiment with barasertib 
is shown in figure 29.  
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Figure 29: Growth Response to Barasertib Treatment. 8.000 cells of MCF-7, LetR-1, LetR-3, ExeR-1 and ExeR-3 were 
seeded in 24-well plates in standard growth medium. On day 1, MCF-7 cells were switched from 1% FBS to 10% 
NCS+Testosterone (10-7M). Experimental medium, which consisted of 10% NCS+Testosterone (10-7M) for MCF-7 cells 
and 10% NCS+Testosterone (10-7M) + either letrozole (10-6M) or exemestane (10-7M) for the AI resistant cells, 
containing 0.1% DMSO in control and barasertib in the indicated concentrations were added on day 2 and renewed 
on day 5. Staining with crystal violet was performed on day 7. Two independent experiments were performed with 3 
sample replicates. Mean cell numbers in percentage of DMSO treated controls and standard deviations are shown. 
Asterisks indicate statistically significant difference from controls.  
 
All tested concentrations of barasertib (0.5, 1.0 or 1.5 µM) significantly inhibited growth of the 
exemestane resistant cell line ExeR-1, compared to the parental cell line. This result did not confirm 
the finding from the kinase inhibitor screen, were barasertib was not identified as a hit for ExeR-1 
(but only for LetR-1). In the kinase inhibitor screen, barasertib exhibited more growth inhibition of the 
four AI resistant cell lines compared to the parental cell line MCF-7. In the dose-response growth 
experiments, however, only ExeR-1 was more growth inhibited by barasertib compared to MCF-7 
(applies to all three concentrations). Because ExeR-1 showed significantly growth inhibition by 
treatment with all concentrations of barasertib and because the validation study with JNJ-7706621 
also points out Aurora kinase B to possibly be important for growth of the resistant cell lines, 
barasertib was investigated further.  
 Validation of Selected Hits – Cell Cycle Analysis 4.8
The second part of the validation studies was to perform cell cycle analysis by FACS to investigate cell 
cycle phase distributions in the AI resistant cell lines LetR-1 and ExeR-1 and their parental cell line 
MCF-7. Due to time limitations, only the AI resistant cell lines LetR-1 and ExeR-1 and the parental 
MCF-7 cell line were utilized. MCF-7 was seeded in 1% FBS and then switched to 10% NCS + 
testosterone (10-7M) on day 1. LetR-1 and ExeR-1 was seeded in standard medium (10% NCS + 
testosterone (10-7) + either letrozole (10-6M) or exemestane (10-7M), respectively). Cells were seeded 
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in 6-well plates and were treated with vehicle (0.1% DMSO) or 1.0 µM of the selected kinase 
inhibitors AZD5438, A-674563, JNJ-7706621 and barasertib, respectively, for 24 and 48 hours prior to 
addition of the nucleic acid dye propidium iodide (PI). Cell cycle phase distributions were measured 
by FACS analysis. A graphic presentation of cell cycle phase distribution following treatment with the 
selected kinase inhibitors is shown in Figure 30, where the percentages of the cells in each cell cycle 
phase are indicated. 
 
 
 
Figure 30: Cell Cycle Phase Distributions in MCF-7, LetR-1 and ExeR-1 Following Treatment with Selected Kinase 
Inhibitors. A) AZD5438. B) A-674563. C) JNJ-7706621. D) Barasertib. 45.000 MCF-7 cells and 40.000 LetR-1, LetR-3, 
ExeR-1 and ExeR-3 cells were seeded in 6-well plates in standard growth medium. On day 1, MCF-7 cells were 
switched from 1% FBS to 10% NCS+Testosterone (10-7M). Treatments in the indicated concentrations were added on 
day 2 and renewed on day 5. Following five days of treatment, cells were harvested for cell cycle analysis. Results are 
shown as percentage of cells in each cell cycle phase.  
 
The normal cell cycle phase distribution for MCF-7, LetR-1 and ExeR-1 is very similar, with 78%, 78% 
and 80% of the cells being in G1 cell cycle phase for MCF-7, LetR-1 and ExeR-1, respectively. 
Furthermore, 16.5%, 16.0% and 16.5% of the cells were in G2/M cell cycle phase while 5%, 5% and 
4% were in S cell cycle phase, for MCF-7, LetR-1 and ExeR-1, respectively.  
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Treatment with 1.0 µM AZD5438 resulted in accumulation of cells in G2/M phase for all three cell 
lines. For the parental cell line MCF-7, 24 hours treatment with 1.0 µM AZD5438 resulted in 
increased fraction of cells in G2/M phase from 16.5% to 21.5%. Upon 48 hours of treatment, 33.5% 
of the cells were in G2/M phase. The results also showed accumulation of cells in S phase upon 
treatment with 1.0 µM AZD5438. In the parental cell line, 24 hours treatment with 1.0 µM AZD5438 
resulted in a shift of cells in S phase from 5% to 8.5% and after 48 hours of treatment 14% of the cells 
were in S phase. For the letrozole resistant cell line LetR-1 and the exemestane resistant cell line ExeR-
1, similar shifts in cell cycle distributions was observed.  
The results further showed that treatment with 1.0 µM of the Akt inhibitor A-674563 only gave a 
minor accumulation of cells in G2/M phase for the parental cell line MCF-7. For MCF-7 cells, 24 hours 
treatment with 1.0 µM A-674563 resulted in increased fraction of cells in G2/M phase from 16.5% to 
22%. After 48 hours of treatment only 20% of the cells were in G2/M phase. The two resistant cell 
lines, however, showed a more evident shift of cells to G2/M phase. LetR-1 showed a shift of cells in 
G2/M phase from 16% to 25% upon 24 hours treatment with 1.0 µM A-674563 and after treatment 
for 48 hours 32% of the cells were in G2/M phase. In the exemestane resistant cell line ExeR-1 a 
similar shift in cell cycle distribution as LetR-1 was observed. There was also observed an 
accumulation of cells in S phase for all three cell lines. For MCF-7, both 24 and 48 hours of treatment 
resulted in a shift of cells in S phase from 5% to 9%, respectively. LetR-1 and ExeR-1 showed similar 
accumulation in S phase upon treatment with this Akt inhibitor. ExeR-1 even showed a more severe 
accumulation with 15% of cells being in S phase upon 48 hours of A-674563 treatment.  
1.0 µM JNJ-7706621 treatment also resulted in accumulation of cells in G2/M phase for all three cell 
lines. For the parental cell line, 24 hours treatment with 1.0 µM JNJ-7706621 resulted in increased 
fraction of cells in G2/M phase from 16.5% to 24% and upon 48 hours of treatment 29% of the cells 
were in G2/M phase. LetR-1 and ExeR-1 also showed similar cell cycle phase shifts, however, as much 
as 31% and 44% of LetR-1 and ExeR-1 cells, respectively, were in G2/M phase after 48 hours of 
treatment. There was only a minor accumulation of cells in S phase for all three cell lines. 
The cell cycle analysis revealed that treatment with 1.0 µM barasertib resulted in major 
accumulation of cells in G2/M phase for all three cell lines. For MCF-7, 24 hours treatment with 1.0 
µM barasertib resulted in increased fraction of cells in G2/M phase from 16.5% to 49%. Upon 48 
hours of treatment 59% of the cells were in G2/M phase. LetR-1 and ExeR-1 showed similar shifts in 
cell cycle phase distribution, with as much as 82% and 74% of LetR-1 and ExeR-1 cells in G2/M phase 
after 48 hours treatment. Treatment with 1.0 µM barasertib only gave a minor accumulation of cells 
in S phase for the three cell lines. As mentioned before, barasertib targets Aurora B, which is 
important for correct cell cycle progression and plays a key role in the maintenance of normal ploidy 
during cell division [105]. Since barasertib earlier has been shown to induce endoreduplication, 
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resulting in increased number of cells with a DNA content above 4N [105], and because JNJ-7706621 
also targets Aurora B, possible differences and/or similarities in cell cycle phase distribution between 
barasertib and JNJ-7706621 treatments were studied. Graphic presentations of cell cycle phase 
distributions following treatments with barasertib and JNJ-7706621 are shown in figure 31, where 
the cell cycle phase distributions are indicated for MCF-7, LetR-1 and ExeR-1, respectively. 
 
 
  
 
 
 
 
 
 
 
Figure 31: Cell Cycle Phase Distributions of MCF-7, LetR-1 and ExeR-1 Cells Following JNJ-7706621 and Barasertib 
Treatments. MCF-7 cells were seeded in 6-well plates in standard growth medium. On day 1, MCF-7 cells were 
switched from 1% FBS to 10% NCS+Testosterone (10-7M). LetR-1 and ExeR-1 cells were seeded in 6-well plates in 
standard growth medium. On day 2, cells were treated with vehicle (0.1% DMSO), JNJ-7706621(1 µM) and barasertib 
(1 µM) for 24 and 48 hours (24 hours is not shown). Following five days of treatment, cells were harvested for cell 
cycle analysis. The histograms depict the cell cycle phase distributions in the following phases: G1 phase (the first 
peak), S phase (area between the two first peaks), G2/M phase (second peak) and polyploid cells (area after second 
peak). 
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Normal MC7-7, LetR-1 and ExeR-1 cell cycle phase distributions showed few cells with DNA content 
above 4N (polyploid cells), see figure 31. In MCF-7, 3% of the cells were polyploid while in LetR-1 and 
ExeR-1, only 2% of the cells were polyploid. However, after 48 hours treatment with 1.0 µM 
barasertib, both the parental cell line and the resistant cell lines showed an increase of cells with 
DNA content above 4N. The parental cell line MCF-7 showed a shift of polyploidy cells from 3% to 7% 
when treated with 1.0 µM barasertib for 48 hours. LetR-1 showed a shift of polyploidy cells from 2% 
to 15% upon treatment and in ExeR-1 as much as 18% of the cells were polyploidy after 48 hours of 
barsertib treatment. Even though JNJ-7706621 also targets Aurora B (in addition to Aurora A and CDK 
1/2), an increase of polyploid cells were not seen in the three cell lines when treated with this 
inhibitor.  
 
Altogether, the cell cycle phase distribution of the parental cell line and the two AI resistant cell lines 
LetR-1 and ExeR-1 seemed to be altered when treated with the selected kinase inhibitors.  
 
 Morphological Changes in MCF-7, LetR-1 and ExeR-1 Cells upon Treatment with 4.9
Selected Kinase Inhibitors 
To determine if treatment with AZD5438, A-674563, JNJ-7706621 and barasertib induced 
morphological changes in the parental and resistant cells, MCF-7, LetR-1 and ExeR-1 cells were studied 
under a microscope. Cell pictures for the MCF-7, LetR-1 and ExeR-1 cell lines can be seen in figure 32, 
33 and 34, respectively. From visual inspection of the cells following 48 hours of 1.0 µM JNJ-7706621 
and 1.0 µM barasertib treatment, it could be seen that both the parental cell line MCF-7 and the two 
resistant cell lines LetR-1 and ExeR-1 increased in size. All three cell lines also increased in size when 
treated with 1.0 µM of AZD5438. However, treatment with barasertib and JNJ-7706621 showed a 
greater increase in cell size, compared to AZD5438 treatment. Treatment with 1.0 µM A-674563 on 
the other hand, did not show visible morphological differences from control. Based on this, the 
results showed that the Aurora B inhibitor barasertib and the CDK- and Aurora A/B inhibitor JNJ-
7706621 gave the greatest change in cell size for both the parental and the resistant cell lines, 
compared to treatment with AZD5438 and A-674563.   
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Figure 32: Cell Pictures of MCF-7 Cells after Treatment with Selected Kinase Inhibitors. MCF-7 cells were seeded in 
6-well plates in standard growth medium. On day 1, MCF-7 cells were switched from 1% FBS to 10% 
NCS+Testosterone (10-7M) and were treated with A) Control, B) 1 µM AZD5438, C) 1 µM A-674563, D) 1 µM JNJ-
7706621 or E) 1 µM barasertib, 48 hours before cell pictures were taken. Cell pictures were taken of the cells using a 
40x magnification.  
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Figure 33: Cell Pictures of LetR-1 Cells after Treatment with Selected Kinase Inhibitors. LetR-1 cells were seeded in 6-
well plates in standard growth medium and treated with A) Control, B) 1 µM AZD5438, C) 1 µM A-674563, D) 1 µM 
JNJ-7706621 or E) 1 µM barasertib, 48 hours before cell pictures were taken. Cell pictures were taken of the cells 
using a 40x magnification.  
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Figure 34: Cell Pictures of ExeR-1 Cells after Treatment with Selected Kinase Inhibitors. ExeR-1 cells were seeded in 
6-well plates in standard growth medium, and treated with A) Control, B) 1 µM AZD5438, C) 1 µM A-674563, D) 1 µM 
JNJ-7706621 or E) 1 µM barasertib, 48 hours before cell pictures were taken. Cell pictures were taken of the cells 
using a 40x magnification.  
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 Protein Expression of Aurora Kinases, Erk and Akt in MCF-7, LetR-1 and ExeR-1   4.10
The majority of the selected hits from the two kinase inhibitor screens with letrozole and 
exemestane resistant cell lines targeted the Aurora family of protein kinases, CDKs and Akt signaling 
kinases. Therefore, western blot analyses were performed to investigate the basal level of total and 
phosphorylated Aurora proteins, total and phosphorylated ERK and total and phosphorylated Akt. 
Due to time limitations only LetR-1, ExeR-1 and the parental cell line were used in this experiment. 
MCF-7 cells were seeded in standard growth medium and switched to 10% NCS + testosterone (10-
7M) at day 1. LetR-1 and ExeR-1 cells were seeded in their standard growth medium. Cells were 
seeded in 6-well plates and for each cell line, treatment was done with vehicle (0.1% DMSO), 1 µM 
AZD5438, 1 µM A-674563, 1 µM JNJ-7706621 or 1 µM barasertib for 1 and 24 hour(s). Figure 35 
shows protein expression of Aurora, Erk 1/2 and Akt proteins in MCF-7, LetR-1 and ExeR-1 cells 
treated with AZD5438 and A-674563. In figure 36, protein expression of Aurora, Erk 1/2 and Akt 
proteins in MCF-7, LetR-1 and ExeR-1 cells treated with JNJ-7706621 and barasertib can be seen. Due 
to technical difficulties, treatment with A-674563 in ExeR-1 was not examined. Neither was p-Akt in 
cells treated with JNJ-7706621 and barasertib, respectively.  
 
 
 
Figure 35: Expression of Aurora Proteins, Erk and Akt Signaling in Cells Treated with AZD5438 and A-674563 
Detected by Western Analysis. Western blots showing total and phosphorylated (p) form of Aurora B (Thr232), total 
and p-form of Aurora A (Thr288), total and p-form of ERK 1/2 (Thr202/Tyr204) and total and p-form of Akt (Ser473). 
Proteins are from lysates from MCF-7, LetR-1 and ExeR-1. Cells were seeded in 6-well plates in their standard growth 
medium. On day 1 MCF-7 cells were switched from 1% FBS to 10% NCS + testosterone (10-7M). On day 2 cells were 
treated with vehicle (0.1% DMSO), 1 µM AZD5438 and 1 µM A-674563 for 1 and 24 hour(s). Cells were harvested for 
western analysis on day 6. 12 µg total protein were loaded in each lane and heat shock protein 70 (Hsp70) and β-
actin were used as loading controls. 
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Figure 36: Expression of Aurora Proteins, Erk and Akt Signaling in Cells Treated with JNJ-7706621 and Barasertib 
Detected by Western Analysis. Western blots showing total and phosphorylated (p) form of Aurora B (Thr232), total 
and p-form of Aurora A (Thr288), total and p-form of ERK 1/2 (Thr202/Tyr204) and total Akt. Proteins are from 
lysates from MCF-7, LetR-1 and ExeR-1. Cells were seeded in 6-well plates in their standard growth medium. On day 1 
MCF-7 cells were switched from 1% FBS to 10% NCS + testosterone (10-7M). On day 2 cells were treated with vehicle 
(0.1% DMSO), 1 µM JNJ-7706621 and 1 µM barasertib for 1and 24 hour(s). Cells were harvested for western analysis 
on day 6. 12 µg total protein were loaded in each lane and heat shock protein 70 (Hsp70) and β-actin were used as 
loading controls. 
 
 
Aurora A has Mw 48 kDa and Aurora B 40 kDa. The antibody recognizing phosphorylated Aurora A, B 
and C detected two bands in the cell lines. The upper band most probably corresponds to p-Aurora A 
and the lower band to p-Aurora B. Generally, p-Aurora A was expressed at increased level in all AI 
resistant cell lines compared to MCF-7. p-Aurora B was expressed consistently in MCF-7 cells and also 
expressed in LetR-1 and ExeR-1. The Aurora A level was similar in MCF-7, LetR-1 and ExeR-1, whereas 
Aurora B was hardly detectable in any of the cell lines. p-Erk 1/2 was highest in MCF-7 cells, whereas 
p-Akt was highest in the AI resistant cell lines. Treatment with 1.0 µM AZD5438 for 24 hours had no 
effect on the level of p-Aurora, but increased total level of Aurora A in all cell lines. Furthermore, 
treatment with AZD5438 for 24 hours reduced both p-Erk 1/2 and p-Akt level in the AI resistant cells. 
Treatment with 1.0 µM A-674563 had no effect on p-Aurora A and B, and increased total level of 
Aurora A and B in MCF-7 and LetR-1 cells. p-Erk 1/2 and in particular p-Akt was severely reduced by A-
674563 treatment of LetR-1 cells. Treatment with 1.0 µM JNJ-7706621 had no major effect on p-
Aurora A expression but total level of Aurora A and B was increased in all tested cell lines after 24 
hours. Barasertib reduced p-Aurora B expression in MCF-7 cells and reduced p-Aurora A in LetR-1 
cells, whereas both p-Aurora A and B was reduced in ExeR-1 cells. No effect of barasertib was 
observed on expression of total Aurora A and B. Noteworthy, the increased level of p-Aurora A in 
both AI resistant cell lines and the increased level of total Aurora A upon treatment with the CDK 
inhibitor AZD5438 and the CDK and Aurora kinase inhibitor JNJ-7706621 indicated an important role 
of Aurora A for growth of AI resistant cell lines.       
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 Knockdown of Aurora A in MCF-7, LetR-1 and ExeR-1   4.11
The earlier presented results showed both increased p-Aurora A and total Aurora A in the AI resistant 
cell lines LetR-1 and ExeR-1, compared to the parental MCF-7 cell line. Treatment with 1.0 µM JNJ-
7706621, which targets Aurora kinases as well as CDKs, showed growth inhibition of all resistant cell 
lines and also showed altered cell cycle phase distribution. Based on this, Aurora A kinase could be 
important for growth of the letrozole and exemestane resistant cell lines. To further investigate the 
importance of Aurora A for AI resistance, siRNA-mediated knockdown of the Aurora A protein was 
performed. MCF-7, LetR-1 and ExeR-1 cells were nucleofected with 300 nM control siRNA or Aurora A 
siRNA. Following nucleofection, cells were seeded in 24-well plates in their standard growth medium. 
One day after nucleofection, MCF-7 cells were switched from 1% FBS to 10% NCS + testosterone (10-
7M). Cell number was determined by a crystal violet colometric assay on day 1, 2, 3 and 4 after 
nucleofection. 
  
 
 
 
 
 
Figure 37: Knockdown of Aurora A – Growth Experiments. 
MCF-7, LetR-1 and ExeR-1 cells were nucleofected with 300 
nM control siRNA or Aurora A siRNA. Following nucleofection, 
the cells were seeded in 24-well plates in standard growth 
medium. One day after nucleofection, MCF-7 cells were 
switched from 1% FBS to 10% NCS + testosterone (10-7M). Cell 
number was determined by a crystal violet colometric assay 
on day 1, 2, 3 and 4 after nucleofection. Cell numbers in 
percentage of siRNA transfected control are shown. Two 
independent experiments were performed with four sample 
replicates. 
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siRNA-mediated knockdown of Aurora A exerted a minor growth inhibition of MCF-7 after four days. 
However, growth inhibition in the resistant cell lines LetR-1 and ExeR-1 was seen already two days 
after transfection and an even greater effect was seen after four days (figure 37).  
 
Western analysis was performed to measure knockdown efficiency and showed complete 
knockdown of the Aurora A protein in all cell lines (figure 38), but with a clearer effect in the two 
resistant cell lines compared with MCF-7. Aurora A expression in all cell lines grown in 10% NCS + 
testosterone (without nucleofection) was determined as extra control and the level of Aurora A in 
these controls were similar to the nucleofected cell cultures.    
 
 
 
Figure 38: Knockdown of Aurora A – Western Analysis. Western blot analysis performed to determine the efficiency 
of siRNA-mediated knockdown of Aurora A. MCF-7, LetR-1 and ExeR-1 cells were nucleofected with 300 nM control 
siRNA or Aurora A siRNA. Upon nucleofection, cells were seeded in 6-well plates and harvested in RIPA on day 2. One 
day after nucleofection, MCF-7 cells were switched from 1% FBS to 10% NCS + testosterone (10-7M). 20 µg total 
protein were loaded in each lane and heat shock protein 70 (Hsp70) was used as loading control. MCF-7, LetR-1 and 
ExeR-1 cells that were not nucleofected were also loaded on the gel. 
 
 
The experiments showed that Aurora A efficiently can be shut down by siRNA-mediated knockdown 
in both the parental cell line and the AI resistant cell lines LetR-1 and ExeR-1, and knock down of 
Aurora A inhibits growth of the AI resistant cell lines.  
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5 Discussion 
During the last ten years, the third generation AIs letrozole, exemestane and anastrozole have 
proven superiority to tamoxifen in treatment of both advanced breast cancer and in the adjuvant 
setting, and are therefore now recommended as first line therapy for postmenopausal ER+ breast 
cancer patients [49]. However, resistance to both the steroidal and the non-steroidal AI is a major 
clinical problem, and knowledge of the molecular basis for resistance to AIs is needed. Pre-clinical 
studies have shown that combination of an AI and the anti-estrogen fulvestrant is a more effective 
treatment than the AI alone [57]. Also, increased activation of growth factor receptors such as the 
EGFR, and downstream signaling intermediates such as PI3K/Akt signaling, have been observed in AI 
resistant cell models [123, 124]. Targeting these signaling pathways, including ER itself, might 
therefore represent a potential strategy to overcome AI resistance. Identification of drugs that target 
AI resistant breast cancer and understanding their mechanisms of action are important to find new 
and better treatment options for patients with AI resistant breast cancer. It is therefore of great 
importance to elucidate the molecular mechanisms driving growth of AI resistant breast cancer cells. 
In this thesis, an in vitro model with two cell lines resistant to the non-steroidal AI letrozole, two cell 
lines resistant to the steroidal AI exemestane, and the parental MCF-7 cell line were used to explore 
the molecular mechanisms for AI resistance, to test new treatment and to unravel cross-resistance 
between the two types of AIs. Both the non-steroidal and the steroidal AI resistant cell lines were 
established from the ER+ breast cancer cell line MCF-7.  
 MCF-7 Cells Stimulated by Aromatase-mediated Conversion of Testosterone to 5.1
Estradiol are used for Establishment of AI Resistant Cell Lines 
Aromatase is expressed in breast cancer cells, but also in surronding cells in the breast and in 
periferal tissues [32]. Thus, breast cancer cells are stimulated from both in situ estrogen synthesis 
within the carcinoma cells by paracrine interactions and from uptake of circulating estrogens.  
In the model system used in this study, culture conditions were used under which cancer cells were 
growth stimulated by estrogen via aromatase-mediated conversion of the androgen testosterone to 
estradiol. Testosterone mediated dose-dependent growth stimulation of MCF-7 cells and although 
the stimulation was significant, it did not reach the level obtained by estradiol (figure 14), showing 
that endogenous aromatase is functional and that aromatase enzyme activity is rate limiting for the 
growth stimulation. This is in agreement with previous observations [149]. Complete inhibition of 
testosterone mediated growth stimulation of MCF-7 cells was obtained by treatment with the AIs 
letrozole and exemestane (figure 15), demonstrating that aromatization of testosterone is 
responsible for the growth.       
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 The Aromatase Inhibitor Resistant Cell Lines are Resistant to both Letrozole and 5.2
Exemestane 
The AI resistant cell lines were growth stimulated by the androgen testosterone (figure 15A, C and 
D). However, in one experiment, ExeR-1 displayed no growth stimulation by testosterone (figure 
15B). This experiment was performed using an early passage of ExeR-1, and lack of testosterone 
stimulation might be due to ExeR-1 having a better basal growth rate in the experiments performed 
in the beginning compared to experiments performed at a later point (figure 15D, 16B and 16D).  
 
Both letrozole and exemestane completely inhibited the testosterone stimulated growth of the 
parental MCF-7 cell line (figure 15). LetR-1 and LetR-3 were only partially growth inhibited by the AI 
letrozole and could grow continuously in the presence of this AI, demonstrating that LetR-1 and LetR-
3 are resistant to letrozole. Furthermore, the letrozole resistant cell lines were also only partially 
growth inhibited by exemestane and could grow continuously in the presence of exemestane, 
suggesting that the letrozole resistant cells also are resistant to exemestane, indicating that a switch 
from a non-steroidal to a steroidal AI will not be a treatment option for the letrozole resistant cells. 
ExeR-3 was minor growth inhibited by exemestane and could grow continuously in the presence of 
this AI, demonstrating that ExeR-3 is resistant to exemestane. ExeR-1 seemed not to be growth 
inhibited by exemestane, which most probably is due to the lack of testosterone stimulation in this 
experiment (figure 15B). Both ExeR-1 and ExeR-3 were partially growth inhibited by letrozole, but 
could still grow in the presence of letrozole, showing that the exemestane resistant cell lines are also 
resistant to letrozole. The reason why ExeR-1 was partially growth inhibited by letrozole, but not by 
exemestane, could be that in the experiment with exemestane treatment, testosterone stimulation 
was lacking, whereas in the experiment with letrozole treatment, stimulation with the androgen was 
evident.  
 
In summary, whereas MCF-7 cells displayed very low growth in medium with 10% NCS and require 
estrogen to proliferate rapidly, the AI resistant cell lines have increased ability to grow in 10% NCS. 
The AI resistant cell lines are all growth stimulated by testosterone and the testosterone stimulation 
can be abolished by treatment with both a steroidal and a non-steroidal AI. However, in the presence 
of the AIs, the LetR-1, LetR-3, ExeR-1 and ExeR-3 cell lines were able to grow continuously, which is our 
definition of resistance. The finding of cross-resistance between the non-steroidal and steroidal AI 
was unexpected, since clinical data have showed lack of cross-resistance between a non-steroidal AI 
and a steroidal AI, allowing a switch from non-steroidal inhibitor to steroidal inhibitor upon 
development of resistance [121, 122]. It should be mentioned that although clinical benefit is 
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observed after switch from a non-steroidal to a steroidal AI, it is only a minor fraction of the patients 
who have benefit from the switch [122].   
 The Aromatase Inhibitor Resistant Cell Lines Respond to Anti-Estrogen Treatment  5.3
Anti-estrogens have been used as treatment for breast cancer patients for many years and the 
selective estrogen modulator tamoxifen was the first approved endocrine therapy used to treat 
postmenopausal women before AI were proven to be superior [140]. To study if the AI resistant cell 
lines were responsive to anti-estrogen treatment, dose-response growth experiments with tamoxifen 
and the pure anti-estrogen fulvestrant were performed. Testosterone stimulated growth of MCF-7 
cells was significantly inhibited by both tamoxifen (figure 16A and 16B) and fulvestrant (figure 16C 
and 16D). However, fulvestrant was most efficient as it completely abrogated the testosterone 
stimulation. The four AI resistant cell lines were only partially growth inhibited by tamoxifen. 
Fulvestrant, on the other hand, exerted growth inhibition below the basal growth level for the AI 
resistant cell lines, demonstrating that the resistant cell lines require ER for growth, and indicating 
that fulvestrant might be used as a second-line treatment upon aquired AI resistance. The results 
corresponded well with pre-clinical data, where the non-steroidal AI anastrozole combined with 
fulvestrant has been shown to be more effective than anastrozole alone [57]. Furthermore, 
treatment of LetR-1 cells with fulvestrant for two weeks showed reduced cell number compared to 
growth in standard medium after one week, and after another week, only a two-fold increase was 
observed (figure 17). To evaluate whether LetR-1 cells survives or dies by long-term fulvestrant 
treatment, further experiments with longer duration are needed. In summary, these in vitro data 
indicates that fulvestrant treatment might be a better second-line treatment than tamoxifen for the 
AI resistant cells, which could indicate that ER+ breast cancer patients might benefit from using 
fulvestrant as a second-line treatment upon relapse with an AI. 
 ER is Functional in the Aromatase Inhibitor Resistant Cell Lines 5.4
Western blot analyses revealed that ER level was higher in the AI resistant cell lines compared to the 
parental cell line MCF-7, and both estradiol and testosterone down regulated ER expression whereas 
AI treatment resulted in ER level as in the 10% NCS culture (figure 18 and 19). Thus, the AI resistant 
cell lines have increased level of ER, which is in agreement previous observations showing increased 
level of ER in the AI resistant LTED cell lines [158], and in the in vivo model with MCF-7 cells with 
exogenous aromatase expression [128]. We were able to show that ER was functional in the resistant 
cell lines with respect to stimulation of the estrogen regulated proteins; PgR, IGF1-R and Bcl-2. 
Furthermore, the observed down regulation of ER protein in the AI resistant cells upon treatment 
with estradiol and testosterone, indicate that estradiol-bound ER receptor is unstable as also shown 
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previously for MCF-7 cells [70]. In both the studies with the LTED model and the in vivo model, ER 
was an important driver of growth. Our finding of total block of growth of AI resistant cell lines with 
the anti-estogen fulvestrant demonstrates that also in our model with aquired AI resistance, ER is 
involved in AI resistant cell growth. 
 Western Analysis showed Up Regulation of EGFR in LetR-1 and LetR-3 5.5
Expression of HERs like EGFR and HER4, and downstream signalling pathways, such as Erk 1/2 and 
Akt, were investigated in the AI resistant cell lines and the parental MCF-7 cell line by western blot 
analyses. The most interesting finding was the increased level of EGFR observed in the letrozole 
resistant cell lines, compared to the exemestane resistant cell lines and the parental MCF-7 cell line 
(figure 20 and 21). The increased level of EGFR in LetR-1 and LetR-3 indicates that signaling via EGFR 
might be involved in letrozole resistant cell growth. Furthermore, Ser473-phosphorylated Akt, 
corresponding to the activated form of Akt, was expressed but not at increased level in MCF-7, LetR-1 
and ExeR-1 cells (figure 20). Additional investigations are required to measure Akt phosphorylation in 
all AI resistant cell lines.  
 Kinase Inhibitor Screen Revealed Kinases Important for AI Resistant Cell Growth 5.6
To identify kinases important for growth of the AI resistant cell lines, two kinase inhibitor screens 
were performed. The first kinase inhibitor screen compared growth of the letrozole resistant cell 
lines to growth of the parental MCF-7 cell line (figure 22) whereas the second screen compared 
growth of the exemestane resistant cell lines to growth of the MCF-7 cell line (figure 23). As 
mentioned before, the kinase inhibitor screen consisted of treatment with 195 different kinase 
inhibitors. The standard growth medium for the AI resistant cell lines was 10% NCS + testosterone 
(10-7M) + AI, to investigate kinases important for the basal growth of AIs.   
In the kinase inhibitor screen with the letrozole resistant cell lines, 20 inhibitors which preferentially 
inhibited growth of letrozole resistant cell lines compared to the parental MCF-7 cell line were 
identified. In the screen with the exemestane resistant cell lines, only 11 inhibitors which 
preferentially growth inhibited the exemestane resistant cell lines compared to MCF-7 were 
identified. It is important to note that the screens were performed with only one concentration of 
the inhibitors (1.0 µM), which potentially can be a toxic concentration of some of the compounds. 
Furthermore, many of the kinase inhibitors also inhibit several targets at the investigated 
concentration, which means that the resulting growth reduction not necessarily reflects inhibition of 
the main inhibitor target. In the kinase inhibitor screen performed with the letrozole resistant cell 
lines, six common hits were identified whereas in the screen performed with the exemestane 
resistant cell lines, four common hits were found (table 3). The relatively low number of identified 
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kinase inhibitors exhibiting a twofold preferential growth inhibition of the AI resistant cells could be 
due to the limitations in the sceen, for example using only one concentration of the inhibitors and 
exclusion of possible hits where MCF-7 cells showed more than 50% growth inhibiton. Both kinase 
inhibitor screens showed relatively low SDs and several of the identified hits could be confirmed in 
validation studies performed as dose-response growth experiments. This demonstrates the reliability 
of the results obtained with the kinase inhibitor screen. However, some differences between the 
screen and the validation studies were observed; e.g. when parental and AI resistant cell lines were 
treated with AZD5438, WP-1130 and barasertib (see later).  
Kinase inhibitor screens in MCF-7 based cell lines (e.g. tamoxifen and fulvestrant resistant cell lines) 
have previously been performed in our laboratory (C.W. Yde, unpublished data); however, a kinase 
inhibitor screen performed with AI resistant cell lines has not yet been published, making it a new 
oppurtunity to find kinases driving growth of AI resistant cell lines.  
The two kinase inhibitor screens showed that the majority of the hits targeted the same kinases; 
Aurora kinases, CDKs and Akt signaling kinases, indicating that these kinases might be important for 
growth of the AI resistant cell lines. However, there were some differences between the letrozole 
and exemestane resistant cell lines, e.g; WP-1130, a DUB inhibtor, was a hit only in the letrozole 
resistant cells, while the PDGFR inhibitor crenolanib, was a hit only in the two exemestane resistant 
cell lines. This indicates that letrozole and exemestane resistant cells might have different drivers for 
growth.  
 Cell Cycle Proteins and Akt Signaling Kinases might be Important for Aromatase Inhibitor 5.6.1
Resistant Cell Growth  
Validation studies were performed with all four AI resistant cell lines to unravel similarites and 
differences between the cell lines.  
As mentioned before, the results from the two kinase inhibitor screens showed that the majority of 
the hits targeted kinases involved in cell cycle regulation (Aurora kinases and CDKs) and Akt signaling. 
Studies have previously shown that the Aurora kinasess are overexpressed in several cancer types, 
including breast cancer, and since the Aurora kinase family plays a critical role in the regulation of 
cell cycle processes, it has been subject of many resent investigations [106]. Activation of the 
PI3K/Akt pathway stimulates cell cycle progression and is important in cell survival [81, 90], and 
furthermore, activation of the PI3K/Akt pathway has been found in many cancer types and has 
shown to play a major role in breast cancer cell proliferation [91]. 
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The Akt inhibitor A-674563 and the Aurora A/B and CDK inhibitor JNJ-7706621, were chosen for 
validation studies because they were common hits in all four AI resistant cell lines, and thus could be 
important for cell growth of all AI resistant cell lines. Furthermore, we thought it would be 
interesting to study other kinase inhibitor within these pathways, and therefore, the CDK inhibitor 
AZD5438 (hit in LetR-1 and ExeR-1 cells ) and the selective Aurora B inhibitor barasertib (hit in LetR-1 
cells) were chosen for further investigations. Due to the increased EGFR protein level in LetR-1 and 
LetR-3 cells (figure 20), indicating that EGFR might be important for growth of the letrozole resistant 
cell lines, gefitinib which target EGFR, was chosen to be a part of the validation studies, even though 
gefitinib was not defined as a hit (due to p-value 0.054 in LetR-1). As mentioned, WP-1130 was a hit 
only in the letrozole resistant cell lines, indicating its importance for growth of the letrozole resistant 
cell lines, and were therefore chosen to be examined further, both in the letrozole and in the 
exemestane resistant cell lines, to study possible differences. 
The first part of the validations studies included dose-response growth experiments with the AI 
resistant cell lines and the parental MCF-7 cell line whereas the second part comprised of cell cycle 
analysis by FACS to investigate cell cycle phase distributions in the AI resistant cell lines LetR-1 and 
ExeR-1, and the parental  MCF-7 cell line. Results from the cell cycle analysis are discussed in the next 
section.   
The dose-response growth experiments with A-674563, JNJ-7706621 and gefitinib treatments (figure 
25, 26 and 27, respectively), confirmed the findings in the kinase inhibitor screen. Growth inhibition 
of the resistant cells with A-674563 (the Akt-inhibitor) and JNJ-7706621 (the pan-Aurora and CDK 1/2 
inhibitor) treatment, suggests that Akt signaling kinases, Aurora kinases and CDK 1/2 might be of 
great importance for growth of the AI resistant cell lines. The EGFR inhibitor gefitinib did not inhibit 
growth of the AI resistant cell lines compared to the parental cell line MCF-7 in the validation studies. 
Therefore, the validations studies confirmed the findings from the kinase inhibitor screen, indicating 
that EGFR might not be of great important for growth of the resistant cell lines, despite the clear up 
regulation of EGFR seen in the letrozole resistant cell lines. Repeated studies with the EGFR inhibitor 
are needed to reach a final conclusion. 
Treatment with 1.0 µM of the CDK 1/2/9 inhibitor AZD5438 gave no significant growth inhibition in 
the dose-response growth experiments (figure 24), but was identified as a hit in the kinase inhibitor 
screen for both resistant cell lines. In the dose-response growth experiments, the SD for MCF-7 cells 
was quite high, which might explain the variation between the results. Therefore dose-response 
experiments with AZD5438 should be repeated. Regardless, the results from the validation studies 
with AZD5438 confirmed greater growth inhibition of LetR-1 and ExeR-1 compared to LetR-3 and ExeR-
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3, and a significant growth inhibition of the AI resistant cell lines was observed with treatment of 1.5 
µM AZD5438. These results together with the fact that JNJ-770621, which targets CDK 1/2 (in 
addition to Aurora kinase A and B), inhibited growth of the resistant cell lines, indicates that CDKs 
might be important for growth of the AI resistant cell lines.  
The DUB inhibitor WP-1130 has previously been identified as a hit in a similar kinase inhibitor screen 
using tamoxifen and fulvestrant resistant cell lines (C.W. Yde, unpublished data). Because WP-1130 
showed major growth inhibition of both LetR-1 and LetR-3 in the kinase inhibitor screen, it was of 
interest to test whether this inhibitor could inhibit growth of both the letrozole and exemestane 
resistant cell lines in the dose-response growth experiments. However, no growth inhibition of the AI 
resistant cell lines were observed (figure 28), suggesting that additional dose-response experiments 
are needed to reach a conclusion.       
In the kinase inhibitor screen, barasertib which targets Aurora B, was not identified as a hit for ExeR-1 
cells; however, in the validations studies ExeR-1 showed significantly growth inhibition by treatment 
with all concentrations of barasertib (0.5, 1.0 and 1.5 µM), see figure 29. The difference between the 
screen and the valdidation studies could be the relatively large variation in MCF-7 cells in the dose-
response growth experiments, and additional dose-response growth experiments are needed to 
make a final conclusion.   
In summary, both kinase inhibitor screens and dose-response growth experiments points out Aurora 
kinase A, Aurora kinase B, CDK 1/2/9 and Akt signaling kinases to be important for growth of the AI 
resistant cell lines.  
 Treatment with Selected Kinase Inhibitors Alters Cell Cycle Phase Distribution in the 5.6.2
Aromatase Inhibitor Resistant Cell Lines  
Aurora kinase A and B are important for correct progression through G2/M phase of the cell cycle 
and cytokinesis [106]. While barasertib is an selective Aurora B inhibitor, JNJ-7706621 inhibits both 
Aurora A and B, in addition to CDK 1 and CDK 2. CDK 1-cyclin A complex is important to promote 
entry into mitosis and mitosis is furthermore regulated by CDK 1-cyclin B complex. The CDK 2-cyclin A 
complex regulates progression through the S phase [97]. Like JNJ-7706621, AZD5438 also targets CDK 
1 and CDK 2, in addition to CDK 9, which has not been shown to be active during the cell cycle [97]. 
Further, activation of the PI3K/Akt pathway might have impact on cell cycle regulation as it 
stimulates cell cycle progression and is important in cell survival [81, 90]. The Aurora kinases and the 
CDKs have a major importance in cell cycle control and regulation. Given the importance of these 
kinases in successful cell cycle completion, inhibiting them would cause cell cycle phase disturbance. 
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Therefore, cell cycle analysis was performed on the AI resistant cell lines LetR-1 and ExeR-1 as well as 
the parental cell line MCF-7 upon treatment with AZD5438, A-674563, JNJ 7706621 and barasertib. 
The results revealed that the normal cell cycle phase distribution for MCF-7, LetR-1 and ExeR-1 was 
very similar. Treatment with 1.0 µM barasertib resulted in a major accumulation of cells in G2/M 
phase for MCF-7, LetR-1 and ExeR-1 cells. Treatment with 1.0 µM of JNJ-7706621 and AZD5438 also 
resulted in accumulation of cells in G2/M phase whereas treatment with 1.0 µM of the Akt inhibitor 
A-674563 only gave a minor accumulation of cells in G2/M phase for all three cell lines (figure 30). 
The minor accumulation of cells in G2/M phase when treated with A-674563 could be explained by 
the fact that A-674567 is an Akt inhibitor, indicating that Akt might not be as important for cell cycle 
regulation as CDKs and Aurora kinases.   
From the microscope pictures it could be seen that treatment with AZD5438, JNJ-7706621 and 
barasertib induced morphological changes in the resistant cell lines LetR-1 and ExeR-1 as well as in the 
parental MCF-7 cell line. From the pictures, it seemed that upon 48 hours treatment of 1.0 µM JNJ-
7706621 and 1.0 µM barasertib, both the parental cell line MCF-7 and the two resistant cell lines 
LetR-1 and ExeR-1 increased in size (figure 32, 33 and 34). All three cell lines also increased in size 
when treated with 1.0 µM AZD5438; however, treatment with barasertib and JNJ-7706621 seemed 
to result in a greater increase in cell size compared to AZD5438 treatment. Treatment with 1.0 µM A-
674563, did not show visible morphological differences from control, and could be explained as 
previously, because the Akt inhibitor A-674563 might not be as important for cell cycle regulation as 
AZD5438, JNJ-7706621 and barasertib, respectively. The observed increase in cell size in JNJ-7706621 
and barasertib treated cells is in agreement with the accumulation of the cells in G2/M phase, in 
which the cells have duplicated all materials and are ready for division into two daugther cells. 
As mentioned earlier, Aurora B is important for correct cell cycle progression and plays a key role in 
the maintenance of normal ploidy during cell division [105]. Since barasertib earlier has been shown 
to induce endoreduplication, resulting in increased number of cells with a DNA content above 4N 
[105], and because JNJ-7706621 also targets Aurora B, possible differences and/or similarities in cell 
cycle phase distributions between barasertib and JNJ-7706621 treatments were studied. The results 
revealed that normal MC7-7, LetR-1 and ExeR-1 cell cycle phase distributions had few polyploid cells. 
However, after 48 hours treatment with 1.0 µM barasertib, both the parental cell line and the 
resistant cell lines showed a major increase of polyploid cells (figure 31), which is in agreement with 
previous studies [105]. The reason for formation of polyploid cells upon barasertib treatment might 
be because Aurora B directly phosphorylate the Rb protein, which plays a critical role in regulating 
the postmitotic checkpoint to prevent endoreduplication (replication of the nuclear genome in 
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absence of cell division, which leads to elevated nuclear gene content and polyploidy) after an 
abnormal mitosis [105]. Even though JNJ-7706621 also targets Aurora B, an increase of polyploid 
cells was not seen in the three tested cell lines when treated with this inhibitor. The reason for lack 
of polyploidy in cells treated with JNJ-7706621 could be due to JNJ-7706621 dual targeting of both 
Aurora A/B and CDK 1/2, in contrast to barasertib, which is a specific Aurora B inhibitor. As 
mentioned earlier, Aurora A is important for centrosome maturation in the G2 phase and also plays 
an important role in promoting timely mitotic entry whereas Aurora B plays an important role for 
proper condensation and is an important regulator of mitotic spindle assembly [114]. Furthermore, it 
could be speculated if JNJ-7706621 targets Aurora A and CDK 1/2 more efficiently than it targets 
Aurora B.  
 Aurora A is Important for Growth of the Aromatase Inhibitor Resistant Cell Lines  5.7
Since the majority of the selected hits from the two kinase inhibitor screens targeted the Aurora 
kinases, CDKs and Akt signaling kinases, the basal level of total and phosphorylated Aurora proteins, 
total and phosphorylated Erk and total and phosphorylated Akt, was investigated. As mentioned 
previously, overexpressed Aurora A appeares to be phosphorylated on Thr288, which is known to be 
required for its enzymatic activation [116]. We found that Thr288-phosphorylated Aurora A was 
expressed at increased level in the AI resistant cell lines compared to MCF-7. Phosphorylation of 
Aurora A on Thr288 in its catalytic domain increases kinase activity [159], indicating that 
phosphorylation of Aurora A might lead to proliferation of the AI resistant cells. Total Aurora A 
expression was similar in MCF-7, LetR-1 and ExeR-1, whereas Aurora B was hardly detectable in any of 
the cell lines. Treatment with AZD5438 and JNJ-7706621 increased total level of Aurora A in all cell 
lines (figure 35 and 36), which is most probably due to arrest of cells in G2/M phase. As mentioned 
previously, the level of Aurora A is low in all cell cycle phases except in G2/M phase [106]. Together, 
these results suggests an important role of Aurora A for growth of AI resistant cell lines.  
To further investigate the importance of Aurora A for AI resistant cell growth, siRNA-mediated 
knockdown of the Aurora A protein was performed with MCF-7, LetR-1 and ExeR-1 cells. The results 
showed that knockdown of Aurora A exerted a minor growth inhibition of MCF-7 cells after four 
days. However, growth inhibition of LetR-1 and ExeR-1 cells was seen already two days after 
transfection and an even greater effect was seen after four days (figure 37). Western analysis 
showed complete knockdown of the Aurora A protein in all cell lines (figure 38). It should be 
mentioned that total Aurora A was more expressed in MCF-7 cells in the experiments studying 
Aurora A protein level treated with specific kinase inhibitors (figure 35 and 36), compared to the 
knockdown experiments (figure 38). Noteworthy, Aurora A could efficiently be shut down by siRNA-
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mediated knockdown in both the parental cell line and the AI resistant cell lines LetR-1 and ExeR-1, 
and the specific knock down of Aurora A inhibited growth of the AI resistant cell lines. Thus, Aurora 
kinase A appears to play an important role for growth of AI resistant cell lines. Aurora kinase A has 
been shown to phosphorylate ER leading to activation of the trancriptional activity of ER [115], and 
this may be the mechanism rendering the cells resistant to AI treatment (see later).  
 Patients might benefit from Combined Treatment with Aromatase Inhibitor and 5.8
Fulvestrant or an Aurora A Inhibitor 
Resistance to AIs is emerging and knowledge of the molecular mechanisms of AI resistance is of great 
importance to improve treatment. So far, research of aquired AI resistance has focused primarily on 
growth factors and intracellular crosstalk [50, 123, 124]. Furthermore, pre-clinical data have shown 
that the non-steroidal AI anastozole combined with the pure anti-estrogen fulvestrant is more 
effective than the AI alone [57]. Dose-response experiments with fulvestrant obtained in this thesis 
showed that fulvestrant exerted growth inhibition below the basal growth level for the AI resistant 
cell lines (figure 16C and D), demonstrating that ER is a major driver of AI resistant cell growth, and 
indicating that fulvestrant might be used as new treatment option for breast cancer patients upon 
relapse with an AI. 
A study has shown that Aurora A directly interacts with ER and phosphorylates ER on serine 167 and 
serine 305, leading to an increase in ER DNA-binding and transcriptional activity [115]. Our results 
indicate that Aurora kinase A is important for growth of the AI resistant cell lines. As mentioned, we 
have also shown that ER is functional in the AI resistant cells and is a major driver of AI resistant cell 
growth. Together, these results indicate that there could be a link between ER and Aurora kinase A, 
where increased level of Aurora A could lead to phosphorylation of ER and thus proliferation of the 
AI resistant breast cancer cells. Combined treatment wih an AI and an Aurora A inhibitor might 
therefore be a new treatment option for ER+ breast cancer patient upon relapse with an AI.  
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6 Conclusion 
We found that both letrozole and exemestane resistant cell lines had progressed towards reduced 
dependence of estrogen stimulation. However, the AI resistant cell lines could be growth stimulated 
by testosterone if the AI was omitted from the growth medium. Thus, we conclude that the AI 
resistant cell lines are not completely estrogen independent, but have the ability to grow continously 
without estrogen, and that aromatization of testosterone is responsible for the growth.  
Noteworty, we found cross-resistance between the non-steroidal AI letrozole and the steroidal AI 
exemestane, suggesting that the resistance mechanisms to the two AIs may include similar growth 
pathways and that resistant cell growth is not due to escape from suppression of aromatase enzyme 
activity by the specific AI.  
Our findings that both tamoxifen and fulvestrant could suppress growth of the AI resistant cell lines 
demonstrated that ER is involved in AI resistant cell growth, and based on the observation that the 
ER down modulator fulvestrant could exert complete growth inhibition, we conclude that ER is a 
major driver of growth of both letrozole and exemestane resistant cell lines. Furthermore, the 
complete growth inhibition by fulvestrant, indicates that fulvestrant may be used as second line 
treatment for AI resistant cells. Western analyses confirmed the presence of a functional ER in both 
letrozole and exemestane resistant cell lines. Noteworty, EGFR was up regulated in the letrozole 
resistant cell lines, but not in exemestane resistant cells, suggesting that the different types of AIs 
select for different growth promoting changes in the resistant cells. This must be taken with 
precaution, as we were not able to show that the EGFR played a major role for growth of the 
letrozole resistant cell lines.  
The kinase inhibitor screens and the validation studies unraveled both similarities and differences 
between the letrozole and exemestane resistant cells. We conclude that Aurora kinase A is important 
for both letrozole and exemestane resistant cell growth, and as recently published data have shown 
that Aurora A kinase can activate the ER via phosphorylation [115], activation of Aurora kinase A may 
be responsible for the ER mediated growth. Therefore, we suggest that treatment with an AI in 
combination with an Aurora A inhibitor may be an efficient treatment option for breast cancer 
patients with aquired resistance to both letrozole and exemestane.   
In summary, these studies with an in vitro cell culture model showed many similarities between cell 
lines resistant to letrozole and exemestane, where the most important findings were ER as a major 
driver of growth of the AI resistant cell lines and the importance of Aurora A kinase for AI resistant 
cell growth. 
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7 Future Perspectives  
Data from the kinase inhibitor screens revealed that the majority of the kinase inhibitors, which 
exerted a preferentially and twofold higher growth inhibition of the AI resistant cell lines compared 
to the parental MCF-7 cell lines, targeted Aurora kinases, CDKs and Akt signaling kinases. Especially, 
Aurora kinase A appeared to play an important role in AI resistant cells, but the mechanisms whereby 
Aurora A may confer AI resistance are unclear. Since Aurora kinase A have been shown to play an 
important role in cell cycle regulation, where it regulates several functions, it could be thought that 
Aurora A might be involved in the ability of the AI resistant cells to survive treatment with an AI, but 
also in promoting growth despite of treatment. If expression of Aurora A correlates with cancer 
progression, it would be expected that tumors with acquired AI resistance, have a higher expression 
of Aurora A protein at time of progression, compared to the level in the primary tumor. It could 
therefore be considered to examine clinical material (e.g. by immunohistochemical analysis) from 
primary tumors and corresponding metastases from breast cancer patients treated with AI, with 
respect to level of Aurora A in these tissue samples. In order to evaluate whether high Aurora A 
expression is related to poor response to AI treatment, analysis of time to progression for breast 
cancer patients receiving adjuvant AI therapy in relation to the expression level of Aurora A protein 
in the primary tumor could be performed.    
A recent paper has shown that Aurora kinase A phosphorylates ER and thereby activates the 
transcriptional activity of ER [115]. To explore whether this is the main function of Aurora A in AI 
resistant cell lines, phosphorylated ER could be measured in AI resistant cell lines grown with and 
without an Aurora kinase A inhibitor. The transcriptional activity of ER in presence and absence of an 
Aurora kinase A inhibitor could also be measured via transfection with ERE reporter constructs and 
by measurement of expression of endogenous proteins regulated by estrogen.  
The cell cycle analysis performed with the Aurora A/B and CDK 1/2 inhibitor, JNJ-7706621, were only 
performed once and should therefore be verified by repeating the experiments. Also, cell cycle 
analysis with AZD5438, A-674563 and barasertib should be verified by repeating the experiments. 
Furthermore, western analysis with  AZD5438-, A-674563-, JNJ-7706621- and barasertib treatments, 
investigating phosphorylated and total expression of Aurora kinases, which was not fully optimal, 
should be replicated to reach a conclusion. To investigate if cell cycle phase distribution in the 
resistant cells is altered upon Aurora A protein knockdown, cell cycle analysis by FACS could be 
performed, which may provide more knowledge about the role of Aurora kinase A for AI resistant cell 
growth. Further, it would be interesting to examine growth of the AI resistant cells, when treated 
with both JNJ-7706621 and AZD5438, JNJ-7706621 and A-674563 or JNJ-7706621 and barasertib. If 
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additional growth inhibition is obtained with any of the combined treatments, compared to 
treatment with an inhibitor alone, combined treatment might be better to inhibit AI resistant cell 
growth, and in the future, might be a new treatment option for breast cancer patients. 
To study whether growth inhibition of the AI resistant cell lines treated with the selected kinase 
inhibitors was due to cell death, a cell death assay (e.g. LDH assay) could be performed, treating the 
cells with both a kinase inhibitor and an AI. If cell death occurs, it could be considered to further 
investigate the nature of cell death induced by the selected kinase inhibitor, by measuring levels of 
anti-apoptotic proteins such as Bcl-2, Mcl-1 or cleavage of poly ADP-ribose polymerase (PARP, which 
is indicative of apoptosis).  
Aurora kinase A, which was found to be the most important kinase driving AI resistant cell growth, 
has previously shown to be overexpressed in human breast cancer [105]. We found that five of the 
hits from the kinase inhibitor screen targetet Aurora A, but only one of them; JNJ-7706621, was 
selected for validation studies. Therefore, it would be interesting to investigate if the four other 
Aurora A inhibitors also can inhibit growth of the AI resistant cell lines.  
Aquired resistance to AI is a major problem in the clinic and better understanding of the molecular 
mechanisms responsible for development of resistance would be beneficial for effectively treating 
hormone-dependent breast cancer. Understanding the signaling pathways involved in AI resistance 
and develop new inhibitors to target these pathways are a challenge, but it is also challenging to 
deside which drugs to pick, how to combine them, and find out how good they will be tolerated with 
respect to side effects. To get a better insight into the molecular mechanisms involved in AI 
resistance, additional AI resistant cell lines may be used. At the Breast Cancer Group, several AI 
resistant cell lines are available; both additional clones of letrozole resistant cell lines (LetR-2 and 
LetR-4) and exemestane resistant cell lines (ExeR-2 and ExeR-4) are available, and also cell lines 
resistant to the non-steroidal AI anastrozole are available. It may also be beneficial to use another 
model system, e.g. model system with T47D cells, and in our laboratory, it has been shown that T47D 
cells can be stimulated with testosterone and inhibited by an AI (A.L. Lykkesfeldt, unpublished data).  
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Appendix 1 
The figure below shows the optimization experiment performed to investigate whether wash with 
1% PBS before crystal violet staining was necessary when seeding in a 96-well plate.  
 
 
 
 
Figure A1: Optimization of Cell Number Measured by Crystal Violet Staining With and Without PBS wash. 800 MCF-
7 cells were seeded in 96-well plates in medium containing 1% FBS and 1200 cells were seeded in 96-well plates in 
medium containing 10% NCS. On day 2 experimental medium (10% NCS+Testosterone (10-7M)) were added to MCF-7 
cells seeded in 10% NCS and crystal violet staining was performed on day 7. Before staining, 1/3 of the cells were not 
washed with PBS, 1/3 were washed with 1xPBS and 1/3 were washed with 2xPBS. The experiment was performed 
with eight sample replicates. Mean cell numbers in percentage of controls and standard deviations are shown.  
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Appendix 2 
An optimization experiment of cell number (measured by crystal violet staining) for setup for the 
kinase inhibitor screen is shown in the figure below.  
 
 
 
Figure A2: Optimization of Cell Number Measured by Crystal Violet Staining. 500, 1000, 1500 and 2000 MCF-7 and 
LetR-1 were seeded in 96-well plates in standard growth medium. On day 1 MCF-7 cells were switched from 1% FBS 
to 10% NCS+Testosterone (10-7M). On day 2 and 5 medium was renewed and on day 7 cells were stained with crystal 
violet. The experiment was performed with four sample replicates. OD versus cell number is shown.  
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Appendix 3 
An optimization experiment of cell number (measured by luminescence) for setup for the kinase 
inhibitor screen is shown in the figure below.  
 
 
 
Figure A3: Optimization of Cell Number Measured by Luminescence. 500, 1000, 1500 and 2000 MCF-7 and LetR-1 
were seeded in 96-well plates in standard growth medium. On day 1 MCF-7 cells were switched from 1% FBS to 10% 
NCS+Testosterone (10-7M). On day 2 experimental medium containing A) vehicle, B) 10-8M fulvestrant or C) 10-7M 
fulvestrant were added and renewed on day 5. Treatment with fulvestrant was used as a control for the setup, since 
fulvestrant is known to inhibit growth of these cells. Crystal violet staining was performed on day 7 and the 
experiment was performed with four sample replicates. Mean Relative Light Unit (RLU) versus cell number is shown.  
 
A 
B 
C 
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Appendix 4 
In the figure below, an optimization experiment of cell number (measured by crystal violet staining) 
for setup for the kinase inhibitor screen is shown.  
 
 
 
Figure A4: Optimization of Cell Number Measured by Crystal Violet Staining. 2000 MCF-7 cells, 500 LetR-1 cells and 
500 LetR-3 cells were seeded in 96-well plates in standard growth medium. On day 1 MCF-7 cells were switched from 
1% FBS to 10% NCS+Testosterone (10-7M). On day 2 experimental medium containing vehicle and fulvestrant in the 
indicated concentrations were added and renewed on day 5. Treatment with fulvestrant was used as a control for 
the setup, since fulvestrant is known to inhibit growth of these cells. Crystal violet staining was performed on day 7 
and the experiment was performed with eight sample replicates. Cell number versus fulvestrant treatment is shown. 
Asterisks indicate statistically significant difference between cells treated with fulvestrant and controls.  
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Appendix 5 
The figures below show the establishment of letrozole and exemestane resistant cell lines. 
 
 
 
 
Figure A5: Establishment of Letrozole Resistant Cell Lines. The letrozole resistant cell lines were established from 
the parental estrogen receptor positive (ER+) MCF-7 breast cancer cell line, and were treated with letrozole (10-6M) 
for 9 days and then the culture was trypsinized and seeded in multiwell dishes with different amounts of cells. 
Isolated single colonies of growing cells were found in the wells seeded with 40 or 80 cells per well. After about one 
month, surviving colonies could be isolated and after further 1.5 months, isolated colonies were established as cell 
lines which could be passaged weekly. 
 
 
Figure A6: Establishment of Exemestane Resistant Cell Lines. The exemestane resistant cell lines were established 
from the parental estrogen receptor positive (ER+) MCF-7 breast cancer cell line, and were treated with exemestane 
(10-7M) for one week and then the culture was trypsinized and seeded in multiwell dishes with different amounts of 
cells. Isolated single colonies of growing cells were found in the wells seeded with 40 or 80 cells per well. After about 
one month, surviving colonies could be isolated and after further 1.5 months, isolated colonies were established as 
cell lines which could be passaged weekly. 
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Appendix 6 
The table below shows data from the kinase inhibitor screen with the letrozole resistant cell lines.  
 
Table A1:Results from the Kinase Inhibitor Screen with the Letrozole Resistant Cell Lines. Triplicate samples of 
parental MCF-7 and letrozole resistant Let
R
-1 and Let
R
-3 cells were treated with 1.0 µM of the indicated kinase 
inhibitors for 5 days. Cell number was determined by a cell viability assay. Inhibitory effect  standard deviation 
(SD) and targets of the kinase inhibitors are shown. 
 Inhibitory Effect ± SD (%) p-value  
Inhibitor MCF-7 Let
R
-1 Let
R
-3 
Let
R
-
1 vs. 
MCF-
7 
Let
R
-
3 vs. 
MCF-
7 
Target(s) 
BMS-599626 -2.10 ± 3.85 31.31 ± 18.91 16.71 ± 5.35 0.02 0.00 EGFR,   HER2 
Erlotinib 
Hydrochloride 
14.67 ± 5.83 44.65 ± 35.79 20.24 ± 2.54 0.11 0.05 EGFR 
Gefitinib(Iressa) 4.08 ± 2.43 34.58 ± 24.85 10.04 ± 9.98 0.05 0.21 EGFR, Akt 
Neratinib 72.46 ± 8.53 68.72 ± 24.61 76.28 ± 0.41 0.40 0.03 HER2 
PD153035 
hydrochloride 
-0.76 ± 2.67 25.29 ± 15.19 6.37 ± 10.23 0.03 0.20 EGFR 
Pelitinib 46.50 ± 4.18 56.96 ± 8.08 52.71 ± 4.38 0.05 0.05 EGFR 
Vandetanib 20.00 ± 11.99 16.19 ± 17.53 17.25 ± 3.07 0.37 0.20 
VEGFR, EGFR, 
SFKs 
WZ3146 7.66 ± 2.82 16.62 ± 28.31 20.42 ± 4.69 0.32 0.08 EGFR 
WZ4002 -0.42 ± 8.86 20.56 ± 8.15 1.02 ± 7.03 0.01 0.38 EGFR 
WZ8040 -4.42 ± 8.78 16.47 ± 4.04 11.79 ± 5.11 0.01 0.03 EGFR 
AV-951 
(Tivozanib) 
0.47 ± 4.69 10.10 ± 2.58 3.52 ± 3.85 0.07 0.31 VEGFR, PDGFR 
Axitinib 8.79 ± 3.29 24.13 ± 1.18 19.94 ± 6.38 0.00 0.04 VEGFR 
BIBF1120 
(Nintedanib) 
64.03 ± 4.33 68.06 ± 7.45 63.05 ± 4.57 0.22 0.39 
SFKs,FGFR, 
VEGFR, PDGFR 
BMS 794833 0.42 ± 13.06 3.27 ± 6.01 2.13 ± 7.62 0.27 0.38 
VEGFR, c-Met, 
Flt 
Cediranib 
(AZD2171) 
10.63 ± 1.16 11.73 ± 3.63 12.82 ± 9.18 0.45 0.41 VEGFR 
CYC116 28.69 ± 1.41 58.95 ± 0.76 46.64 ± 5.50 0.00 0.00 Aurora, VEGFR 
Imatinib(STI571) -14.10 ± 6.14 -9.09 ± 6.14 
-
14.95 
± 2.95 0.12 0.34 VEGFR, PDGFR 
Imatinib Mesylate -13.86 ± 2.72 -0.87 ± 12.59 6.56 ± 8.02 0.09 0.01 c-Kit, PDGFR 
Ki8751 11.75 ± 5.99 16.11 ± 10.04 11.92 ± 2.48 0.25 0.47 
c-Kit, VEGFR, 
PDGFR, 
KRN 633 1.38 ± 2.36 7.12 ± 3.41 7.41 ± 2.43 0.11 0.09 VEGFR 
Masitinib 
(AB1010) 
1.40 ± 5.18 7.93 ± 9.83 6.80 ± 5.11 0.16 0.09 
c-Kit, PDGFR, 
FGFR 
MGCD-265 7.66 ± 2.69 3.83 ± 6.83 1.31 ± 6.71 0.24 0.13 
c-Met, VEGFR, 
Tie-2 
Motesanib 
Diphosphate 
1.15 ± 8.53 2.06 ± 6.23 2.14 ± 7.84 0.41 0.42 
VEGFR, PDGFR, 
SFKs 
MP-470 7.81 ± 3.15 1.15 ± 1.88 4.12 ± 8.75 0.13 0.31 
c-Kit, PDGFR, c-
Met 
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OSI-930 -23.42 ± 4.84 -11.3 ± 3.67 -4.59 ± 7.11 0.01 0.01 c-Kit, VEGFR 
Pazopanib 
Hydrochloride 
-1.11 ± 4.35 7.03 ± 8.89 1.66 ± 3.43 0.12 0.23 VEGFR 
Sorafenib Tosylate -23.76 ± 4.72 
-
11.92 
± 9.46 3.69 ± 5.41 0.06 0.00 
VEGFR, PDGFR, 
RAF 
Sunitinib Malate 13.21 ± 5.17 19.65 ± 4.75 8.78 ± 3.25 0.09 0.13 
FLT3, PDGFR, 
VEGFR 
TSU-68 -14.87 ± 5.23 0.13 ± 6.88 -3.12 ± 9.48 0.02 0.07 
VEGFR, PDGFR, 
FGFR 
Vatalanib 14.64 ± 1.43 11.88 ± 10.00 7.49 ± 7.99 0.35 0.13 
VEGFR, c-Kit, 
VEGFR, 
XL880 
(GSK1363089) 
38.77 ± 3.01 56.44 ± 2.88 57.34 ± 2.59 0.00 0.00 c-Met, VEGFR 
PHA-739358 
(Danusertib) 
58.89 ± 0.59 83.22 ± 4.24 75.36 ± 1.34 0.00 0.00 Aurora, Bcr-Abl 
AT9283 33.01 ± 4.75 62.32 ± 0.38 61.25 ± 4.16 0.00 0.00 
Aurora, JAK, 
Bcr-Abl 
AZD0530 
(Saracatinib) 
30.82 ± 3.20 48.25 ± 6.90 41.09 ± 5.37 0.01 0.03 SFKs, Abl 
Bosutinib 
(SKI-606) 
23.45 ± 2.15 48.17 ± 6.65 42.79 ± 5.13 0.00 0.00 SFKs 
Dasatinib 43.71 ± 4.09 52.21 ± 7.61 37.78 ± 7.23 0.07 0.12 SFKs, Abl, c-kit 
Nilotinib 12.21 ± 5.23 2.68 ± 6.15 1.15 ± 11.04 0.04 0.09 Bcr-Abl 
Quercetin 
(Sophoretin) 
-7.93 ± 4.24 
-
11.15 
± 4.93 -4.41 ± 6.23 0.24 0.25 PI3K, PKC 
NVP-ADW742 22.38 ± 9.14 33.38 ± 6.14 23.94 ± 3.30 0.03 0.32 IGF-1R 
AC-220 3.50 ± 5.55 19.84 ± 8.44 18.89 ± 4.01 0.04 0.03 FLT-3 
AP24534 30.60 ± 1.01 49.69 ± 5.77 40.84 ± 2.92 0.01 0.02 
VEGFR, FGFR, 
PDGFR 
Tandutinib (MLN518) -0.51 ± 2.35 -0.75 ± 4.07 3.78 ± 5.66 0.46 0.13 
FLT-3, PDGFR, 
KIT 
KW 2449 22.89 ± 0.82 52.08 ± 6.80 45.00 ± 0.91 0.00 0.00 
FLT-3, ABL, 
Aurora 
CI-1033 
(Canertinib) 
31.73 ± 3.25 30.18 ± 2.07 19.74 ± 4.39 0.15 0.00 HER2, EGFR 
CP-724714 7.34 ± 8.70 10.09 ± 10.64 8.10 ± 7.48 0.35 0.44 HER2 
BAY 73-4506 
(Regorafenib) 
-6.41 ± 4.19 -3.37 ± 8.42 5.53 ± 3.14 0.34 0.04 
c-KIT, VEGFR, 
B-Raf 
JNJ-38877605 -4.95 ± 7.76 4.00 ± 6.48 1.08 ± 3.09 0.06 0.06 c-Met 
PF-04217903 -7.18 ± 10.74 4.42 ± 6.87 8.09 ± 8.86 0.06 0.04 c-Met 
PF-2341066 -1.11 ± 8.14 16.76 ± 6.01 18.97 ± 7.68 0.03 0.03 c-Met, ALK 
SGX-523 -8.56 ± 9.38 -5.67 ± 12.54 -2.87 ± 10.50 0.38 0.25 c-Met 
SU11274 
(PKI-SU11274) 
12.88 ± 0.55 11.81 ± 6.04 19.28 ± 3.48 0.44 0.16 c-Met 
NVP-TAE684 48.86 ± 2.52 68.70 ± 0.42 52.77 ± 2.37 0.00 0.02 ALK 
SB 525334 10.60 ± 2.20 8.41 ± 2.74 25.42 ± 2.56 0.18 0.00 ALK, TGF-β 
R406 26.71 ± 0.17 28.96 ± 1.34 16.40 ± 5.45 0.10 0.02 Syk 
R406 (free base) 22.74 ± 4.10 23.74 ± 2.54 20.85 ± 7.34 0.27 0.34 Syk 
XL184 8.80 ± 0.53 7.44 ± 1.55 7.32 ± 8.35 0.31 0.40 
c-Met, FLT-3, 
Tie2 
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BI 2536 67.26 ± 3.23 95.93 ± 0.24 90.62 ± 0.74 0.00 0.00 PLK 
GSK461364 52.42 ± 5.75 93.41 ± 0.83 85.70 ± 1.68 0.00 0.00 PLK 
HMN-214 57.95 ± 2.52 93.82 ± 0.57 85.65 ± 1.09 0.00 0.00 PLK 
ON-01910 69.85 ± 0.98 96.31 ± 0.19 87.01 ± 2.50 0.00 0.00 PLK 
AT7519 91.09 ± 1.07 97.50 ± 0.25 97.91 ± 0.27 0.00 0.00 CDK 
Flavopiridol 
(Alvocidib) 
86.54 ± 0.65 97.83 ± 0.19 96.70 ± 0.54 0.00 0.00 CDK 
BS-181 hydrochloride 4.29 ± 2.03 5.00 ± 6.89 7.60 ± 0.20 0.43 0.00 CDK 
PD0332991 53.25 ± 1.11 52.23 ± 2.53 57.15 ± 3.57 0.31 0.09 CDK 
PHA-793887 56.73 ± 0.68 77.81 ± 0.21 71.42 ± 3.46 0.00 0.00 CDK 
Roscovitine 
(CYC202) 
2.29 ± 2.61 -7.91 ± 7.19 -0.29 ± 3.48 0.04 0.14 CDK 
SNS-032 
(BMS-387032) 
86.85 ± 2.36 98.71 ± 0.17 97.59 ± 0.01 0.00 0.00 CDK 
AZD7762 66.69 ± 2.09 91.10 ± 0.65 87.91 ± 0.93 0.00 0.00 Chk1/2 
Aurora A Inhibitor I 51.56 ± 10.80 67.21 ± 1.23 63.26 ± 3.18 0.00 0.00 Aurora A 
AZD1152-HQPA 
(Barasertib) 
21.30 ± 3.79 46.70 ± 3.16 39.29 ± 0.63 0.01 0.02 Aurora B 
CCT129202 33.32 ± 8.65 64.40 ± 31.29 29.14 ± 5.16 0.08 0.16 Aurora 
ENMD-2076 33.47 ± 1.80 75.65 ± 21.16 60.11 ± 2.15 0.02 0.00 
Aurora, Flt3/4, 
SFKs, VEGFR2 
Hesperadin 71.58 ± 5.48 86.84 ± 1.49 81.57 ± 2.07 0.00 0.00 Aurora B 
MLN8237 35.61 ± 2.33 55.64 ± 4.61 46.08 ± 2.14 0.00 0.02 Aurora 
PHA-680632 49.34 ± 3.39 71.18 ± 2.90 54.98 ± 4.95 0.00 0.07 Aurora 
SNS-314 Mesylate 33.26 ± 8.22 41.75 ± 2.03 32.77 ± 5.64 0.01 0.45 Aurora 
VX-680 32.74 ± 5.37 54.66 ± 10.27 47.15 ± 3.07 0.02 0.02 Aurora 
ZM-447439 34.32 ± 0.92 51.96 ± 5.78 48.15 ± 1.05 0.01 0.01 Aurora 
AS703026 28.17 ± 20.01 26.31 ± 6.88 9.94 ± 6.60 0.33 0.00 MEK 
AZD6244 
(Selumetinib) 
6.95 ± 2.04 18.65 ± 5.57 6.69 ± 2.39 0.19 0.49 MEK 
AZD8330 22.67 ± 18.24 46.64 ± 46.46 40.16 ± 51.66 0.21 0.29 MEK 
BIX 02188 1.92 ± 4.64 35.55 ± 56.49 7.70 ± 2.03 0.19 0.31 MEK 
BIX 02189 11.18 ± 7.16 23.96 ± 5.90 11.63 ± 8.65 0.02 0.47 MEK 
BMS 777607 -0.21 ± 6.71 13.81 ± 10.47 -1.55 ± 5.86 0.06 0.41 c-Met 
CI-1040 (PD184352) 12.04 ± 7.29 27.71 ± 2.28 7.90 ± 4.85 0.01 0.22 MEK 
PD318088 20.63 ± 5.17 23.73 ± 13.12 12.18 ± 5.90 0.37 0.10 MEK 
PD0325901 16.58 ± 7.91 19.13 ± 6.00 7.99 ± 0.62 0.30 0.02 MEK 
PD98059 13.85 ± 6.85 10.02 ± 11.89 -3.03 ± 8.33 0.33 0.03 MEK 
U0126-EtOH 7.39 ± 11.27 11.79 ± 1.64 -1.51 ± 5.37 0.17 0.08 MEK 
LY2228820 -1.97 ± 7.11 -6.66 ± 8.59 -7.36 ± 4.67 0.30 0.24 p38 MAPK 
BIRB 796 10.84 ± 10.13 -5.64 ± 4.52 
-
10.52 
± 5.89 0.01 0.01 p38 MAPK 
SB 202190 -4.96 ± 17.84 -8.80 ± 15.03 -3.05 ± 5.01 0.37 0.39 p38 MAPK 
SB 203580 -0.43 ± 0.40 8.08 ± 6.65 7.76 ± 6.08 0.24 0.25 p38 MAPK 
Vinorelbine 
(Navelbine) 
83.11 ± 7.72 97.88 ± 0.51 97.77 ± 0.26 0.00 0.00 p38 MAPK 
VX-702 8.16 ± 5.25 4.39 ± 6.59 8.71 ± 4.88 0.28 0.46 p38 MAPK 
APPENDIX 
 
113 
 
VX-745 3.98 ± 3.51 1.20 ± 4.63 2.91 ± 2.45 0.26 0.38 p38 MAPK 
GDC-0879 -26.49 ± 3.21 
-
10.87 
± 4.07 4.23 ± 6.05 0.00 0.00 B-Raf 
PLX-4720 -15.69 ± 3.00 
-
12.88 
± 4.45 
-
20.06 
± 4.64 0.21 0.13 B-Raf 
RAF265 7.61 ± 1.68 4.52 ± 12.31 14.66 ± 1.05 0.35 0.01 RAF, VEGFR 
SP600125 -5.96 ± 4.91 -5.65 ± 3.96 -4.95 ± 6.12 0.45 0.40 JNK 
AZD6482 13.76 ± 6.34 13.17 ± 2.69 12.01 ± 7.55 0.43 0.38 PI3K 
AS-605240 11.01 ± 3.98 5.46 ± 10.15 11.09 ± 3.48 0.23 0.49 PI3K 
GDC-0941 71.38 ± 3.27 86.27 ± 0.76 90.40 ± 1.76 0.00 0.00 PI3K 
IC-87114 5.59 ± 3.84 3.96 ± 11.32 -0.45 ± 7.41 0.41 0.13 PI3K 
LY294002 8.48 ± 5.65 -0.23 ± 1.66 2.96 ± 3.97 0.01 0.08 
PI3K, casein 
kinase II 
PIK-293 -1.53 ± 3.04 -5.36 ± 3.04 1.81 ± 3.74 0.18 0.22 PI3K 
PIK-90 72.09 ± 0.32 84.91 ± 1.72 88.02 ± 1.69 0.00 0.00 PI3K 
PIK-93 33.88 ± 2.37 40.70 ± 6.71 48.53 ± 3.80 0.13 0.01 PI3K 
TG100-115 9.67 ± 5.90 5.48 ± 2.06 4.95 ± 5.11 0.04 0.11 PI3K 
TGX-221 10.22 ± 2.61 6.97 ± 8.72 10.56 ± 4.57 0.31 0.47 PI3K 
XL147 7.09 ± 3.74 1.78 ± 5.80 5.75 ± 1.20 0.11 0.23 PI3K 
XL765 1.79 ± 0.93 -4.06 ± 8.98 0.86 ± 3.96 0.18 0.39 PI3K 
ZSTK474 65.33 ± 2.52 75.03 ± 4.86 79.26 ± 1.35 0.01 0.00 PI3K 
AZD8055 82.88 ± 1.40 97.11 ± 0.09 95.69 ± 0.31 0.00 0.00 mTOR 
Deforolimus(MK-
8669) 
62.79 ± 3.31 73.23 ± 2.87 75.29 ± 1.40 0.00 0.00 mTOR 
Everolimus(RAD001) 59.65 ± 3.19 40.59 ± 3.97 74.34 ± 1.65 0.00 0.00 mTOR 
KU-0063794 79.69 ± 1.66 92.01 ± 1.35 93.31 ± 0.32 0.00 0.00 mTOR 
Rapamycin(Sirolimus) 60.88 ± 2.87 69.90 ± 2.34 76.88 ± 4.46 0.00 0.00 mTOR 
Temsirolimus 50.60 ± 2.11 72.26 ± 2.59 74.38 ± 2.70 0.00 0.00 mTOR 
WYE-354 79.42 ± 0.95 92.99 ± 1.30 92.78 ± 0.49 0.00 0.00 mTOR 
PIK-75 Hydrochloride 93.00 ± 2.13 98.95 ± 0.07 98.68 ± 0.19 0.00 0.00 PI3K 
CHIR-99021 0.46 ± 7.44 -7.46 ± 8.61 
-
13.70 
± 5.86 0.10 0.01 GSK-3 
Indirubin 7.95 ± 8.99 17.90 ± 6.13 21.46 ± 3.05 0.07 0.02 GSK-3 
SB 216763 -1.99 ± 3.45 9.36 ± 11.15 2.91 ± 1.89 0.12 0.20 GSK-3 
KU-55933 -2.32 ± 5.49 2.34 ± 3.60 -7.61 ± 9.65 0.09 0.21 ATM 
KU-60019 26.62 ± 3.70 -6.02 ± 2.78 6.55 ± 2.49 0.00 0.00 ATM 
MK-2206 (AKT inh) 36.70 ± 5.96 69.25 ± 1.41 83.92 ± 1.11 0.00 0.00 Akt 
AT7867 (AKT inh) 4.29 ± 3.94 20.75 ± 3.35 25.87 ± 7.39 0.01 0.01 Akt, S6 kinase 
AZD1480 20.17 ± 1.45 19.10 ± 1.56 18.69 ± 0.99 0.34 0.28 JAK 
LY2784544 26.78 ± 8.63 33.37 ± 6.51 16.12 ± 4.76 0.08 0.01 JAK 
Enzastaurin -4.63 ± 5.94 
-
10.98 
± 7.91 -3.71 ± 5.13 0.20 0.44 PKC 
SB 431542 0.61 ± 5.25 0.96 ± 9.03 12.35 ± 4.04 0.48 0.02 ALK 
ABT-869(Linifanib) 1.15 ± 3.82 1.16 ± 4.47 2.08 ± 9.58 0.50 0.44 
RTK, VEGFR, 
PDGFR 
AEE788 20.63 ± 8.17 33.97 ± 3.23 31.91 ± 1.58 0.00 0.00 
EGFR, HER2, 
VEGFR 
BIBW2992(Tovok) 3.62 ± 2.72 10.94 ± 13.72 9.51 ± 10.68 0.24 0.25 EGFR, HER2 
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Lapatinib Ditosylate -0.85 ± 3.92 6.66 ± 6.18 2.46 ± 5.04 0.06 0.19 EGFR, HER2 
JNJ-7706621 5.34 ± 0.94 26.39 ± 5.95 27.47 ± 1.08 0.00 0.00 Aurora, CDK 
BEZ235 83.65 ± 4.69 95.92 ± 0.75 94.61 ± 0.55 0.00 0.00 PI3K, mTOR 
GSK1059615 77.58 ± 4.81 81.00 ± 4.19 91.53 ± 2.10 0.20 0.00 PI3K, mTOR 
PI-103 73.38 ± 2.69 94.19 ± 1.03 94.07 ± 0.45 0.00 0.00 PI3K, mTOR 
AG-490 -1.67 ± 4.81 2.25 ± 10.48 -1.89 ± 5.09 0.28 0.48 EGFR, JAK 
CP-690550 
(Tofacitinib) 
-3.28 ± 5.40 2.75 ± 7.29 -1.38 ± 4.30 0.15 0.32 JAK 
Crenolanib (CP-
868569) 
-4.92 ± 3.33 19.47 ± 1.98 9.76 ± 6.96 0.00 0.02 PDGFR 
GSK1838705A 7.56 ± 2.79 24.67 ± 5.63 12.28 ± 5.92 0.01 0.15 IGF-1R 
KX2-391 71.10 ± 5.40 97.72 ± 0.23 92.20 ± 0.14 0.00 0.00 SFKS 
NVP-BSK805 -4.08 ± 5.15 -5.03 ± 6.47 -6.12 ± 5.36 0.43 0.33 JAK 
PCI-32765 10.99 ± 2.47 17.66 ± 10.05 13.57 ± 2.19 0.18 0.23 SFKS 
PF-562271 13.09 ± 9.28 17.83 ± 3.18 -0.86 ± 4.95 0.06 0.01 FAK, Pyk2 
DCC-2036 0.39 ± 8.44 8.91 ± 14.42 10.72 ± 1.41 0.22 0.06 SFKs, bcr-Abl 
LDN193189 -3.03 ± 10.88 16.65 ± 8.53 23.02 ± 11.16 0.02 0.02 BMP 
AZD8931 17.31 ± 19.43 26.49 ± 6.90 24.87 ± 9.16 0.14 0.20 EGFR, HER2 
Raf265 derivative -13.68 ± 25.75 2.24 ± 5.54 -7.79 ± 11.59 0.12 0.34 Syk 
NVP-BHG712 -14.97 ± 12.37 6.51 ± 8.80 2.42 ± 7.54 0.12 0.16 
VEGFR, SFKS, c-
Abl 
OSI-420 -14.20 ± 17.11 4.67 ± 6.83 12.73 ± 11.68 0.05 0.04 EGFR 
R935788 
(Fostamatinib) 
3.61 ± 10.12 22.06 ± 4.74 16.89 ± 9.22 0.07 0.15 Syk 
AZ 960 50.61 ± 6.35 84.90 ± 2.23 75.73 ± 3.06 0.00 0.01 JAK, Aurora 
Mubritinib (TAK 165) 29.44 ± 62.89 13.77 ± 4.28 10.20 ± 5.28 0.01 0.01 EGFR, CDK 
PP242 43.32 ± 13.85 93.12 ± 0.81 93.31 ± 0.72 0.12 0.12 mTOR 
Cyt387 32.59 ± 14.32 12.69 ± 8.63 7.58 ± 5.23 0.05 0.02 JAK 
Apatinib -24.87 ± 20.41 4.61 ± 4.63 -5.28 ± 1.69 0.01 0.04 EGFR 
CAL-101 2.50 ± 12.60 10.86 ± 10.99 -1.96 ± 10.52 0.28 0.38 PI3K 
PIK-294 -4.71 ± 14.83 8.30 ± 6.07 15.95 ± 9.69 0.09 0.04 PI3K 
VX-765 -5.46 ± 8.51 3.59 ± 8.50 4.33 ± 3.99 0.21 0.17 Caspase 
Telatinib 
(BAY 57-9352) 
-16.47 ± 7.42 -5.54 ± 4.09 8.93 ± 5.78 0.06 0.01 
VEGFR,PDGFR, 
c-Kit 
BI6727 (Volasertib) 67.04 ± 8.33 96.81 ± 0.40 93.30 ± 0.87 0.00 0.00 PLK 
WP1130 23.54 ± 5.25 89.58 ± 1.22 57.21 ± 10.03 0.00 0.01 DUB 
BKM120 
(NVP-BKM120) 
77.02 ± 9.81 93.31 ± 1.15 94.65 ± 2.66 0.00 0.00 PI3K 
CX-4945 17.81 ± 14.19 6.31 ± 6.05 10.83 ± 8.25 0.08 0.20 CK2 
Phenformin hydro-
chloride 
-21.21 ± 15.05 1.38 ± 3.70 -0.51 ± 7.55 0.03 0.04 NULL 
TAK-733 42.26 ± 14.06 31.96 ± 4.85 17.26 ± 1.35 0.16 0.02 MEK 
AZD5438 27.57 ± 1.45 59.38 ± 4.49 46.14 ± 1.49 0.01 0.04 CDK 
PP-121 75.53 ± 3.04 91.40 ± 1.29 91.44 ± 1.17 0.00 0.00 
DNA-PK, 
mTOR, PDGF 
OSI-027 75.11 ± 17.57 85.82 ± 0.70 89.17 ± 1.44 0.00 0.00 mTOR 
LY2603618 (IC-83) 27.45 ± 9.12 53.84 ± 6.82 67.23 ± 6.76 0.04 0.01 CHK 
PKI-587 87.61 ± 6.64 99.86 ± 0.01 99.74 ± 0.01 0.04 0.04 mTOR, PI3K 
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CCT128930 58.95 ± 7.30 81.78 ± 1.40 90.50 ± 1.18 0.00 0.00 Akt 
A66 51.24 ± 12.68 63.04 ± 3.06 70.11 ± 5.30 0.03 0.01 PI3K 
NU7441 12.11 ± 3.43 21.75 ± 3.49 30.90 ± 8.50 0.14 0.05 
ATM, DNA-PK, 
mTOR 
GSK2126458 81.76 ± 2.76 98.37 ± 0.16 95.45 ± 0.22 0.00 0.00 PI3K 
WYE-125132 84.77 ± 6.58 98.16 ± 0.25 95.95 ± 0.28 0.00 0.00 mTOR 
WYE-687 81.75 ± 6.88 93.66 ± 1.10 93.22 ± 0.71 0.02 0.02 mTOR 
A-674563 13.84 ± 8.42 46.25 ± 2.35 46.49 ± 6.44 0.00 0.00 Akt 
AS-252424 30.20 ± 20.11 16.14 ± 8.17 15.73 ± 11.98 0.05 0.08 PI3K 
GSK1120212 (JTP-
74057) 
41.63 ± 7.57 31.80 ± 1.54 22.28 ± 9.25 0.22 0.10 MEK 
Flavopiridol 
hydrochloride 
79.82 ± 1.89 98.09 ± 0.20 97.04 ± 0.16 0.01 0.01 CDK 
AS-604850 -1.51 ± 2.98 2.79 ± 4.18 5.93 ± 4.79 0.09 0.03 PI3K 
WAY-600 61.65 ± 5.91 81.95 ± 1.48 83.15 ± 1.40 0.00 0.00 mTOR 
TG101209 46.27 ± 2.25 53.27 ± 1.01 47.05 ± 3.60 0.06 0.43 FLT-3, JAK 
GDC-0980 (RG7422) 85.36 ± 17.45 98.37 ± 0.24 97.22 ± 0.29 0.00 0.00 mTOR, PI3K 
A-769662 8.28 ± 1.32 13.06 ± 0.60 8.81 ± 2.36 0.33 0.48 AMPK 
TAK-901 65.75 ± 17.10 80.36 ± 1.13 77.08 ± 1.70 0.00 0.00 Aurora 
AMG900 44.63 ± 4.35 52.17 ± 5.49 44.81 ± 3.48 0.25 0.49 Aurora 
ZM336372 2.53 ± 22.60 4.99 ± 12.27 4.92 ± 3.88 0.38 0.26 B-Raf 
PH-797804 9.27 ± 5.75 9.63 ± 1.68 4.36 ± 10.16 0.49 0.37 p38 MAPK 
PF-04691502 84.43 ± 0.00 99.03 ± 0.27 98.01 ± 0.23 0.01 0.01 mTOR, PI3K 
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Appendix 7 
The table below shows data from the kinase inhibitor screen with the exemestane resistant cell lines.  
 
Table A2: Results from the Kinase Inhibitor Screen with the Exemestane Resistant Cell Lines. Triplicate samples of 
parental MCF-7 and exemestane resistant ExeR-1 and ExeR-3 cells were treated with 1.0 µM of the indicated kinase 
inhibitors for 5 days. Cell number was determined by a cell viability assay. Inhibitory effect  standard deviation (SD) 
and targets of the kinase inhibitors are shown.  
 Inhibitory Effect ± SD (%) p-value  
Inhibitor MCF-7 Exe
R
-1 Exe
R
-3 
Exe
R
-
1 vs. 
MCF-
7 
Exe
R
-3 
vs. MCF-
7 
Target(s) 
BMS-599626 1.74 ± 7.53 21.97 ± 27.32 -1.76 ± 4.16 0.14 0.26 
EGFR,   
HER2 
Erlotinib 
Hydrochloride 
8.60 ± 6.06 33.96 ± 34.01 -0.06 ± 2.81 0.14 0.04 EGFR 
Gefitinib(Iressa) 8.60 ± 3.20 27.59 ± 30.85 4.12 ± 6.41 0.17 0.17 EGFR, Akt 
Neratinib 69.41 ± 1.54 59.67 ± 20.95 66.98 ± 3.51 0.23 0.17 HER2 
PD153035 
hydrochloride 
6.04 ± 6.46 8.71 ± 14.75 -2.20 ± 8.05 0.39 0.12 EGFR 
Pelitinib 38.83 ± 2.31 39.12 ± 5.13 43.48 ± 5.14 0.47 0.11 EGFR 
Vandetanib 10.93 ± 6.71 -1.79 ± 6.28 0.76 ± 5.79 0.04 0.06 
VEGFR, 
EGFR, SFKs 
WZ3146 7.17 ± 9.38 1.03 ± 7.40 2.05 ± 4.49 0.21 0.22 EGFR 
WZ4002 0.32 ± 7.65 6.84 ± 9.88 -2.18 ± 7.00 0.21 0.35 EGFR 
WZ8040 -3.08 ± 6.29 -2.76 ± 15.80 -5.34 ± 11.54 0.49 0.39 EGFR 
AV-951 
(Tivozanib) 
2.73 ± 9.57 -0.19 ± 2.81 5.13 ± 9.49 0.32 0.39 
VEGFR, 
PDGFR 
Axitinib 13.15 ± 2.14 16.45 ± 4.41 17.59 ± 5.15 0.15 0.12 VEGFR 
BIBF1120 
(Nintedanib) 
66.92 ± 2.65 53.21 ± 0.56 54.04 ± 4.44 0.00 0.01 
SFKs,FGFR, 
VEGFR, 
PDGFR 
BMS 794833 1.09 ± 4.01 0.34 ± 5.51 0.88 ± 5.42 0.43 0.48 
VEGFR, c-
Met, Flt 
Cediranib 
(AZD2171) 
13.62 ± 1.63 6.54 ± 5.19 11.73 ± 4.89 0.04 0.28 VEGFR 
CYC116 29.47 ± 3.74 46.39 ± 2.73 54.68 ± 2.44 0.00 0.00 
Aurora, 
VEGFR 
Imatinib(STI571) -3.32 ± 4.62 -6.62 ± 3.57 -1.24 ± 5.53 0.19 0.32 
VEGFR, 
PDGFR 
Imatinib Mesylate -1.87 ± 6.98 -8.98 ± 2.76 -3.13 ± 6.49 0.09 0.42 
c-Kit, 
PDGFR 
Ki8751 8.57 ± 4.09 2.65 ± 3.40 5.49 ± 1.35 0.06 0.14 
c-Kit, 
VEGFR, 
PDGFR, 
KRN 633 7.34 ± 5.28 8.31 ± 5.82 6.63 ± 1.17 0.42 0.42 VEGFR 
Masitinib 
(AB1010) 
4.64 ± 3.71 7.76 ± 7.14 6.47 ± 3.07 0.27 0.27 
c-Kit, 
PDGFR, 
FGFR 
MGCD-265 3.46 ± 6.38 7.12 ± 6.32 10.36 ± 4.42 0.26 0.10 
c-Met, 
VEGFR, Tie-
2 
Motesanib 
Diphosphate 
2.37 ± 2.19 3.54 ± 5.61 2.85 ± 6.66 0.38 0.46 
VEGFR, 
PDGFR, 
SFKs 
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MP-470 8.17 ± 1.52 6.34 ± 3.62 4.97 ± 4.74 0.23 0.16 
c-Kit, 
PDGFR, c-
Met 
OSI-930 -6.88 ± 4.64 -0.15 ± 5.40 -4.74 ± 3.60 0.09 0.28 
c-Kit, 
VEGFR 
Pazopanib 
Hydrochloride 
3.33 ± 5.38 -4.19 ± 2.53 9.49 ± 4.78 0.05 0.11 VEGFR 
Sorafenib Tosylate -8.55 ± 6.92 -5.95 ± 2.59 -4.96 ± 3.82 0.29 0.24 
VEGFR, 
PDGFR, RAF 
Sunitinib Malate 10.85 ± 2.24 9.59 ± 2.24 2.92 ± 3.83 0.26 0.02 
FLT3, 
PDGFR, 
VEGFR 
TSU-68 -1.81 ± 4.39 -5.95 ± 1.37 -4.54 ± 1.83 0.10 0.19 
VEGFR, 
PDGFR, 
FGFR 
Vatalanib 4.86 ± 6.03 -2.71 ± 3.11 5.58 ± 4.23 0.06 0.44 
VEGFR, c-
Kit, VEGFR, 
XL880 
(GSK1363089) 
34.57 ± 3.19 53.36 ± 4.11 47.18 ± 9.04 0.00 0.04 
c-Met, 
VEGFR 
PHA-739358 
(Danusertib) 
62.00 ± 3.98 71.82 ± 2.54 71.59 ± 4.37 0.01 0.02 
Aurora, Bcr-
Abl 
AT9283 24.26 ± 7.15 58.25 ± 5.42 46.87 ± 2.56 0.00 0.00 
Aurora, 
JAK, Bcr-Abl 
AZD0530 
(Saracatinib) 
25.19 ± 0.48 31.57 ± 4.12 31.22 ± 9.12 0.03 0.16 SFKs, Abl 
Bosutinib 
(SKI-606) 
20.66 ± 1.52 23.33 ± 1.92 25.39 ± 7.52 0.07 0.17 SFKs 
Dasatinib 46.35 ± 2.60 43.06 ± 1.62 46.20 ± 1.56 0.07 0.47 
SFKs, Abl, c-
kit 
Nilotinib -10.11 ± 2.23 -1.50 ± 2.32 -0.61 ± 3.39 0.00 0.01 Bcr-Abl 
Quercetin 
(Sophoretin) 
-0.03 ± 3.52 -4.90 ± 4.60 -9.07 ± 5.71 0.11 0.04 PI3K, PKC 
NVP-ADW742 18.29 ± 5.98 16.73 ± 3.45 12.99 ± 6.04 0.36 0.17 IGF-1R 
AC-220 8.31 ± 0.95 8.54 ± 6.83 17.30 ± 4.43 0.48 0.01 FLT-3 
AP24534 24.29 ± 2.03 14.71 ± 6.01 36.09 ± 5.83 0.03 0.01 
VEGFR, 
FGFR, 
PDGFR 
Tandutinib 
(MLN518) 
3.20 ± 2.01 5.07 ± 4.68 4.22 ± 6.49 0.28 0.40 
FLT-3, 
PDGFR, KIT 
KW 2449 25.82 ± 2.28 42.93 ± 4.52 48.14 ± 3.73 0.00 0.00 
FLT-3, ABL, 
Aurora 
CI-1033 
(Canertinib) 
19.86 ± 6.17 24.72 ± 0.59 15.62 ± 0.21 0.12 0.15 HER2, EGFR 
CP-724714 7.66 ± 3.43 13.40 ± 2.66 2.86 ± 7.19 0.04 0.18 HER2 
BAY 73-4506 
(Regorafenib) 
-0.69 ± 1.00 0.02 ± 6.32 5.64 ± 6.62 0.43 0.09 
c-KIT, 
VEGFR, B-
Raf 
JNJ-38877605 -3.18 ± 3.55 3.68 ± 1.64 4.57 ± 4.41 0.02 0.04 c-Met 
PF-04217903 -3.22 ± 5.49 0.86 ± 2.75 2.46 ± 9.61 0.16 0.21 c-Met 
PF-2341066 4.53 ± 1.84 6.06 ± 7.60 9.42 ± 4.52 0.38 0.08 c-Met, ALK 
SGX-523 -2.46 ± 1.03 -6.69 ± 1.99 -5.77 ± 5.44 0.02 0.18 c-Met 
SU11274 
(PKI-SU11274) 
3.69 ± 2.63 3.85 ± 8.72 12.85 ± 7.95 0.49 0.07 c-Met 
NVP-TAE684 44.87 ± 1.53 38.69 ± 3.97 46.18 ± 1.16 0.03 0.15 ALK 
SB 525334 12.95 ± 2.29 23.05 ± 1.76 20.93 ± 6.10 0.00 0.05 ALK, TGF-β 
R406 18.48 ± 7.19 14.06 ± 1.17 15.14 ± 3.84 0.18 0.26 Syk 
APPENDIX 
 
118 
 
R406 (free base) 17.86 ± 2.30 16.21 ± 3.47 12.13 ± 5.68 0.26 0.09 Syk 
XL184 4.37 ± 3.31 8.02 ± 10.91 2.02 ± 8.55 0.30 0.34 
c-Met, FLT-
3, Tie2 
BI 2536 70.99 ± 1.88 93.00 ± 0.13 93.79 ± 0.69 0.00 0.00 PLK 
GSK461364 59.90 ± 1.29 86.80 ± 1.33 92.97 ± 0.55 0.00 0.00 PLK 
HMN-214 64.34 ± 1.24 86.88 ± 0.57 85.23 ± 1.61 0.00 0.00 PLK 
ON-01910 71.96 ± 1.25 90.06 ± 0.27 91.83 ± 1.15 0.00 0.00 PLK 
AT7519 90.92 ± 0.76 96.42 ± 0.27 97.78 ± 0.29 0.00 0.00 CDK 
Flavopiridol 
(Alvocidib) 
84.87 ± 1.50 94.48 ± 0.89 96.94 ± 0.23 0.00 0.00 CDK 
BS-181 
hydrochloride 
3.97 ± 2.28 12.48 ± 2.08 3.35 ± 4.17 0.00 0.42 CDK 
PD0332991 59.47 ± 1.65 55.07 ± 3.52 49.17 ± 7.61 0.06 0.04 CDK 
PHA-793887 61.75 ± 6.13 86.94 ± 1.74 86.14 ± 1.63 0.00 0.00 CDK 
Roscovitine 
(CYC202) 
1.46 ± 2.96 7.09 ± 1.94 6.06 ± 7.27 0.03 0.18 CDK 
SNS-032 
(BMS-387032) 
87.91 ± 0.41 95.68 ± 0.62 97.20 ± 0.56 0.00 0.00 CDK 
AZD7762 60.51 ± 0.78 88.25 ± 0.58 86.47 ± 0.63 0.00 0.00 Chk1/2 
Aurora A Inhibitor I 54.59 ± 1.81 70.16 ± 3.78 66.58 ± 4.02 0.00 0.00 Aurora A 
AZD1152-HQPA 
(Barasertib) 
29.14 ± 3.53 43.33 ± 1.64 40.84 ± 3.94 0.00 0.01 Aurora B 
CCT129202 30.13 ± 1.86 47.62 ± 6.83 36.32 ± 8.09 0.01 0.13 Aurora 
ENMD-2076 44.47 ± 2.70 58.19 ± 1.59 61.17 ± 3.28 0.00 0.00 
Aurora, 
Flt3/4, 
SFKs, 
VEGFR2 
Hesperadin 74.26 ± 2.49 78.71 ± 3.06 81.01 ± 0.31 0.06 0.00 Aurora B 
MLN8237 35.39 ± 1.59 48.29 ± 5.17 50.98 ± 2.24 0.01 0.00 Aurora 
PHA-680632 45.79 ± 5.96 57.66 ± 1.50 59.29 ± 4.62 0.01 0.02 Aurora 
SNS-314 Mesylate 30.03 ± 4.72 43.88 ± 1.35 39.99 ± 7.50 0.00 0.06 Aurora 
VX-680 37.33 ± 4.45 55.75 ± 3.80 45.27 ± 3.41 0.00 0.04 Aurora 
ZM-447439 26.64 ± 2.10 46.39 ± 6.88 46.80 ± 5.12 0.00 0.00 Aurora 
AS703026 24.12 ± 3.72 17.39 ± 7.31 11.06 ± 2.42 0.11 0.00 MEK 
AZD6244 
(Selumetinib) 
15.03 ± 0.71 7.52 ± 0.98 0.93 ± 6.72 0.00 0.01 MEK 
AZD8330 21.02 ± 5.26 5.97 ± 4.67 6.34 ± 6.82 0.01 0.02 MEK 
BIX 02188 2.69 ± 3.52 -6.82 ± 3.84 -3.87 ± 4.07 0.02 0.05 MEK 
BIX 02189 9.36 ± 5.36 33.78 ± 33.72 12.62 ± 2.48 0.14 0.20 MEK 
BMS 777607 -1.94 ± 6.97 -4.55 ± 9.19 -2.46 ± 2.53 0.36 0.45 c-Met 
CI-1040 
(PD184352) 
17.44 ± 2.78 10.31 ± 6.95 10.61 ± 6.67 0.09 0.09 MEK 
PD318088 24.98 ± 5.37 9.23 ± 4.83 8.83 ± 3.82 0.01 0.01 MEK 
PD0325901 26.30 ± 2.80 4.84 ± 12.19 12.22 ± 3.89 0.02 0.00 MEK 
PD98059 8.03 ± 5.65 7.39 ± 4.58 4.53 ± 9.36 0.44 0.30 MEK 
U0126-EtOH 6.25 ± 6.55 5.12 ± 21.48 0.73 ± 7.98 0.47 0.20 MEK 
LY2228820 -4.39 ± 3.45 -5.56 ± 3.98 -4.31 ± 2.33 0.36 0.49 p38 MAPK 
BIRB 796 0.90 ± 5.23 -7.04 ± 9.90 -1.90 ± 3.06 0.14 0.23 p38 MAPK 
SB 202190 -2.65 ± 12.77 
-
10.94 
± 11.13 -2.08 ± 1.90 0.22 0.47 p38 MAPK 
SB 203580 -4.89 ± 4.27 -6.38 ± 3.51 -8.35 ± 7.05 0.33 0.25 p38 MAPK 
Vinorelbine 
(Navelbine) 
85.98 ± 1.35 98.05 ± 0.87 98.61 ± 0.15 0.00 0.00 p38 MAPK 
VX-702 4.40 ± 8.33 -0.46 ± 7.46 9.26 ± 4.45 0.25 0.21 p38 MAPK 
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VX-745 2.71 ± 4.44 -1.58 ± 9.76 6.76 ± 4.07 0.26 0.15 p38 MAPK 
GDC-0879 -13.69 ± 6.52 
-
12.31 
± 9.38 -8.99 ± 5.82 0.42 0.20 B-Raf 
PLX-4720 -8.90 ± 2.38 
-
12.16 
± 6.93 -5.73 ± 5.08 0.24 0.19 B-Raf 
RAF265 12.69 ± 3.01 2.50 ± 19.68 6.01 ± 2.29 0.21 0.02 RAF, VEGFR 
SP600125 0.38 ± 5.48 0.66 ± 2.94 -6.39 ± 8.52 0.47 0.16 JNK 
AZD6482 9.85 ± 1.53 4.40 ± 8.86 12.72 ± 11.19 0.18 0.34 PI3K 
AS-605240 4.37 ± 6.97 0.66 ± 10.49 -1.63 ± 8.69 0.32 0.20 PI3K 
GDC-0941 67.23 ± 1.23 80.28 ± 1.26 78.12 ± 1.80 0.00 0.00 PI3K 
IC-87114 9.45 ± 1.17 36.02 ± 49.37 5.71 ± 2.91 0.20 0.05 PI3K 
LY294002 9.15 ± 3.59 4.58 ± 6.59 7.16 ± 3.61 0.18 0.27 
PI3K, casein 
kinase II 
PIK-293 4.45 ± 2.43 5.10 ± 6.12 3.73 ± 4.27 0.44 0.41 PI3K 
PIK-90 47.85 ± 8.91 63.75 ± 6.02 52.67 ± 9.71 0.03 0.28 PI3K 
PIK-93 18.06 ± 3.06 23.06 ± 12.62 24.11 ± 8.33 0.32 0.21 PI3K 
TG100-115 -0.21 ± 0.75 -2.16 ± 9.75 1.57 ± 10.66 0.37 0.39 PI3K 
TGX-221 3.30 ± 6.62 3.68 ± 19.43 5.68 ± 5.25 0.49 0.33 PI3K 
XL147 0.56 ± 2.28 -1.80 ± 7.90 -0.71 ± 5.31 0.32 0.36 PI3K 
XL765 -1.66 ± 3.16 -5.42 ± 4.22 1.24 ± 4.98 0.14 0.22 PI3K 
ZSTK474 64.83 ± 2.34 65.88 ± 4.06 61.28 ± 4.71 0.36 0.15 PI3K 
AZD8055 89.21 ± 0.26 95.54 ± 1.02 97.86 ± 0.43 0.00 0.00 mTOR 
Deforolimus(MK-
8669) 
66.80 ± 2.85 75.67 ± 10.05 69.55 ± 3.38 0.11 0.17 mTOR 
Everolimus(RAD001
) 
62.75 ± 0.64 60.94 ± 5.56 68.78 ± 2.23 0.30 0.01 mTOR 
KU-0063794 83.97 ± 0.73 88.01 ± 1.07 89.29 ± 1.42 0.00 0.00 mTOR 
Rapamycin(Sirolim
us) 
65.38 ± 0.61 61.15 ± 1.88 64.00 ± 3.92 0.01 0.29 mTOR 
Temsirolimus 60.44 ± 4.74 57.90 ± 5.32 61.34 ± 2.73 0.28 0.40 mTOR 
WYE-354 83.75 ± 0.75 87.93 ± 1.64 89.72 ± 0.94 0.01 0.00 mTOR 
PIK-75 
Hydrochloride 
89.59 ± 0.84 95.53 ± 0.58 97.85 ± 0.15 0.00 0.00 PI3K 
CHIR-99021 -7.99 ± 5.56 
-
11.80 
± 6.21 -7.11 ± 8.14 0.24 0.44 GSK-3 
Indirubin 5.78 ± 3.15 14.43 ± 6.68 22.59 ± 8.40 0.06 0.02 GSK-3 
SB 216763 0.12 ± 2.12 -9.31 ± 10.78 -0.59 ± 10.64 0.11 0.46 GSK-3 
KU-55933 6.65 ± 1.30 36.01 ± 52.67 8.72 ± 4.02 0.19 0.22 ATM 
KU-60019 16.07 ± 2.63 6.41 ± 5.37 7.35 ± 4.00 0.02 0.02 ATM 
MK-2206 (AKT inh) 36.65 ± 1.40 56.11 ± 3.21 57.69 ± 2.62 0.00 0.00 Akt 
AT7867 (AKT inh) 4.78 ± 4.06 13.84 ± 16.81 40.26 ± 9.36 0.21 0.00 
Akt, S6 
kinase 
AZD1480 5.77 ± 5.40 4.73 ± 27.79 2.60 ± 3.32 0.48 0.22 JAK 
LY2784544 20.00 ± 3.15 35.62 ± 3.10 38.85 ± 12.60 0.00 0.03 JAK 
Enzastaurin -4.41 ± 2.76 
-
10.26 
± 4.82 -3.66 ± 3.32 0.07 0.39 PKC 
SB 431542 8.29 ± 5.04 13.85 ± 5.46 12.55 ± 3.68 0.13 0.15 ALK 
ABT-869(Linifanib) 2.63 ± 5.22 -5.10 ± 4.90 1.78 ± 2.98 0.07 0.41 
RTK, 
VEGFR, 
PDGFR 
AEE788 25.85 ± 3.36 26.80 ± 10.84 27.11 ± 5.44 0.45 0.37 
EGFR, 
HER2, 
VEGFR 
BIBW2992(Tovok) 9.25 ± 1.83 19.03 ± 4.82 9.03 ± 5.64 0.02 0.48 EGFR, HER2 
Lapatinib Ditosylate 2.31 ± 6.42 11.95 ± 21.50 1.06 ± 5.83 0.25 0.41 EGFR, HER2 
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JNJ-7706621 6.63 ± 3.58 42.07 ± 7.60 36.72 ± 2.25 0.00 0.00 
Aurora, 
CDK 
BEZ235 87.14 ± 0.42 94.96 ± 0.40 97.24 ± 0.32 0.00 0.00 PI3K, mTOR 
GSK1059615 77.27 ± 1.37 83.30 ± 1.43 82.40 ± 0.25 0.00 0.00 PI3K, mTOR 
PI-103 60.71 ± 8.38 96.00 ± 3.54 93.23 ± 0.18 0.00 0.00 PI3K, mTOR 
AG-490 4.19 ± 3.57 4.15 ± 4.07 5.30 ± 4.08 0.49 0.37 EGFR, JAK 
CP-690550 
(Tofacitinib) 
2.02 ± 5.74 3.07 ± 2.79 -1.37 ± 7.69 0.39 0.29 JAK 
Crenolanib (CP-
868569) 
8.86 ± 1.47 33.60 ± 8.47 42.95 ± 8.53 0.00 0.00 PDGFR 
GSK1838705A 11.54 ± 4.14 9.60 ± 17.98 14.98 ± 2.16 0.43 0.14 IGF-1R 
KX2-391 80.43 ± 0.48 94.68 ± 0.82 94.64 ± 0.60 0.00 0.00 SFKS 
NVP-BSK805 1.14 ± 2.26 1.89 ± 20.31 1.29 ± 5.41 0.48 0.48 JAK 
PCI-32765 14.43 ± 5.13 21.21 ± 6.18 3.88 ± 3.01 0.11 0.02 SFKS 
PF-562271 8.24 ± 3.75 -6.31 ± 6.67 14.48 ± 17.49 0.02 0.29 FAK, Pyk2 
DCC-2036 1.82 ± 5.08 0.52 ± 9.78 12.05 ± 2.29 0.42 0.02 
SFKs, bcr-
Abl 
LDN193189 8.56 ± 2.50 16.35 ± 4.04 19.63 ± 11.42 0.02 0.09 BMP 
AZD8931 14.40 ± 2.91 26.79 ± 7.38 16.42 ± 8.32 0.03 0.36 EGFR, HER2 
Raf265 derivative -4.63 ± 3.98 9.80 ± 5.46 2.86 ± 3.40 0.01 0.03 Syk 
NVP-BHG712 -2.77 ± 3.63 9.06 ± 4.06 3.46 ± 3.70 0.01 0.05 
VEGFR, 
SFKS, c-Abl 
OSI-420 -1.42 ± 0.99 15.60 ± 0.57 0.33 ± 6.26 0.00 0.37 EGFR 
R935788 
(Fostamatinib) 
23.47 ± 3.22 16.93 ± 3.89 17.35 ± 7.54 0.04 0.13 Syk 
AZ 960 69.18 ± 1.52 83.22 ± 1.23 83.41 ± 4.17 0.00 0.00 JAK, Aurora 
Mubritinib (TAK 
165) 
46.12 ± 1.90 28.50 ± 5.00 20.80 ± 5.04 0.00 0.00 EGFR, CDK 
PP242 84.58 ± 0.63 91.53 ± 0.48 91.94 ± 0.71 0.00 0.00 mTOR 
Cyt387 9.76 ± 2.40 22.98 ± 2.96 10.78 ± 3.26 0.00 0.34 JAK 
Apatinib -4.77 ± 5.52 0.47 ± 2.08 -4.58 ± 4.37 0.10 0.48 EGFR 
CAL-101 -3.82 ± 1.42 5.24 ± 7.03 8.85 ± 13.66 0.05 0.09 PI3K 
PIK-294 4.65 ± 4.01 13.05 ± 8.25 10.05 ± 5.46 0.09 0.12 PI3K 
VX-765 4.14 ± 1.04 6.30 ± 4.09 3.78 ± 3.98 0.21 0.44 Caspase 
Telatinib 
(BAY 57-9352) 
3.92 ± 2.22 6.83 ± 5.90 -1.77 ± 5.34 0.23 0.08 
VEGFR,PDG
FR, c-Kit 
BI6727 (Volasertib) 73.33 ± 0.35 95.20 ± 0.16 95.12 ± 0.27 0.00 0.00 PLK 
WP1130 4.51 ± 3.98 3.10 ± 3.88 3.96 ± 1.63 0.34 0.42 DUB 
BKM120 
(NVP-BKM120) 
80.15 ± 1.55 82.06 ± 2.54 78.60 ± 2.79 0.16 0.22 PI3K 
CX-4945 12.39 ± 1.26 10.12 ± 5.55 10.81 ± 4.19 0.26 0.28 CK2 
Phenformin hydro-
chloride 
-4.53 ± 4.76 -0.86 ± 3.63 -3.28 ± 2.10 0.17 0.35 NULL 
TAK-733 27.16 ± 3.32 12.09 ± 3.14 14.18 ± 5.18 0.00 0.01 MEK 
AZD5438 24.86 ± 3.13 59.94 ± 2.21 42.33 ± 6.48 0.00 0.01 CDK 
PP-121 79.65 ± 1.27 83.94 ± 1.14 86.45 ± 1.30 0.01 0.00 
DNA-PK, 
mTOR, 
PDGF 
OSI-027 78.36 ± 3.26 77.19 ± 1.66 79.33 ± 1.64 0.30 0.33 mTOR 
LY2603618 (IC-83) 21.46 ± 4.72 75.74 ± 2.59 51.61 ± 4.40 0.00 0.00 CHK 
PKI-587 96.21 ± 0.13 98.36 ± 0.11 99.68 ± 0.06 0.00 0.00 mTOR, PI3K 
CCT128930 25.29 ± 2.09 40.42 ± 2.41 46.11 ± 1.93 0.00 0.00 Akt 
A66 35.48 ± 3.57 46.94 ± 1.66 35.68 ± 5.57 0.00 0.48 PI3K 
NU7441 11.20 ± 4.00 7.08 ± 3.02 5.39 ± 5.74 0.11 0.11 
ATM, DNA-
PK, mTOR 
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GSK2126458 89.24 ± 0.39 95.65 ± 0.12 98.49 ± 0.12 0.00 0.00 PI3K 
WYE-125132 90.48 ± 0.58 95.95 ± 0.31 97.95 ± 0.50 0.00 0.00 mTOR 
WYE-687 85.31 ± 1.31 89.84 ± 0.34 91.28 ± 0.91 0.00 0.00 mTOR 
A-674563 3.14 ± 2.02 13.93 ± 6.40 25.56 ± 0.85 0.02 0.00 Akt 
AS-252424 4.02 ± 3.66 0.36 ± 4.34 0.41 ± 1.27 0.16 0.09 PI3K 
GSK1120212 (JTP-
74057) 
31.59 ± 4.32 18.21 ± 3.93 24.83 ± 7.77 0.01 0.13 MEK 
Flavopiridol 
hydrochloride 
86.70 ± 0.62 95.50 ± 0.42 97.08 ± 0.03 0.00 0.00 CDK 
AS-604850 3.36 ± 3.70 7.59 ± 4.60 4.67 ± 3.44 0.14 0.34 PI3K 
WAY-600 67.43 ± 0.62 75.26 ± 0.68 68.75 ± 6.50 0.00 0.37 mTOR 
TG101209 41.79 ± 4.23 26.31 ± 3.93 39.05 ± 6.15 0.00 0.28 FLT-3, JAK 
GDC-0980 
(RG7422) 
91.41 ± 0.58 96.72 ± 0.39 98.26 ± 0.07 0.00 0.00 mTOR, PI3K 
A-769662 1.15 ± 3.17 1.80 ± 5.91 -4.42 ± 1.73 0.44 0.03 AMPK 
TAK-901 73.13 ± 2.29 80.86 ± 0.69 80.82 ± 2.31 0.00 0.01 Aurora 
AMG900 31.41 ± 2.36 47.05 ± 1.83 47.24 ± 0.38 0.00 0.00 Aurora 
ZM336372 -9.42 ± 3.60 0.71 ± 5.00 -7.85 ± 3.92 0.02 0.32 B-Raf 
PH-797804 7.09 ± 3.20 5.84 ± 4.84 9.76 ± 2.35 0.36 0.15 p38 MAPK 
PF-04691502 92.54 ± 0.49 97.65 ± 0.24 98.99 ± 0.10 0.00 0.00 mTOR, PI3K 
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Appendix 8 
The purchased 195 kinase inhibitors were provided in three 96-well plates and the setup of plate 1, 2, 
and 3 is shown below. 
 Plate 1 
            1 2 3 4 5 6 7 8 9 10 11 12 
a Control 
BMS-
599626 
Erlotinib 
Hydrochlori
de 
Gefitinib 
(Iressa) 
Neratinib 
PD153035 
hydrochlorid
e 
Pelitinib Vande-tanib WZ3146 WZ4002 WZ8040 Empty 
b 
AV-951 
(Tivozanib
) 
Axitinib 
BIBF1120 
(Nintedanib
) 
BMS 
794833 
Control 
Cediranib 
(AZD2171) 
Control CYC116 Control 
Imatinib 
(STI571) 
Imatinib 
Mesylate 
Empty 
c Ki8751 KRN 633 
Masitinib 
(AB1010) 
MGCD-265 
Motesanib 
Diphosphat
e 
MP-470 OSI-930 
Pazopanib 
Hydrochlorid
e 
Sorafenib 
Tosylate 
Sunitinib 
Malate 
TSU-68 Empty 
d Vatalanib 
XL880 
(GSK136308
9) 
PHA-
739358 
(Danusertib
) 
AT9283 
AZD0530 
(Saracatini
b) 
Bosutinib 
(SKI-606) 
Dasatinib Nilotinib 
Quercetin 
(Sophoretin
) 
NVP-
ADW742 
AC-220 Empty 
e AP24534 
Tandutinib 
(MLN518) 
KW 2449 
CI-1033 
(Canertinib
) 
CP-724714 
BAY 73-4506 
(Regorafenib
) 
JNJ-
38877605 
PF-04217903 PF-2341066 Control SGX-523 Empty 
f 
SU11274(
PKI-
SU11274) 
NVP-
TAE684 
SB 525334 R406 
R406(free 
base) 
XL184 BI 2536 GSK461364 HMN-214 ON-01910 AT7519 Empty 
g 
Flavopirid
ol 
(Alvocidib
) 
BS-181 
hydrochlori
de 
PD0332991 
PHA-
793887 
Roscovitine 
(CYC202) 
SNS-032 
(BMS-
387032) 
AZD7762 
Aurora A 
Inhibitor I 
AZD1152-
HQPA 
(Barasertib) 
CCT129202 ENMD-2076 Empty 
h 
Hesperadi
n 
MLN8237 Control 
PHA-
680632 
SNS-314 
Mesylate 
VX-680 
ZM-
447439 
AS703026 
AZD6244 
(Selumetini
b) 
AZD8330 BIX 02188 Empty 
 
Plate 2 
  1 2 3 4 5 6 7 8 9 10 11 12 
a BIX 02189 BMS 777607 
CI-1040 
(PD184352) 
PD318088 PD0325901 PD98059 
U0126-
EtOH 
LY2228820 BIRB 796 SB 202190 SB 203580 Empty 
b 
Vinorelbin
e(Navelbi
ne) 
VX-702 VX-745 GDC-0879 Control PLX-4720 RAF265 SP600125 AZD6482 AS-605240 GDC-0941 Empty 
c IC-87114 LY294002 PIK-293 PIK-90 PIK-93 TG100-115 TGX-221 XL147 XL765 ZSTK474 AZD8055 Empty 
d 
Deforolim
us(MK-
8669) 
Everolimus 
(RAD001) 
KU-
0063794 
Rapamycin 
(Sirolimus) 
Temsirolimus WYE-354 Control 
PIK-75 
Hydrochlorid
e 
CHIR-99021 Indirubin SB 216763 Empty 
e KU-55933 KU-60019 MK-2206 Control AT7867 Control AZD1480 Control LY2784544 Control Enzastaurin Empty 
f Control Control SB 431542 ABT-869 (Linifanib) AEE788 
BIBW2992 
(Tovok) 
Lapatinib 
Ditosylat
e 
JNJ-7706621 Control BEZ235 
GSK105961
5 
Empty 
g PI-103 AG-490 
CP-690550 
(Tofacitinib
) 
Crenolanib 
(CP-
868569) 
GSK1838705A KX2-391 
NVP-
BSK805 
PCI-32765 PF-562271 DCC-2036 LDN193189 Empty 
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Plate 3 
  1 2 3 4 5 6 7 8 9 10 11 12 
a AZD8931 Raf265 derivative 
NVP-
BHG712 
OSI-420 
R935788 
(Fostamatinib
) 
AZ 960 
Mubritini
b (TAK 
165) 
PP242 Cyt387 Apatinib CAL-101 Empty 
b PIK-294 VX-765 
Telatinib  
(BAY 57-
9352) 
BI6727 
(Volasertib) 
WP1130 
BKM120 
(NVP-
BKM120) 
CX-4945 
Phenformin 
hydrochloride 
TAK-733 AZD5438 PP-121 Empty 
c OSI-027 
LY2603618 
(IC-83) 
PKI-587 CCT128930 A66 NU7441 
GSK21264
58 
WYE-125132 WYE-687 A-674563 AS-252424 Empty 
d 
GSK1120
212 
 (JTP-
74057) 
Flavopirido
l 
hydrochlori
de 
AS-604850 WAY-600 TG101209 
GDC-0980 
(RG7422) 
A-769662 TAK-901 AMG900 ZM336372 Control Empty 
e PH-797804 
PF-
04691502 
Control Control Control Control Control Control Control Control Control Empty 
Setup of Plate 1-3 Containing Kinase Inhibitors. 96-well plates containing either kinase inhibitors, control (DMSO) or 
empty wells (Selleck Chemicals, 2012). 
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Appendix 9 
The 195 kinase inhibitors were distributed across three 96-well plates (blue) (named plate 1, plate 2, 
and plate 3) with additional DMSO controls (red). The screen is performed in triplicates and thus 9 
plates were set up for each cell line. 
 
 
Figure A7: Kinase Inhibitor Screen Setup. Triplicate samples of each cell line (MCF-7, LetR-1, LetR-3, ExeR-1 and ExeR-
3) were treated for 5 days with vehicle (0.1% DMSO) (red wells) or 1.0 µM of 195 different kinase inhibitors (blue 
wells). Subsequently, cell number was determined by a cell viability assay. 
 
 
  
 
